US20020197605A1 - Novel Polynucleotides - Google Patents

Novel Polynucleotides Download PDF

Info

Publication number
US20020197605A1
US20020197605A1 US09/738,626 US73862600A US2002197605A1 US 20020197605 A1 US20020197605 A1 US 20020197605A1 US 73862600 A US73862600 A US 73862600A US 2002197605 A1 US2002197605 A1 US 2002197605A1
Authority
US
United States
Prior art keywords
amino acid
corynebacterium
polypeptide
seq
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/738,626
Other languages
English (en)
Inventor
Satoshi Nakagawa
Hiroshi Mizoguchi
Seiko Ando
Mikiro Hayashi
Keiko Ochiai
Haruhiko Yokoi
Naoko Tateishi
Akihiro Senoh
Masato Ikeda
Akio Ozaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to KYOWA HAKKO KOGYO CO., LTD. reassignment KYOWA HAKKO KOGYO CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ANDO, SEIKO, HAYASHI, MIKIRO, MIZOGUCHI, HIROSHI, NAKAGAWA, SATOSHI, OCHIAI, KEIKO, SENOH, AKIHIRO, TATEISHI, NAOKO, YOKO, HARUHIKO
Publication of US20020197605A1 publication Critical patent/US20020197605A1/en
Priority to US10/805,394 priority Critical patent/US7332310B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C12N15/03—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/08—Lysine; Diaminopimelic acid; Threonine; Valine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01003—Homoserine dehydrogenase (1.1.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y604/00—Ligases forming carbon-carbon bonds (6.4)
    • C12Y604/01—Ligases forming carbon-carbon bonds (6.4.1)
    • C12Y604/01001—Pyruvate carboxylase (6.4.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/15—Corynebacterium

Definitions

  • the contents of the attached CD-R compact discs are incorporated herein by reference in their entirety.
  • the attached discs contain an identical copy of a file “SEQ2.TXT” which were created on the discs on Dec. 13, 2000, and are each 25,891 KR.
  • the present invention relates to novel polynucleotides derived from microorganisms belonging to coryneform bacteria and fragments thereof, polypeptides encoded by the polynucleotides and fragments thereof, polynucleotide arrays comprising the polynucleotides and fragments thereof, computer readable recording media in which the nucleotide sequences of the polynucleotide and fragments thereof have been recorded, and use of them as well as a method of using the polynucleotide and/or polypeptide sequence information to make comparisons.
  • Coryneform bacteria are used in producing various useful substances, such as amino acids, nucleic acids, vitamins, saccharides (for example, ribulose), organic acids (for example, pyruvic acid), and analogues of the above-described substances (for example, N-acetylamino acids) and are very useful microorganisms industrially. Many mutants thereof are known.
  • Corynebacterium glutamicum is a Gram-positive bacterium identified as a glutamic acid-producing bacterium, and many amino acids are produced by mutants thereof.
  • L-glutamic acid which is useful as a seasoning for umami (delicious taste)
  • L-lysine which is a valuable additive for livestock feeds and the like
  • other amino acids such as L-arginine, L-proline, L-glutamine, L-tryptophan, and the like, have been produced in the world (Nikkei Bio Yearbook 99, published by Nikkei BP (1998)).
  • arginine The biosynthesis of arginine is controlled by repressing the expression of its biosynthesis gene by arginine so as not to biosynthesize an excessive amount of arginine ( Microbiology, 142:99-108 (1996)) It is considered that these metabolic regulatory mechanisms are deregulated in amino acid-producing mutants. Similarly, the metabolic regulation is deregulated in mutants producing nucleic acids, vitamins, saccharides, organic acids and analogues of the above-described substances so as to improve the productivity of the objective product.
  • a chromosomal physical map of Corynebacterium glutamicum ATCC 13032 is reported and it is known that its genome size is about 3,100 kb ( Mol. Gen. Genet., 252:255-265 (1996)). Calculating on the basis of the usual gene density of bacteria, it is presumed that about 3,000 genes are present in this genome of about 3,100 kb. However, only about 100 genes mainly concerning amino acid biosynthesis genes are known in Corynebacterium glutamicum, and the nucleotide sequences of most genes have not been clarified hitherto.
  • An object of the present invention is to provide a polynucleotide and a polypeptide derived from a microorganism of coryneform bacteria which are industrially useful, sequence information of the polynucleotide and the polypeptide, a method for analyzing the microorganism, an apparatus and a system for use in the analysis, and a method for breeding the microorganism.
  • the present invention provides a polynucleotide and an oligonucleotide derived from a microorganism belonging to coryneform bacteria, oligonucleotide arrays to which the polynucleotides and the oligonucleotides are fixed, a polypeptide encoded by the polynucleotide, an antibody which recognizes the polypeptide, polypeptide arrays to which the polypeptides or the antibodies are fixed, a computer readable recording medium in which the nucleotide sequences of the polynucleotide and the oligonucleotide and the amino acid sequence of the polypeptide have been recorded, and a system based on the computer using the recording medium as well as a method of using the polynucleotide and/or polypeptide sequence information to make comparisons.
  • FIG. 1 is a map showing the positions of typical genes on the genome of Corynebacterium glutamicum ATCC 13032.
  • FIG. 2 is electrophoresis showing the results of proteome analyses using proteins derived from (A) Corynebacterium glutamicum ATCC 13032, (B) FERM BP-7134, and (C) FERM BP-158.
  • FIG. 3 is a flow chart of an example of a system using the computer readable media according to the present invention.
  • FIG. 4 is a flow chart of an example of a system using the computer readable media according to the present invention.
  • the present invention relates to the following (1) to (65):
  • polynucleotide array by adhering to a solid support at least two polynucleotides selected from the group consisting of first polynucleotides comprising the nucleotide sequence represented by any one of SEQ ID NOS:1 to 3501, second polynucleotides which hybridize with the first polynucleotides under stringent conditions, and third polynucleotides comprising a sequence of 10 to 200 continuous bases of the first or second polynucleotides,
  • the at least two polynucleotides can be at least two of the first polynucleotides, at least two of the second polynucleotides, at least two of the third polynucleotides, or at least two of the first, second and third polynucleotides.
  • coryneform bacterium is a microorganism belonging to the genus Corynebacterium, the genus Brevibacterium, or the genus Microbacterinum.
  • polynucleotide derived from a coryneform bacterium, the polynucleotide derived from a mutant of the coryneform bacterium or the polynucleotide to be examined is a gene relating to the biosynthesis of at least one compound selected from an amino acid, a nucleic acid, a vitamin, a saccharide, an organic acid, and analogues thereof.
  • a polynucleotide array comprising:
  • At least two polynucleotides selected from the group consisting of first polynucleotides comprising the nucleotide sequence represented by any one of SEQ ID NOS:1 to 3501, second polynucleotides which hybridize with the first polynucleotides under stringent conditions, and third polynucleotides comprising 10 to 200 continuous bases of the first or second polynucleotides, and
  • the at least two polynucleotides can be at least two of the first polynucleotides, at least two of the second polynucleotides, at least two of the third polynucleotides, or at least two of the first, second and third polynucleotides.
  • a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO:1 or a polynucleotide having a homology of at least 80% with the polynucleotide.
  • a polynucleotide comprising any one of the nucleotide sequences represented by SEQ ID NOS:2 to 3431, or a polynucleotide which hybridizes with the polynucleotide under stringent conditions.
  • a recombinant DNA comprising the polynucleotide of any one of (8) to (11).
  • a transformant comprising the polynucleotide of any one of (8) to (11) or the recombinant DNA of (12).
  • a method for producing a polypeptide comprising:
  • a polypeptide encoded by a polynucleotide comprising the nucleotide sequence selected from SEQ ID NOS:2 to 3431.
  • a polypeptide comprising the amino acid sequence selected from SEQ ID NOS:3502 to 6931.
  • a polypeptide comprising an amino acid sequence having a homology of at least 60% with the amino acid sequence of the polypeptide of (16) or (17), and having an activity which is substantially the same as that of the polypeptide.
  • a polypeptide array comprising:
  • a polypeptide array comprising:
  • a system based on a computer for identifying a target sequence or a target structure motif derived from a coryneform bacterium comprising the following:
  • a user input device that inputs at least one nucleotide sequence information selected from SEQ ID NOS:1 to 3501, and target sequence or target structure motif information;
  • a comparator that compares the at least one nucleotide sequence information selected from SEQ ID NOS:1 to 3501 with the target sequence or target structure motif information, recorded by the data storage device for screening and analyzing nucleotide sequence information which is coincident with or analogous to the target sequence or target structure motif information;
  • a method based on a computer for identifying a target sequence or a target structure motif derived from a coryneform bacterium comprising the following:
  • a system based on a computer for identifying a target sequence or a target structure motif derived from a coryneform bacterium comprising the following:
  • a user input device that inputs at least one amino acid sequence information selected from SEQ ID NOS:3502 to 7001, and target sequence or target structure motif information;
  • a comparator that compares the at least one amino acid sequence information selected from SEQ ID NOS:3502 to 7001 with the target sequence or target structure motif information, recorded by the data storage device for screening and analyzing amino acid sequence information which is coincident with or analogous to the target sequence or target structure motif information;
  • a method based on a computer for identifying a target sequence or a target structure motif derived from a coryneform bacterium comprising the following:
  • a user input device that inputs at least one nucleotide sequence information selected from SEQ ID NOS:2 to 3501, function information of a polypeptide encoded by the nucleotide sequence, and target nucleotide sequence information;
  • a comparator that compares the at least one nucleotide sequence information selected from SEQ ID NOS:2 to 3501 with the target nucleotide sequence information, and determining a function of a polypeptide encoded by a polynucleotide having the target nucleotide sequence which is coincident with or analogous to the polynucleotide having at least one nucleotide sequence selected from SEQ ID NOS:2 to 3501;
  • nucleotide sequence information selected from SEQ ID NOS:2 to 3501, function information of a polypeptide encoded by the nucleotide sequence, and target nucleotide sequence information;
  • a system based or a computer for determining a function of a polypeptide having a target amino acid sequence derived from a coryneform bacterium comprising the following:
  • a user input device that inputs at least one amino acid sequence information selected from SEQ ID NOS:3502 to 7001, function information based on the amino acid sequence, and target amino acid sequence information;
  • a comparator that compares the at least one amino acid sequence information selected from SEQ ID NOS:3502 to 7001 with the target amino acid sequence information for determining a function of a polypeptide having the target amino acid sequence which is coincident with or analogous to the polypeptide having at least one amino acid sequence selected from SEQ ID NOS-3502 to 7001;
  • a method based on a computer for determining a function of a polypeptide having a target amino acid sequence derived from a coryneform bacterium comprising the following:
  • a coryneform bacterium is a microorganism of the genus Corynebacterium, the genus Brevibacterium, or the genus Microbacterinum
  • a coryneform bacterium is a microorganism of the genus Corynebacterium, the genus Brevibacterium, or the genus Microbacterinum.
  • a recording medium or storage device which is readable by a computer is which at least one nucleotide sequence information or selected from SEQ ID NOS:1 to 3501 or function information based or the nucleotide sequence is recorded, and is usuable in the system of (23) or (27) or the method of (24) or (28)
  • a recording medium or storage device which is readable by a computer in which at least one amino acid sequence information selected from SEQ ID NOS:2502 to 7001 or function information based on the amino acid sequence is recorded, and is usable in the system of (25) or (29) or the method of (26) or (30).
  • the recording medium or storage device wherein is a computer readable recording medium selected from the group consisting of a floppy disc, a hard disc, a magnetic tape, a random access memory (RAM), a read only memory (ROM), a magneto-optic disc (MO), CD-ROM, CD-R, CD-RW, DVD-ROM, DVD-RAM and DVD-RW.
  • a computer readable recording medium selected from the group consisting of a floppy disc, a hard disc, a magnetic tape, a random access memory (RAM), a read only memory (ROM), a magneto-optic disc (MO), CD-ROM, CD-R, CD-RW, DVD-ROM, DVD-RAM and DVD-RW.
  • a polypepide having a homoserine dehydrogenase activity comprising an amino acid sequence in which the Val residue at the sequence in the amino acid sequence of homoserine dehydrogenase derived from a coryneform bacterium is replaced with amino acid residue other than a Val residue.
  • a polypeptide comprising an amino acid sequence in which the Val residue at the 59th position at the amino acid sequence as represented by SEQ ID NO:6957 is replaced with amino acid residue other than a Val residue.
  • a polypeptide having private carboxylase activity comprising an amino acid sequence in which the Pro residue at the 458th position in the amino acid sequence of private carboxylase derived from a coryneform bacterium is replaced with an amino acid residue other than a Pro residue.
  • a method for producing L-lysine comprising:
  • Coryneform bacterium according to (61), wherein the microorganism belonging to the genus Corynebacterium is selected from the group consisting of Corynebacterium glutamicum, Corynebacterium acetoacidophilum, Corynebacterium acetoglutamicum, Corynebacterium callunae, Corynebacterium herculis, Corynebacterium lilium, Corynebacterium melassecola, Corynebacterium thermoaminogenes, and Corynebacterium ammoniagenes.
  • a protein derived from a bacterium of a production strain of a coryneform bacterium which has been subjected to mutation breeding by a fermentation process so as to produce at least one compound selected from an amino acid, a nucleic acid, a vitamin, a saccharide, an organic acid, and analogues thereof, and
  • proteome which is a coined word by combining “protein” with “genome”, refers to a method for examining of a gene at the polypeptide level.
  • coryneform bacterium is a microorganism belonging to the genus Corynebacterium, the genus Brevibacterium, or the genus Microbacterinum.
  • coryneform bacteria as used herein means a microorganism belonging to the genus Corynebacterium, the genus Brevibacterium or the genus Microbacterinum as defined in Bergeys of Determination Bacteriology, 8:599 (1974)
  • Examples include Corynebacterium acetoacidophilum, Corynebacterium acetoglutamicum, Corynebacterium callunae, Corynebacterium glutamicum, Corynebacterium herculis, Corynebacterium lilium, Corynebacterium melassecola, Corynebacterium thermoaminogenes, Brevibacterium saccharolyticum, Brevibacterium immariophilum, Brevibacterium roseum, Brevibacterium thiogenitalis, Microbacterinum ammoniaphilum, and the like.
  • Corynebacterium acetoacidophilum ATCC 13870 Corynebacterium acetoglutamicum ATCC 15806, Corynebacterium callunae ATCC 15991, Corynebacterium glutamicum ATCC 13032, Corynebacterium glutamicum ATCC 13060, Corynebacterium glutamicum ATCC 13826 (prior genus and species: Brevibacterium flavum, or Corynebacterium lactofermentum ), Corynebacterium glutamicum ATCC 14020 (prior genus and species: Breribacterium divaricatum ), Corynebacterium glutamicum ATCC 13869 (prior genus and species: Brevibacterium lactofermentum ), Corynebacterium herculis ATCC 12868, Corynebacterium lilium ATCC 15990, Corynebacteriunm melassecola ATCC 17965, Corynebacterium thermo
  • Coryneform bacteria can be cultured by a conventional method.
  • Any of a natural medium and a synthetic medium can be used, so long as it is a medium suitable for efficient culturing of the microorganism, and it contains a carbon source, a nitrogen source, an inorganic salt, and the like which can be assimilated by the microorganism.
  • Corynebacterium glutamicum for example, a BY medium (7 g/l meat extract, 10 g/l peptone, 3 g/l sodium chloride, 5 g/l yeast extract, pH 7.2) containing 1% of glycine and the like can be used. The culturing is carried out at 25 to 35° C. overnight.
  • the cells are recovered from the culture by centrifugation. The resulting cells are washed with a washing solution.
  • washing solution examples include STE buffer (10.3% sucrose, 25 mol/l Tris hydrochloride, 25 mmol/l ethylenediaminetetraacetic acid (hereinafter referred to as “EDTA”), pH 8.0), and the like.
  • STE buffer (10.3% sucrose, 25 mol/l Tris hydrochloride, 25 mmol/l ethylenediaminetetraacetic acid (hereinafter referred to as “EDTA”), pH 8.0), and the like.
  • Genome DNA can be obtained from the washed cells according to a conventional method for obtaining genome DNA, namely, lysing the cell wall of the cells using a lysozyme and a surfactant (SDS, etc.), eliminating proteins and the like using a phenol solution and a phenol/chloroform solution, and then precipitating the genome DNA with ethanol or the likes Specifically, the following method can be illustrated.
  • SDS surfactant
  • the washed cells are suspended in a washing solution containing 5 to 20 mg/l lysozyme. After shaking, 5 to 20% SDS is added to lyse the cells. In usual, shaking is gently performed at 25 to 40° C. for 30 minutes to 2 hours. After shaking, the suspension is maintained at 60 to 70° C. for 5 to 15 minutes for the lysis.
  • the suspension is cooled to ordinary temperature, and 5 to 20 ml of Tris-neutralized phenol is added thereto, followed by gently shaking at room temperature for 15 to 45 minutes.
  • the genome bNk is dissolved again in a buffer containing 0.01 to 0.04 ng/ml RNase.
  • a buffer containing 0.01 to 0.04 ng/ml RNase.
  • TR buffer 10 mmol/l Tris hydrochloride, 1 mol/l EDTA, pH 8.0
  • the resultant solution is maintained at 25 to 40° C. for 20 to 50 minutes and then extracted successively with phenol, phenol/chloroform and chloroform as in the above case.
  • a method for produce a genome DNA library using the genome DNA of the coryneform bacteria prepared in the above (1) include a method described in Molecular Cloning, A laboratory Manual, Second Edition (1989) (hereinafter referred to as “ Molecular Cloning, 2nd ed.”). In particular, the following method can be exemplified to prepare a genome DNA library appropriately usable in determining the full nucleotide sequence by the shotgun method.
  • a buffer such as TE buffer or the like
  • a sonicator Yamato Powersonic Model SO
  • the treatment with the sonicator is performed at an output of 20 continuously for 5 seconds.
  • the resulting genome DN fragments are blunt-ended using DNA blunting kit (manufactured by Takara Shuzo) or the like.
  • the blunt-ended genome fragments are fractionated by agarose gel or polyacrylamide gel electrophoresis and genome fragments of 1 to 2 kb are cut out from the gel.
  • a buffer for eluting DNA such as MG elution buffer (0.5 mol/l amonium acetate, 10 mmol/l magnesium acetate, 1 mmol/l EDTA, 0.1% SDS) or the like, is added, followed by shaking at 25 to 40° C. overnight to elute DNA.
  • MG elution buffer 0.5 mol/l amonium acetate, 10 mmol/l magnesium acetate, 1 mmol/l EDTA, 0.1% SDS
  • the resulting DNA eluate is treated with phenol/chloroform and then precipitated with ethanol to obtain a genome library insert.
  • This insert is ligated into a suitable vector, such as pUC18 SmaI/BAP (manufactured by Amersham Pharmacia Biotech) or the like, using T4 ligase (manufactured by Takara Shuzo) or the like.
  • a suitable vector such as pUC18 SmaI/BAP (manufactured by Amersham Pharmacia Biotech) or the like, using T4 ligase (manufactured by Takara Shuzo) or the like.
  • T4 ligase manufactured by Takara Shuzo
  • Escherichia coli is transformed in accordance with a conventional method using 0.5 to 2 ⁇ l of the ligation solution.
  • the transformation method include the electroporation method using ELECTRO MAX DH10B (manufactured by Life Technologies) for Escherichia coli.
  • the electroporation method can be carried out under the conditions as described in the manufacturer's instructions.
  • the transformed Escherichia coli is spread on a suitable selection medium containing agar, for example, LB plate medium containing 10 to 100 mg/l ampicillin (LB medium (10 g/l bactotrypton, 5 g/l yeast extract, 10 g/l sodium chloride, pH 7.0) containing 1.6% of agar) when pUC18 is used as the cloning vector, and cultured therein.
  • a suitable selection medium containing agar, for example, LB plate medium containing 10 to 100 mg/l ampicillin (LB medium (10 g/l bactotrypton, 5 g/l yeast extract, 10 g/l sodium chloride, pH 7.0) containing 1.6% of agar) when pUC18 is used as the cloning vector, and cultured therein.
  • the transformant can be obtained as colonies formed on the plate medium. In this step, it is possible to select the transformant having the recombinant DNA containing the genome DNA as white colonies by adding X-gal and IPTG (isopropyl- ⁇ -thiogalactopyranoside) to the plate medium.
  • X-gal and IPTG isopropyl- ⁇ -thiogalactopyranoside
  • the transformant is allowed to stand for culturing in a 96-well titer plate to which 0.05 ml of the LB medium containing 0.1 mg/ml of ampicillin has been added in each well.
  • the resulting culture can be used in an experiment of (4) described below.
  • the culture solution can be stored at ⁇ 80° C. by adding 0.05 ml per well of the LB medium containing 20% glycerol to the culture solution, followed by mixing, and the stored culture solution can be used at any time.
  • the genome DNA (0.l mg) of the coryneform bacteria prepared in the above (1) is partially digested with a restriction enzyme, such as Sau3AI or the like, and then ultracentrifuged (26,000 rpm, 18 hours, 20° C.) under a 10 to 40% sucrose density gradient using a 10% sucrose buffer (1 mol/l NaCl, 20 mmol/l Tris hydrochloride, 5 mnol/l EDTA, 10% sucrose, pH 8.0) and a 40% sucrose buffer (elevating the concentration of the 10% sucrose buffer to 40%).
  • a restriction enzyme such as Sau3AI or the like
  • the thus separated solution is fractionated into tubes in 1 ml per each tube. After confirming the DNA fragment size of each fraction by agarose gel electrophoresis, a fraction rich in DNA fragments of about 40 kb is precipitated with ethanol.
  • the resulting DNA fragment is ligated to a cosmid vector having a cohesive end which can be ligated to the fragment.
  • the partially digested product can be ligated to, for example, the BamRI site of superCos1 (manufactured by Stratagene) in accordance with the manufacture's instructions.
  • the resulting ligation product is packaged using a packaging extract which can be prepared by a method described in Molecular Cloning, 2nd ed. and then used in transforming Escherichia coli. More specifically, the ligation product is packaged using, for example, a commercially available packaging extract, Gigapack III Gold Packaging Extract (manufactured by Stratagene) in accordance with the manufacture's instructions and then introduced into Escherichia coli XL-1-BlueMR (manufactured by Stratagene) or the like.
  • a packaging extract which can be prepared by a method described in Molecular Cloning, 2nd ed. and then used in transforming Escherichia coli. More specifically, the ligation product is packaged using, for example, a commercially available packaging extract, Gigapack III Gold Packaging Extract (manufactured by Stratagene) in accordance with the manufacture's instructions and then introduced into Escherichia coli XL-1-BlueMR (manufactured by Stratagen
  • the thus transformed Escherichia coli is spread on an LB plate medium containing ampicillin, and cultured therein.
  • the transformant can be obtained as colonies formed on the plate medium.
  • the transformant is subjected to standing culture in a 96-well titer plate to which 0.05 ml of the LB medium containing 0.1 mg/ml ampicillin has been added.
  • the resulting culture can be employed in an experiment of (4) described below. Also, the culture solution can be stored at ⁇ 80° C. by adding 0.05 ml per well of the LB medium containing 20% glycerol to the culture solution, followed by mixing, and the stored culture solution can be used at any time.
  • the template used in the whole genome shotgun method can be prepared by PCR using the library prepared in the above (2) ( DNA Research, 5:1-9 (1998)).
  • the template can be prepared as follows.
  • the clone derived from the whole genome shotgun library is inoculated by using a replicator (manufactured by CENETIX) into each well of a 96-well plate to which 0.08 ml per well of the LB medium containing 0.1 mg/ml ampicillin has been added, followed by stationarily culturing at 37° C. overnight.
  • a replicator manufactured by CENETIX
  • the culture solution is transported, using a copy plate (manufactured by Tokken), into each well of a 96-well reaction plate (manufactured by PE Riosystems) to which 0.025 ml per well of a PCR reaction solution has been added using TaKaRa Ex Taq (manufactured by Takara Shuzo).
  • PCP is carried out in accordance with the protocol by Makino et al. ( DNA Research, 5:1-9 (1998)) using GeneAmp PCR System 9700 (manufactured by PE Biosystems) to amplify the inserted fragments.
  • the excessive primers and nucleotides are eliminated using a kit for purifying a PCR product, and the product is used as the template in the sequencing reaction.
  • the double-stranded DNA plasmid used as the template can be obtained by the following method.
  • the clone derived from the whole genome shotgun library is inoculated into each well of a 24- or 96-well plate to which 1.5 ml per well of a 2 ⁇ YT medium (16 g/l bactotrypton, 10 g/l yeast extract, 5 g/l sodium chloride, pH 7.0) containing 0.05 mg/ml ampicillin has been added, followed by culturing under shaking at 37° C. overnight.
  • a 2 ⁇ YT medium (16 g/l bactotrypton, 10 g/l yeast extract, 5 g/l sodium chloride, pH 7.0) containing 0.05 mg/ml ampicillin has been added, followed by culturing under shaking at 37° C. overnight.
  • the double-stranded DNA plasmid can be prepared from the culture solution using an automatic plasmid preparing machine K AO PI-SO (manufactured by Kurabo Industries), a multiscreen (manufactured by Millipore) or the like, according to each protocol.
  • K AO PI-SO manufactured by Kurabo Industries
  • a multiscreen manufactured by Millipore
  • Biomek 2000 manufactured by Beckman Coulter and the like can be used.
  • the resulting purified double-stranded DNA plasmad is dissolved in water to give a concentration of about 0.1 mg/ml. Then, it can be used as the template in sequencing.
  • the sequencing reaction can be carried out according to a commercially available sequence kit or the like. A specific method is exemplified below.
  • a dye terminator sequencing reaction (35 to 55 cycles) is carried out using this reaction solution and Gent PCR System 9700 (manufactured by PE Biosystems) or the like.
  • the cycle parameter can be determined in accordance with a commercially available kit, for example, the manufacturer's instructions attached with ABI PRISM Big Dye Terminator Cycle Sequencing Ready Reaction Kit.
  • the sample can be purified using a commercially available product, such as Multi Screen HV plate (manufactured by Millipore) or the like, according to the manufacture's instructions.
  • a commercially available product such as Multi Screen HV plate (manufactured by Millipore) or the like, according to the manufacture's instructions.
  • the thus purified reaction product is precipitated with ethanol, dried and then used for the analysis.
  • the dried reaction product can be stored in the dark at ⁇ 30° C. and the stored reaction product can be used at any time.
  • the dried reaction product can be analyzed using a commercially available sequencer and an analyzer according to the manufacture's instructions
  • Examples of the commercially available sequencer include ABI PRISM 377 DNA Sequencer (manufactured by PP Biosystems).
  • Example of the analyzer include ABI PRISM 3700 DNA Analyzer (manufactured by PE Biosystems).
  • a software such as phred (The University of Washington) or the like, can be used as base call for use in analyzing the sequence information obtained in the above (4).
  • a software such as Cross_Match (The University of Washington) or SPS Cross_Match (manufactured by Southwest Parallel Software) or the like, can be used to mask the vector sequence information.
  • a software such as phrap (The University of Washington), SPS phrap (manufactured by Southwest Parallel Software) or the like, can be used.
  • Contig obtained by the assembly can be analyzed using a graphical editor such as consed (The University of Washington) or the like.
  • each of the cosmids in the cosmid library constructed in the above (3) is prepared in the same manner as in the preparation of the double-stranded DNA plasmid described in the above (4-1).
  • the nucleotide sequence at the end of the insert fragment of the cosmid is determined using a commercially available kit, such as ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction Kit (manufactured by PE Biosystems) according to the manufacture's instructions.
  • the sequence in the region which cannot be covered with the contigs (gap part) can be determined by the following method.
  • Clones containing sequences positioned at the ends of the contigs are selected. Among these, a clone wherein only one end of the inserted fragment has been determined is selected and the sequence at the opposite end of the inserted fragment is determined.
  • a shotgun library clone or a cosmid clone derived therefrom containing the sequences at the respective ends of the inserted fragments in the two contigs is identified and the full nucleotide sequence of the inserted fragment of the clone is determined.
  • the nucleotide sequence of the gap part can be determined.
  • primers complementary to the end sequences of the two different contigs are prepared and the DNA fragment in the gap part is amplified. Then, sequencing is performed by the primer walking method using the amplified DNA fragment as a template or by the shotgun method in which the sequence of a shotgun clone prepared from the amplified DNA fragment is determined. Thus, the nucleotide sequence of the above-described region can be determined.
  • primers are synthesized using AUTOFINISH function and NAVIGATING function of consed (The University of Washington), and the sequence is determined by the primer walking method to improve the sequence accuracy.
  • Examples of the thus determined nucleotide sequence of the full genome include the full nucleotide sequence of genome of Coryebacterium glutamicum ATCC 13032 represented by SEQ ID NO:1.
  • a nucleotide sequence of a polynucleotide having a homology of 80% or more with the full nucleotida sequence of Corynebacterium glutamicum ATCC 13032 represented by SEQ ID NO:1 as determined above can also be determined using the nucleotide sequence represented by SEQ ID NO:1, and the polynucleotide having at nucleotide sequence having a homology of 80% or more with the nucleotide sequence represented by SEQ ID NO:1 of the present invention is within the scope of the present invention.
  • polynucleotide having a nucleotide sequence having a homology of 80% or more with the nucleotide sequence represented by SEQ ID NO:1 of the present invention is a polynucleotide in which a full nucleotide sequence of the chromosome DNA can be determined using as a primer an oligonucleotide composed of continuous 5 to 50 nucleotides in the nucleotide sequence represented by SEQ ID NO:1, for example, according to PCR using the chromosome DNA as a template
  • a particularly preferred primer in determination of the full nucleotide sequence is an oligonucleotide having nucleotide sequences which are positioned at the interval of about 300 to 500 bp, and among such oligonucleotides, an oligonucleotide having a nucleotide sequence selected from DNAs encoding a protein relating to a main metabolic pathway is particularly preferred.
  • the polynucleotide in which the full nucleotide seuence of the chromosome DNA can be determined using the oligonucleotide includes polynucleotides constituting a chromosome DNA derived from a microorganism belonging to coryneform bacteria.
  • a polynucleotide is preferably a polynucleotide constituting chromosome DNA derived from a microorganism belonging to the genus Corynebacterium, more preferably a polynucleotide constituting a chromosome DNA of Corynebacterium glutamicum.
  • the ORF means a continuous region in the nucleotide sequence of mRNA which can be translated as an amino acid sequence to mature to a protein.
  • a region of the DNA coding for the ORF of mRNA is also called ORF.
  • the expression modulating fragment (hereinafter referred to as “EMF”) is used herein to define a series of polynucleotide fragments which modulate the expression of the ORF or another sequence ligated operatably thereto.
  • the expression “modulate the expression of a sequence ligated operatably” is used herein to refer to changes in the expression of a sequence due to the presence of the EMF.
  • Examples of the EMF include a promoter, an operator, an enhancer, a silencer, a ribosome-binding sequence, a transcriptional termination sequence, and the like.
  • an EMF is usually present in an intergenic segment (a fragment positioned between two genes; about 10 to 200 nucleotides in length).
  • an EMF is frequently present in an intergenic segment of 10 nucleotides or longer. It is also possible to determine or discover the presence of an EMF by using known EMF sequences as a target sequence or a target structural motif (or a target motif) using an appropriate software or comparator, such as FASTA ( Proc. Natl. Acad. Sci. USA, 85:2444-48 (1988)), BLAST ( J. Mbl. Biol., 215:403-410 (1990)) or the like. Also, it can be identified and evaluated using a known EMF-capturing vector (for example, pKK232-8; manufactured by Amersham Pharmacia Biotech).
  • FASTA Proc. Natl. Acad. Sci. USA, 85:2444-48 (1988)
  • BLAST J. Mbl. Biol., 215:403-410 (1990)
  • EMF-capturing vector for example, pKK232-8; manufactured by Amersham Pharmacia Biotech.
  • target sequence is used herein to refer to a nucleotide sequence composed of 6 or more nucleotides, an amino acid sequence composed of 2 or more amino acids, or a nucleotide sequence encoding this amino acid sequence composed of 2 or more amino acids. A longer target sequence appears at random in a data base at the lower possibility.
  • the target sequence is preferably about 10 to 100 amino acid residues or about 30 to 300 nucleotide residues.
  • target structural motif or “target motif” is used herein to refer to a sequence or a combination of sequences selected optionally and reasonably. Such a motif is selected on the basis of the three-dimensional structure formed by the folding of a polypeptide by means known to one of ordinary skill in the art. Various motives are known.
  • Examples of the target motif of a polypeptide include, but are not limited to, an enzyme activity site, a protein-protein interaction site, a signal sequence, and the like.
  • Examples of the target motif of a nucleic acid include a promoter sequence, a transcriptional regulatory factor binding sequence, a hair pin structure, and the like.
  • Examples of highly useful EMF include a high-expression promoter, an inducible-expression promoter, and the like.
  • Such an EMF can be obtained by positionally determining the nucleotide sequence of a gene which is known or expected as achieving high expression (for example, ribosomal RNA gene:GenBank Accession No. M16175 or Z46753) or a gene showing a desired induction pattern (for example, isocitrate lyase gene induced by acetic acid:Japanese Published Unexamined Patent Application No.
  • the ORF can be identified by extracting characteristics common to individual ORFs, constructing a general model based on these characteristics, and measuring the conformity of the subject sequence with the model.
  • a software such as GeneMark (Nuc. Acids. Res., 22:4756-67 (1994):manufactured by GenePro)), GeneMark.hrm (manufactured by GenePro), GeneHacker ( Protein, Nucleic Acid and Enzyme, 42:3001-07 (1997)), Glimmer ( Nuc. Acids. Res., 26:544-548 (1998):manufactured by The Institute of Genomic Research), or the like, can be used.
  • the default (initial setting) parameters are usually used, though the parameters can be optionally changed.
  • a computer such as UNIX, PC, Macintosh, or the like, can be used.
  • Examples of the ORF determined by the method of the present invention include ORFs having the nucleotide sequences represented by SEQ ID NOS:2 to 3501 present in the genome of Corynebacterium glutamicum as represented by SEQ ID NO:1.
  • polypeptides having the amino acid sequences represented by SEQ ID NOS.,3502 to 7001 are encoded.
  • the function of an ORF can be determined by comparing the identified amino acid sequence of the ORF with known homologous sequences using a homology searching software or comparator, such as BLAST, FAST, Smith & Waterman ( Meth. Enzym., 164:765 (1988)) or the like on an amino acid data base, such as Swith-Prot, PIR, GenBank-nr-aa, GenPept constituted by protein-encoding domains derived from GenBank data base, OWL or the like.
  • a homology searching software or comparator such as BLAST, FAST, Smith & Waterman ( Meth. Enzym., 164:765 (1988)) or the like
  • amino acid data base such as Swith-Prot, PIR, GenBank-nr-aa, GenPept constituted by protein-encoding domains derived from GenBank data base, OWL or the like.
  • polypeptides each having 10 amino acids are different in the positions of 3 amino acids
  • these polypeptides have an identity of 70% with each other.
  • one of the different 3 amino acids is analogue (for example, leonine and isoleucine)
  • these polypeptides have a similarity of 80%.
  • Table 1 shows the registration numbers in known data bases of sequences which are judged as having the highest similarity with the nucleotide sequence of the ORF derived from Corynebacterium glutamicum ATCC 13032, genes of these sequences, functions of these genes, and identities thereof compared with known amino acid translation sequences.
  • coryneform bacteria are industrially highly useful microorganisms, many of the identified genes are industrially useful.
  • the ORF corresponding to the :microorganism is prepared and obtained according to the general method as disclosed in Molecular Cloning, 2nd ed. or the like. Specifically, an oligonucleotide having a nucleotide sequence adjacent to the ORF is synthesized, and the ORF can be isolated and obtained using the oligonucleotide as a primer and a chromosome DNA derived from coryneform bacteria as a template according to the general PCR cloning technique.
  • obtained ORF sequences include polynucleotides comprising the nucleotide sequence represented by any one of SEQ ID NOS:2 to 3501.
  • the ORF or primer can be prepared using a polypeptide synthesizer based on the above sequence information.
  • polynucleotide of the present invention examples include a polynucleotide containing the nucleotide sequence of the ORBF obtained in the above, and a polynucleotide which hybridizes with the polynucleotide under stringent conditions.
  • the polynucleotide of the present invention can be a single-stranded DNA, a double-stranded DNA and a single-stranded RNA, though it is not limited thereto.
  • the polynucleotide which hybridizes with the polynucleotide containing the nucleotide sequence of the ORP obtained in the above under stringent conditions includes a degenerated mutant of the ORF.
  • a degenerated mutant is a polynucleotide fragment having a nucleotide sequence which is different from the sequence of the ORF of the present invention which encodes the same amino acid sequence by degeneracy of a gene code.
  • Specific examples include a polynucleotide comprising the nucleotide sequence represented by any one of SEQ ID NOS:2 to 3431, and a polynucleotide which hybridizes with the polynucleotide under stringent conditions.
  • a polynucleotide which hybridizes under stringent conditions is a polynucleotide obtained by colony hybridization, plaque hybridization, Southern blot hybridization or the like using, as a probe, the polynucleotide having the nucleotide sequence of the ORF identified in the above.
  • Specific examples include a polynucleotide which can be identified by carrying out hybridization at 65° C. in the presence of 0.7-1.0 M NaCl using a filter on which a polynucleotide prepared from colonies or plaques is immobilized, and then washing the filter with 0.1 ⁇ to 2 ⁇ SSC solution (the composition of 1 ⁇ SSC contains 150 mM sodium chloride and 15 mM sodium citrate) at 65° C.
  • the hybridization can be carried out in accordance with known methods described in, for example, Molecular Cloning, 2nd ed., Current Protocols in Molecular Biology, DNA Cloning 1:Core Techniques, A Practical Approach, Second Edition, Oxford University (1995) or the like.
  • Specific examples of the polynucleotide which can be hybridized include a DNA having a homology of 60% or more, preferably 80% or more, and particularly preferably 95% or more, with the nucleotide sequence represented by any one of SEQ ID NO:2 to 3431 when calculated using default (initial setting) parameters of a homology searching software, such as BLAST, FASTA, Smith-Waterman or the like.
  • the polynucleotide of the present invention includes a polynucleotide encoding a polypeptide comprising the amino acid sequence represented by any one of SEQ ID NOS:3502 to 6931 and a polynucleotide which hybridizes with the polynucleotide under stringent conditions.
  • the polynucleotide of the present invention includes a polynucleotide which is present in the 51 upstream or 3′ downstream region of a polynucleotide comprising the nucleotide sequence of any one of SEQ ID NOS:2 to 3431 in a polynucleotide comprising the nucleotide sequence represented by SEQ ID NO:1, and has an activity of regulating an expression of a polypeptide encoded by the polynucleotide.
  • polynucleotide having an activity of regulating an expression of a polypeptide encoded by the polynucleotide includes a polynucleotide encoding the above described EMF, such as a promoter, an operator, an enhancer, a silencer, a ribosome-binding sequence, a transcriptional termination sequence, and the like.
  • the primer used for obtaining the ORF according to the above PCR cloning technique includes an oligonucleotide comprising a sequence which is the same as a sequence of 10 to 200 continuous nucleotides in the nucleotide sequence of the ORF and an adjacent region or an oligonucleotide comprising a sequence which is complementary to the oligonucleotide.
  • oligonucleotide comprising a sequence which is the same as a sequence of 10 to 200 continuous nucleotides of the nucleotide sequence represented by any one of SEQ ID NOS:1 to 3431, and an oligonucleotide comprising a sequence complementary to the oligonucleotide comprising a sequence of at least 10 to 20 continuous nucleotide of any one of SEQ ID NOS:1 to 3431.
  • T m melting temperature
  • the oligonucleotide of the present invention includes an oligonucleotide comprising a sequence which is the same as 10 to 200 continuous nucleotides of the nucleotide sequence represented by any one of SEQ ID NOS:1 to 3431 or an oligonucleotide comprising a sequence complementary to the oligonucleotide.
  • analogues of these oligonucleotides are also provided by the present invention and are useful in the methods described herein.
  • analogous oligonucleotides include analogous oligonucleotides in which a phosphodiester bond in an oligonucleotide is converted to a phosphorothioate bond, analogous oligonucleotides in which a phosphodiester bond in an oligonucleotide is converted to an N3′-P5′ phosphoamidate bond, analogous oligonucleotides in which ribosome and a phosphodiester bond in an oligonucleotide is converted to a peptide nucleic acid bond, analogous oligonucleotides in which uric in an oligonucleotide is replaced with C-5 propynyluracil, analogous oligonucleotides in which uric in an oligonucleotide is replaced with C-5 thiazoluracil, analogous oligonucleotides in which cytosine in an oligonucle
  • oligonucleotides and analogous oligonucleotides of the present invention can be used as probes for hybridization and antisense nucleic acids described below in addition to as primers.
  • Examples of a primer for the antisense nucleic acid techniques known in the art include an oligonucleotide which hybridizes the oligonucleotide of the present invention under stringent conditions and has an activity regulating expression of the polypeptide encoded by the polynucleotide, in addition to the above oligonucleotide.
  • genes can be mutated randomly by the mutagenic method using the above-described mutagen, all genes encoding respective isozymes having similar properties relating to the metabolism of intermediates cannot be mutated. In the mutagenic method using a mutagen, genes are mutated randomly. Accordingly, harmful mutations worsening culture characteristics, such as delay in growth, accelerated foaming, and the like, might be imparted at a great frequency, in a random manner.
  • an accurate number and sequence information of the target isozymes in coryneform bacteria can be obtained based on the ORF data obtained in the above item 2.
  • sequence information all of the target isozyme genes can be mutated into genes having the desired properties by, for example, the site-specific mutagenesis method described in Molecular Cloning, 2nd ed. to obtain useful mutants having elevated productivity of useful substances.
  • the functional information of ORF derived from coryneform bacteria as identified by the method of above item 2 is arranged.
  • the term “arranged” means that the ORF is classified based on the biosynthesis pathway of a substance or the signal transmission pathway to which the ORF belongs using known information according to the functional information.
  • the arranged ORF sequence information is compared with enzymes on the biosynthesis pathways or signal transmission pathways of other known organisms.
  • the resulting information is combined with known data on coryneform bacteria.
  • a useful mutant When the thus clarified pathway is judged as important in the synthesis of a useful product, a useful mutant can be obtained by selecting a mutant wherein this pathway has been strengthened. Also, when the thus clarified pathway is judged as not important in the biosynthesis of the target useful product, a useful mutant can be obtained by selecting a mutant wherein the utilization frequency of this pathway is lowered.
  • mutation points contained in production strains can be identified by comparing desired sequences of the genome DNA of the production strains obtained from coryneform bacteria by the mutagenic technique with the nucleotide sequences of the corresponding genome DNA and ORF derived from coryneform bacteria determined by the methods of the above items 1 and 2 and analyzing them
  • the mutation points thus identified can be introduced into a wild strain of coryneform bacteria or a production strain free of the mutation. Then, it is examined whether or not any positive effect can be achieved on the production.
  • a mutation Ala2l3Thr in glucose-6-phosphate dehydrogenase was specified as an effective mutation relating to the production of lysine by detecting glucose-6-phosphate dehydrogenase gene zwf of the B-6 strain.
  • the lysine-productivity of Corynebacterium glutamicum was improved by replacing the base at the 932-position of aspartokinase gene lysC of the Corynebacterium glutamicum ATCC 13032 genome with cytosine to thereby replace threonine at the 311-position by isoleucine, which indicates that this mutation is an effective mutation contributing to the production of lysine.
  • the mutation possessed by the lysine-producing strain is returned to the sequence of a wild type strain by the gene replacement method and whether or not it has a negative influence on the lysine productivity.
  • the amino acid replacement mutation Val59Ala possessed by hom of the lysine-producing B-6 strain was returned to a wild type amino acid sequence, the lysine productivity was lowered in comparison with the B-6 strain.
  • this mutation is an effective mutation contributing to the production of lysine.
  • Effective mutation points can be more efficiently and comprehensively extracted by combining, if needed, the DNA array analysis or proteome analysis described below.
  • mutagenesis methods have largely contributed to the progress of the fermentation industry, they suffer from a serious problem of multiple, random introduction of mutations into every part of the chromosome. Since many mutations are accumulated in a single chromosome each time a strain is improved, a production strain obtained by the random mutation and selecting is generally inferior in properties (for example, showing poor growth, delayed consumption of saccharides, and poor resistance to stresses such as temperature and oxygen) to a wild type strain, which brings about troubles such as failing to establish a sufficiently elevated productivity, being frequently contaminated with miscellaneous bacteria, requiring troublesome procedures in culture maintenance, and the like, and, in its turn, elevating the production cost in practice. In addition, the improvement in the productivity is based on random mutations and thus the mechanism thereof is unclear. Therefore, it is very difficult to plan a rational breeding strategy for the subsequent improvement in the productivity.
  • a useful mutant can be constructed in the following manner.
  • One of the mutation points is incorporated into a wild type strain of coryneform bacteria. Then, it is examined whether or not a positive effect is established on the production. When a positive effect is obtained, the mutation point is saved. When no effect is obtained, the mutation point is removed. Subsequently, only a strain having the effective mutation point is used as the parent strain, and the same procedure is repeated. In general, the effectiveness of a mutation positioned upstream cannot be clearly evaluated in some cases when there is a rate-determining point in the downstream of a biosynthesis pathway. It is therefore preferred to successively evaluate mutation points upward from downstream.
  • a lysine-producing mutant B-6 ( Appl. Microbiol. Biotechnol., 32:262-273 (1989)), which is obtained by multiple rounds of random mutagenesis from a wild type strain Corynebacterium glutamicum ATCC 13032, enables lysine fermentation to be performed at a temperature between 30 and 34° C. but shows lowered growth and lysine productivity at a temperature exceeding 34° C. Therefore, the fermentation temperature should be maintained at 34° C. or lower.
  • the production strain described in the above item 5 which is obtained by reconstituting effective mutations relating to lysine production, can achieve a productivity at 40 to 42° C. equal or superior to the result obtained by culturing at 30 to 34° C. Therefore, this strain is industrially advantageous since it can save the load of cooling during the fermentation.
  • a production strain capable of conducting fermentation production at a high temperature exceeding 43° C. can be obtained by reconstituting useful mutations in a microorganism belonging to the genus Corynebacterium which can grow at high temperature exceeding 43° C.
  • the microorganism capable of growing at a high temperature exceeding 43° C. include Corynebacterium thermoaminogenes, such as Corynebacterium thexmoaminogenes FERM 9244, PERM 9245, FERM 9246 and FERM 9247
  • a strain having a further improved productivity of the target product can be obtained using the thus reconstructed strain as the parent strain and further breeding it using the conventional mutagenesis method, the gene amplification method, the gene replacement method using the recombinant DNA technique, the transduction method or the cell fusion method.
  • the microorganism of the present invention includes, but is not limited to, a mutant, a cell fusion strain, a transformant, a transductant or a recombinant strain constructed by using recombinant DNA techniques, so long as it is a producing strain obtained via the step of accumulating at least two effective mutations in a coryneform bacteria in the course of breeding.
  • the breeding method as described above is applicable to microorganisms, other than coryneform bacteria, which have industrially advantageous properties (for example, microorganisms capable of quickly utilizing less expensive carbon sources, microorganisms capable of growing at higher temperatures).
  • a polynucleotide array can be produced using the polynucleotide or oligonucleotide of the present invention obtained in the above items 1 and 2.
  • Examples include a polynucleotide array comprising a solid support to which at least one of a polynucleotide it comprising the nucleotide sequence represented by SEQ ID NOS:2 to 3501, a polynucleotide which hybridizes with the polynucleotide under stringent conditions, and a polynucleotide comprising 10 to 200 continuous nucleotides in the nucleotide sequence of the polynucleotide is adhered; and a polynucleotide array comprising a solid support to which at least one of a polynucleotide encoding a polypeptide comprising the amino acid sequence represented by any one of SEQ ID NOS:3502 to 7001, a polynucleotide which hybridizes with the polynucleotide under stringent conditions, and a polynucleotide comprising 10 to 200 continuous bases in the nucleotide sequences of the polynucleotides is adhered
  • Polynucleotide arrays of the present invention include substrates known in the art, such as a DNA chip, a DNA microarray and a DNA macroarray, and the like, and comprises a solid support and plural polynucleotides or fragments thereof which are adhered to the surface of the solid support.
  • Examples of the solid support include a glass plate, a nylon membrane, and the like.
  • the polynucleotides or fragments thereof adhered to the surface of the solid support can be adhered to the surface of the solid support using the general technique for preparing arrays. Namely, a method in which they are adhered to a chemically surface-treated solid support, for example, to which a polycation such as polylysine or the like has been adhered ( Nat. Genet., 21:15-19 (1999)).
  • the chemically surface-treated supports are commercially available and the commercially available solid product can be used as the solid support of the polynucleotide array according to the present invention.
  • the polynucleotides or oligonucleotides adhered to the solid support the polynucleotides and oligonucleotides of the present invention obtained in the above items 1 and 2 can be used.
  • Apparatus for achieving a high fixation density such as an arrayer robot or the like, is commercially available from Takara Shuzo (GMS417 Arrayer), and the commercially available product can be used.
  • the oligonucleotides of the present invention can be synthesized directly on the solid support by the photolithography method or the like ( Nat. Genet., 21:20-24 (1999)).
  • a linker having a protective group which can be removed by light irradiation is first adhered to a solid support, such as a slide glass or the like. Then, it is irradiated with light through a mask (a photolithograph mask) permeating light exclusively at a definite part of the adhesion part.
  • a mask a photolithograph mask
  • oligonucleotides each having a desired sequence, different from each other can be synthesized in respective parts.
  • the oligonucleotides to be synthesized have a length of 10 to 30 nucleotides.
  • the gene derived from a mutant of coryneform bacteria or the examined gene include a gene relating to biosynthesis of at least one selected from amino acids, nucleic acids, vitamins, saccharides, organic acids, and analogues thereof.
  • SNP single nucleotide polymorphism
  • the nucleic acid molecule (DNA, RNA) derived from the coryneform bacteria can be obtained according to the general method described in Molecular Cloning, 2nd ed. or the like.
  • MRNA derived from Corynebacterium glutamicum can also be obtained by the method of Bormann et al. ( Molecular Microbiology, 6:317-326 (1992)) or the like.
  • ribosomal RNA (rRNA) is usually obtained in large excess in addition to the target MRNA, the analysis is not seriously disturbed thereby.
  • the resulting nucleic acid molecule derived from coryneform bacteria is labeled. Labeling can be carried out according to a method using a fluorescent dye, a method using a radioisotope or the like.
  • Specific examples include a labeling method in which psoralen-biotin is crosslinked with RNA extracted from a microorganism and, after hybridization reaction, a fluorescent dye having streptoavidin bound thereto is bound to the biotin moiety ( Nat. Biotechnol., 16:45-48 (1998)); a labeling method in which a reverse transcription reaction is carried out using RNA extracted from a microorganism as a template and random primers as primers, and dUTP having a fluorescent dye (for example, Cy3, Cy5) (manufactured by Amersham Pharmacia Biotech) is incorporated into CDNA ( Proc. Natl. Acad. Sci. USA, 96:12833-38 (1999)); and the like.
  • the labeling specificity can be improved by replacing the random primers by sequences complementary to the 3′-end of ORF ( J. Bacteriol., 181:6425-40 (1999)).
  • the hybridization and subsequent washing can be carried out by the general method ( Nat. Bioctechnol., 14:1675-80 (1996), or the like).
  • the hybridization intensity is measured depending on the hybridization amount of the nucleic acid molecule used in the labeling.
  • the mutation point can be identified and the expression amount of the gene can be calculated.
  • the hybridization intensity can be measured by visualizing the fluorescent signal, radioactivity, luminescence dose, and the like, using a laser confocal microscope, a CCD camera, a radiation imaging device (for example, STORM manufactured by Amersham Pharmacia Biotech), and the like, and then quantifying the thus visualized data.
  • a polynucleotide array on a solid support can also be analyzed and quantified using a commercially available apparatus, such as GMS418 Array Scanner (manufactured by Takara Shuzo) or the like.
  • the gene expression amount can be analyzed using a commercially available software (for example, ImaGene manufactured by Takara Shuzo; Array Gauge manufactured by Fuji Photo Film; ImageQuant manufactured by Amersham Pharmacia Biotech, or the like).
  • a commercially available software for example, ImaGene manufactured by Takara Shuzo; Array Gauge manufactured by Fuji Photo Film; ImageQuant manufactured by Amersham Pharmacia Biotech, or the like.
  • a fluctuation in the expression amount of a specific gene can be monitored using a nucleic acid molecule obtained in the time course of culture as the nucleic acid molecule derived from coryneform bacteria.
  • the culture conditions can be optimized by analyzing the fluctuation.
  • the expression profile of the microorganism at the total gene level (namely, which genes among a great number of genes encoded by the genome have been expressed and the expression ratio thereof) can be determined using a nucleic acid molecule having the sequences of many genes determined from the full genome sequence of the microorganism.
  • the expression amount of the genes determined by the full genome sequence can be analyzed and, in its turn, the biological conditions of the microorganism can be recognized as the expression pattern at the full gene level.
  • This detection can be carried out by a method in which an examined gene which is present in an organism other than coryneform bacteria is used instead of the nucleic acid molecule derived from coryneform bacteria used in the above identification/analysis method of (1).
  • recording medium or storage device which is readable by a computer means a recording medium or storage medium which can be directly readout and accessed with a computer.
  • Examples include magnetic recording media, such as a floppy disk, a hard disk, a magnetic tape, and the like; optical recording media, such as CD-ROM, CD-R, CD-RW, DVD-ROM, DVD-RAM, DVD-RW, and the like; electric recording media, such as RAM, ROM, and the like; and hybrids in these categories (for example, magnetic/optical recording media, such as MO and the like).
  • Instruments for recording or inputting in or on the recording medium or instruments or devices for reading out the information in the recording medium can be appropriately selected, depending on the type of the recording medium and the access device utilized.
  • various data processing programs, software, comparator and formats are used for recording and utilizing the polynucleotide sequence information or the like of the present invention in the recording medium.
  • the information can be expressed in the form of a binary file, a text file or an ASCII file formatted with commercially available software, for example.
  • software for accessing the sequence information is available and known to one of ordinary skill in the art.
  • Examples of the information to be recorded in the above-described medium include the full genome nucleotide sequence information of coryneform bacteria as obtained in the above item 2, the nucleotide sequence information of ORF, the amino acid sequence information encoded by the ORF, and the functional information of polynucleotides coding for the amino acid sequences.
  • the recording medium or storage device which is readable by a computer according to the present invention refers to a medium in which the information of the present invention has been recorded.
  • Examples include recording media or storage devices which are readable by a computer storing the nucleotide sequence information represented by SEQ ID NOS:1 to 3501, the amino acid sequence information represented by SEQ ID NOS:3502 to 7001, the functional information of the nucleotide sequences represented by SEQ ID NOS:1 to 3501, the functional information of the amino acid sequences represented by SEQ ID NOS:3502 to 7001, and the information listed in Table 1 below and the like.
  • system based on a computer refers a system composed of hardware device(s), software device(s), and data recording device(s) which are used for analyzing the data recorded in the recording medium of the present invention which is readable by a computer.
  • the hardware device(s) are, for example, composed of an input unit, a data recording unit, a central processing unit and an output unit collectively or individually.
  • the software device(s) By the software device(s), the data recorded in the recording medium of the present invention are searched or analyzed using the recorded data and the hardware device(s) as described herein.
  • the software device(s) contain at least one program which acts on or with the system in order to screen, analyze or compare biologically meaningful structures or information from the nucleotide sequences, amino acid sequences and the like recorded in the recording medium according to the present invention.
  • Examples of the software device(s) for identifying ORF and EMF domains include GeneMark ( Nuc. Acids. Res., 22:4756-67 (1994)), GeneHacker ( Protein, Nucleic Acid and Enzyme, 42:3001-07 (1997)), Glimmer (The Institute of Genomic Research; Nuc. Acids. Res., 26:544-548 (1998)) and the like.
  • the default (initial setting) parameters are usually used, although the parameters can be changed, if necessary, in a manner known to one of ordinary skill in the art.
  • Examples of the software device(s) for identifying a genome domain or a polypeptide domain analogous to the target sequence or the target structural motif include FASTA, BLAST, Smith-Waterman, GenetyxMac (manufactured by Software Development), GCG Package (manufactured by Genetic Computer Group), GenCore (manufactured by Compugen), and the like.
  • FASTA Altschul et al.
  • Such a recording medium storing the full genome sequence data is useful in preparing a polynucleotide array by which the expression amount of a gene encoded by the genome DNA of coryneform bacteria and the expression profile at the total gene level of the microorganism, namely, which genes among many genes encoded by the genome have been expressed and the expression ratio thereof, can be determined.
  • the data recording device(s) provided by the present invention are, for example, memory device(s) for recording the data recorded in the recording medium of the present invention and target sequence or target structural motif data, or the like, and a memory accessing device(s) for accessing the same.
  • the system based on a computer according to the present invention comprises the following:
  • This system is usable in the methods in items 2 to 5 as described above for searching and analyzing the ORP and ZMF domains, target sequence, target structural motif, etc. of a coryneform bacterium, searching homologs, searching and analyzing isozymes, determining the biosynthesis pathway and the signal transmission pathway, and identifying spots which have been found in the proteome analysis.
  • the term “homologs” as used herein includes both of orthologs and paralogs.
  • the polypeptide of the present invention can be produced using a polynucleotide comprising the ORF obtained in the above item 2. Specifically, the polypeptide of the present invention can be produced by expressing the polynucleotide of the present invention or a fragment thereof in a host cell, using the method described in Molecular Cloning, 2nd ed., Current Protocols in Molecular Biology, and the like, for example, according to the following method.
  • a DNA fragment having a suitable length containing a part encoding the polypeptide is prepared from the full length ORF sequence, if necessary.
  • the DNA is useful for efficiently producing the polypeptide of the present invention.
  • a recombinant vector is prepared by inserting the DNA fragment into the downstream of a promoter in a suitable expression vector.
  • the recombinant vector is introduced to a host cell suitable for the expression vector.
  • Any of bacteria, yeasts, animal cells, insect cells, plant cells, and the like can be used as the host cell so long as it can be expressed in the gene of interest.
  • Examples of the expression vector include those which can replicate autonomously in the above-described host cell or can be integrated into chromosome and have a promoter at such a position that the DNA encoding the polypeptide of the present invention can be transcribed.
  • the recombinant vector containing the DNA encoding the polypeptide of the present invention can replicate autonomously in the bacterium and is a recombinant vector constituted by, at least a promoter, a ribosome binding sequence, the DNA of the present invention and a transcription termination sequence.
  • a promoter controlling gene can also be contained therewith in operable combination.
  • Examples of the expression vectors include a vector plasmid which is replicable in Corynebacterium glutamicum, such as pCGl (Japanese Published Unexamined Patent Application No. 134500/82), pCG2 (Japanese Published Unexamined Patent Application No. 35197/83), pCG4 (Japanese Published Unexamined Patent Application No. 183799/82), pCGll (Japanese Published Unexamined Patent Application No. 134500/82), pCG116, pCE54 and pCB101 (Japanese Published Unexamined Patent Application No. 105999/83), pCE51, pCE52 and pCE53 ( Mol. Gen.
  • a vector plasmid which is replicable in Escherichia coli such as pET3 and pET1l (manufactured by Stratagene), PBAD, pThioHis and pTrcHis (manufactured by Invitrogen), pKK223-3 and pGEX2T (manufactured by Amersham Pharmacia Biotech), and the like; and pBTrp2, pBTacl and pBTac2 (manufactured by Boehringer Mannheim Co.), pSE280 (manufactured by Invitrogen), pGEMEX-1 (manufactured by Promega), pQE-8 (manufactured by QIAGEN), pKYP1O (Japanese Published Unexamined Patent Application No.
  • Any promoter can be used so long as it can function in the host cell.
  • Examples include promoters derived from Escherichia coli, phage and the like, such as trp promoter (P trp ), iac promoter, P L promoter, P R promoter, T7 promoter and the like.
  • artificially designed and modified promoters such as a promoter in which two Ptrp are linked in series (P trp ⁇ 2), tac promoter, lacT7 promoter letI promoter and the like, can be used.
  • the transcription termination sequence is not always necessary for the expression of the DNA of the present invention. However, it is preferred to arrange the transcription terminating sequence at just downstream of the structural gene.
  • codons of the above-described elements may be optimized, in a known manner, depending on the host cells and environmental conditions utilized.
  • Examples of the host cell include microorganisms belonging to the genus Escherichia, the genus Serratia, the genus Bacillus, the genus Brevibacterium, the genus Corynebacterium, the genus Microbacterinum, the genus Pseudomonas, and the like.
  • Specific examples include Escherichia coli XL1-Blue, Escherichia coli XL2-Blue, Escherichia coli DH1, Escherichia coli MC1000, Escherichia coli KY3276, Escherichia coli W1485, Escherichia coli JM109, Escherichia coli HB101, Escherichia coli No.
  • an EMF necessary for expressing the polypeptide is not always contained in the vector so long as the polynucleotide of the present invention contains an ENF
  • the EMF is not contained in the polynucleotide, it is necessary to prepare the EMF separately and ligate it so as to be in operable combination.
  • a higher expression amount or specific expression regulation is necessary, it is necessary to ligate the EMF corresponding thereto so as to put the EMF in operable combination with the polynucleotide Examples of using an externally ligated EMF are disclosed in Microbiology, 142:1297-1309 (1996).
  • the method for introducing DNA into the above-described host cells such as a method in which a calcium ion is used ( Proc. Natl. Acad. Sci. USA, 69:2110 (1972)), a protoplast method (Japanese Published Unexamined Patent Application No. 2483942/88), the methods described in Gene, 17:107 (1982) and Molecular & General Genetics, 168:111 (1979) and the like, can be used.
  • yeast When yeast is used as the host cell, examples of the expression vector include pYES2 (manufactured by Invitrogen), YEpl3 (ATCC 37115), YEp24 (ATCC 37051), YCp5O (ATCC 37419), pHSl9, pHS15, and the like.
  • Any promoter can be used so long as it can be expressed in yeast.
  • Examples include a promoter of a gene in the glycolytic pathway, such as hexose kinase and the like, PHO5 promoter, PGK promoter, GAP promoter, ADH promoter, gal 1 promoter, gal 10 promoter, a heat shock protein promoter, MF al promoter, CUP 1 promoter, and the like.
  • Examples of the host cell include microorganisms belonging to the genus Saccharomyces, the genus Schizosaccharomyces, the genus Kluyveromyces, the genus Trichosporon, the genus Schwanniomyces, the genus Pichia, the genus Candida and the like. Specific examples include Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces lactis, Trichosporon pullulans, Schwanniomyces alluviums, Candida utilis and the like.
  • any method for introducing DNA into yeast such as an electroporation method ( Methods. Enzymol., 194:182 (1990)), a spheroplast method ( Proc. Natl. Acad. Sci. USA, 75:1929 (1978)), a lithium acetate method ( J. Bacteriol., 153:163 (1983)), a method described in Proc. Natl. Acad. Sci. USA, 75:1929 (1978) and the like, can be used.
  • an electroporation method Methods. Enzymol., 194:182 (1990)
  • a spheroplast method Proc. Natl. Acad. Sci. USA, 75:1929 (1978)
  • a lithium acetate method J. Bacteriol., 153:163 (1983)
  • a method described in Proc. Natl. Acad. Sci. USA, 75:1929 (1978) and the like can be used.
  • examples of the expression vector include pcDNA3.1, pSinRep5 and pCEP4 (manufactured by Invitorogen), pRev-Tre (manufactured by Clontech), pAxCAwt (manufactured by Takara Shuzo), pcDNAI and pcDM8 (manufactured by Funakoshi), pAGE107 (Japanese Published Unexamined Patent Application No. 22979/91; Cytotechnology, 3:133 (1990)), pAS3-3 (Japanese Published Unexamined Patent Application No.
  • Any promoter can be used so long as it can function in animal cells.
  • Examples include a promoter of IE (immediate early) gene of cytomegalovirus (CMV), an early promoter of SV40, a promoter of retrovirus, a metallothionein promoter, a heat shock promoter, SRa promoter, and the like.
  • the enhancer of the IE gene of human CMV can be used together with the promoter.
  • Examples of the host cell include human Namalwa cell, monkey COS cell, Chinese hamster CHO cell, HST5637 (Japanese Published Unexamined Patent Application No. 299/88), and the like.
  • the method for introduction of the recombinant vector into animal cells is not particularly limited, so long as it is the general method for introducing DNA into animal cells, such as an electroporation method ( Cytotechnology, 3:133 (1990)), a calcium phosphate method (Japanese Published Unexamined Patent Application No. 227075/90), a lipofection method ( Proc. Natl. Acad. Sci. USA, 84, 7413 (1987)), the method described in Virology, 52:456 (1973), and the like.
  • the polypeptide when insect cells are used as the host cells, the polypeptide can be expressed, for example, by the method described in Bacurovirus Expression Vectors, A Laboratory Manual, W. H. Freeman and Company, New York (1992), Bio/Technology, 6:47 (1988), or the like.
  • a recombinant gene transfer vector and bacurovirus are simultaneously inserted into insect cells to obtain a recombinant virus in an insect cell culture supernatant, and then the insect cells are infected with the resulting recombinant virus to express the polypeptide.
  • Examples of the gene introducing vector used in the method include pBlueBac4.5, pVL1392, pVL1393 and pBlueBacIII (manufactured by Invitrogen), and the like.
  • bacurovirus examples include Autographa californica nuclear polyhedrosis virus with which insects of the family Barathra are infected, and the like.
  • insect cells examples include Spodoptera frugiperda oocytes Sf9 and Sf21 ( Bacurovirus Expression Vectors, A Laboratory Manual, W. H. Freeman and Company, New York (1992)), Trichoplusia ni oocyte High 5 (manufactured by Invitrogen) and the like.
  • the method for simultaneously incorporating the above-described recombinant gene transfer vector and the above-described bacurovirus for the preparation of the recombinant virus include calcium phosphate method (Japanese Published Unexamined Patent Application No. 227075/90), lipofection method ( Proc. Natl. Acad. Sci. USA, 84:7413 (1987)) and the like.
  • expression vector When plant cells are used as the host cells, examples of expression vector include a Ti plasmid, a tobacco mosaic virus vector, and the like.
  • Any promoter can be used so long as it can be expressed in plant cells. Examples include 35S promoter of cauliflower mosaic virus (CaMV), rice actin 1 promoter, and the like.
  • Examples of the host cells include plant cells and the like, such as tobacco, potato, tomato, carrot, soybean, rape, alfalfa, rice, wheat, barley, and the like.
  • the method for introducing the recombinant vector is not particularly limited, so long as it is the general method for introducing DNA into plant cells, such as the Agrobacterium method (Japanese Published Unexamined Patent Application No. 140885/84, Japanese Published Unexamined Patent Application No. 70080/85, WO 94/00977), the electroporation method (Japanese Published Unexamined Patent Application No. 251887/85), the particle gun method (Japanese Patents 2606856 and 2517813), and the like.
  • Agrobacterium method Japanese Published Unexamined Patent Application No. 140885/84, Japanese Published Unexamined Patent Application No. 70080/85, WO 94/00977
  • the electroporation method Japanese Unexamined Patent Application No. 251887/85
  • the particle gun method Japanese Patents 2606856 and 2517813
  • the transformant of the present invention includes a transformant containing the polypeptide of the present invention per se rather than as a recombinant vector, that is, a transformant containing the polypeptide of the present invention which is integrated into a chromosome of the host, in addition to the transformant containing the above recombinant vector.
  • glycopolypeptide or glycosylated polypeptide When expressed in yeasts, animal cells, insect cells or plant cells, a glycopolypeptide or glycosylated polypeptide can be obtained.
  • the polypeptide can be produced by culturing the thus obtained transformant of the present invention in a culture medium to produce and accumulate the polypeptide of the present invention or any polypeptide expressed under the control of an EMF of the present invention, and recovering the polypeptide from the culture.
  • Culturing of the transformant of the present invention in a culture medium is carried out according to the conventional method as used in culturing of the host.
  • the transformant of the present invention is obtained using a prokaryote, such as Escherichia coli or the like, or a eukaryote, such as yeast or the like, as the host, the transformant is cultured.
  • a prokaryote such as Escherichia coli or the like
  • a eukaryote such as yeast or the like
  • Any of a natural medium and a synthetic medium can be used, so long as it contains a carbon source, a nitrogen source, an inorganic salt and the like which can be assimilated by the transformant and can perform culturing of the transformant efficiently.
  • Examples of the carbon source include those which can be assimilated by the transformant, such as carbohydrates (for example, glucose, fructose, sucrose, molasses containing them, starch, starch hydrolysate, and the like), organic acids (for example, acetic acid, propionic acid, and the like), and alcohols (for example, ethanol, propanol, and the like).
  • carbohydrates for example, glucose, fructose, sucrose, molasses containing them, starch, starch hydrolysate, and the like
  • organic acids for example, acetic acid, propionic acid, and the like
  • alcohols for example, ethanol, propanol, and the like.
  • Examples of the nitrogen source include ammonia, various ammonium salts of inorganic acids or organic acids (for example, ammonium chloride, ammonium sulfate, ammonium acetate, ammonium phosphate, and the like), other nitrogen-containing compounds, peptone, meat extract, yeast extract, corn steep liquor, casein hydrolysate, soybean meal and soybean meal hydrolysate, various fermented cells and hydrolysates thereof, and the like.
  • ammonia various ammonium salts of inorganic acids or organic acids (for example, ammonium chloride, ammonium sulfate, ammonium acetate, ammonium phosphate, and the like)
  • other nitrogen-containing compounds for example, peptone, meat extract, yeast extract, corn steep liquor, casein hydrolysate, soybean meal and soybean meal hydrolysate, various fermented cells and hydrolysates thereof, and the like.
  • inorganic salt examples include potassium dihydrogen phosphate, dipotassium hydrogen phosphate, magnesium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, copper sulfate, calcium carbonate, and the like.
  • the culturing is carried out under aerobic conditions by shaking culture, submerged-aeration stirring culture or the like.
  • the culturing temperature is preferably from 15 to 40° C., and the culturing time is generally from 16 hours to 7 days.
  • the pH of the medium is preferably maintained at 3.0 to 9.0 during the culturing.
  • the pH can be adjusted using an inorganic or organic acid, an alkali solution, urea, calcium carbonate, ammonia, or the like.
  • antibiotics such as ampicillin, tetracycline, and the like, can be added to the medium during the culturing, if necessary.
  • an inducer can be added to the medium, if necessary.
  • IPTG isopropyl- ⁇ -D-thiogalactopyranoside
  • IAA indoleacrylic acid
  • Examples of the medium used in culturing a transformant obtained using animal cells as the host cells include RPMI 1640 medium ( The Journal of the American Medical Association, 199:519 (1967)), Eagle's MEM medium ( Science, 122:501 (1952)), Dulbecco's modified MEM medium ( Virology, 8, 396 (1959)), 199 Medium ( Proceeding of the Society for the Biological Medicine, 73:1 (1950)), the above-described media to which fetal calf serum has been added, and the like.
  • the culturing is carried out generally at a pH of 6 to 8 and a temperature of 30 to 40° C. in the presence of 5% CO 2 for 1 to 7 days.
  • antibiotics such as kanamycin, penicillin, and the like, can be added to the medium during the culturing.
  • Examples of the medium used in culturing a transformant obtained using insect cells as the host cells include TNM-FH medium (manufactured by Pharmingen), Sf-900 II SFM (manufactured by Life Technologies), ExCell 400 and ExCell 405 (manufactured by JRH Biosciences), Grace's Insect Medium ( Nature, 195:788 (1962)), and the like.
  • the culturing is carried out generally at a pH of 6 to 7 and a temperature of 25 to 30° C. for 1 to 5 days.
  • antibiotics such as gentamicin and the like, can be added to the medium during the culturing, if necessary.
  • a transformant obtained by using a plant cell as the host cell can be used as the cell or after differentiating to a plant cell or organ.
  • Examples of the medium used in the culturing of the transformant include Murashige and Skoog (MS) medium, White medium, media to which a plant hormone, such as auxin, cytokinine, or the like has been added, and the like.
  • the culturing is carried out generally at a pH of 5 to 9 and a temperature of 20 to 40° C. for 3 to 60 days.
  • antibiotics such as kanamycin, hygromycin and the like, can be added to the medium during the culturing, if necessary.
  • the polypeptide can be produced by culturing a transformant derived from a microorganism, animal cell or plant cell containing a recombinant vector to which a DNA encoding the polypeptide of the present invention has been inserted according to the general culturing method to produce and accumulate the polypeptide, and recovering the polypeptide from the culture.
  • the process of gene expression may include secretion of the encoded protein production or fusion protein expression and the like in accordance with the methods described in Molecular Cloning, 2nd ed., in addition to direct expression.
  • the method for producing the polypeptide of the present invention includes a method of intracellular expression in a host cell, a method of extracellular secretion from a host cell, or a method of production on a host cell membrane outer envelope.
  • the method can be selected by changing the host cell employed or the structure of the polypeptide produced.
  • the polypeptide of the present invention when produced in a host cell or on a host cell membrane outer envelope, the polypeptide can be positively secreted extracellularly according to, for example, the method of Paulson et al. ( J. Biol. Chem., 264:17619 (1989)), the method of Lowe et al. ( Proc. Natl. Acad. Sci. USA, 86:8227 (1989); Genes Develop., 4:1288 (1990)), and/or the methods described in Japanese Published Unexamined Patent Application No. 336963/93, Wo 94/23021, and the like.
  • the polypeptide of the present invention can be positively secreted extracellularly by expressing it in the form that a signal peptide has been added to the foreground of a polypeptide containing an active site of the polypeptide of the present invention according to the recombinant DNA technique.
  • the amount produced can be increased using a gene amplification system, such as by use of a dihydrofolate reductase gene or the like according to the method described in Japanese Published Unexamined Patent Application No. 227075/90.
  • polypeptide of the present invention can be produced by a transgenic animal individual (transgenic nonhuman animal) or plant individual (transgenic plant).
  • the polypeptide of the present invention can be produced by breeding or cultivating it so as to produce and accumulate the polypeptide, and recovering the polypeptide from the animal individual or plant individual.
  • Examples of the method for producing the polypeptide of the present invention using the animal individual include a method for producing the polypeptide of the present invention in an animal developed by inserting a gene according to methods known to those of ordinary skill in the art ( American Journal of Clinical Nutrition, 63:639S (1996), American Journal of Clinical Nutrition, 63:627S (1996), Bio/Technology, 9:830 (1991)).
  • the polypeptide in the animal individual, can be produced by breeding a transgenic nonhuman animal to which the DNA encoding the polypeptide of the present invention has been inserted to produce and accumulate the polypeptide in the animal, and recovering the polypeptide from the animal.
  • Examples of the production and accumulation place in the animal include milk (Japanese Published Unexamined Patent Application No. 309192/88), egg and the like of the animal.
  • Any promoter can be used, so long as it can be expressed in the animal. Suitable examples include an ⁇ -casein promoter, a ⁇ -casein promoter, a ⁇ -lactoglobulin promoter, a whey acidic protein promoter, and the like, which are specific for mammary glandular cells.
  • Examples of the method for producing the polypeptide of the present invention using the plant individual include a method for producing the polypeptide of the present invention by cultivating a transgenic plant to which the DNA encoding the protein of the present invention by a known method ( Tissue Culture, 20 (1994), Tissue Culture, 21 (1994), Trends in Biotechnology, 15:45 (1997)) to produce and accumulate the polypeptide in the plant, and recovering the polypeptide from the plant.
  • polypeptide according to the present invention can also be obtained by translation in vitro.
  • the polypeptide of the present invention can be produced by a translation system in vitro.
  • a translation system in vitro There are, for example, two in vitro translation methods which may be used, namely, a method using RNA as a template and another method using DNA as a template.
  • the template RNA includes the whole RNA, mRNA, an in vitro transcription product, and the like.
  • the template DNA includes a plasmid containing a transcriptional promoter and a target gene integrated therein and downstream of the initiation site, a PCR/RT-PCR product and the like.
  • the origin of the gene encoding the protein to be synthesized (prokaryotic cell/eucaryotic cell), the type of the template (DNA/RNA), the purpose of using the synthesized protein and the like should be considered.
  • In vitro translation kits having various characteristics are commercially available from many companies (Boehringer Mannheim, Promega, Stratagene, or the like), and every kit can be used in producing the polypeptide according to the present invention.
  • Transcription/translation of a DNA nucleotide sequence cloned into a plasmid containing a T7 promoter can be carried out using an in vitro transcription/translation system E. coli T7 S30 Extract System for Circular DNA (manufactured by Promega, catalogue No. L1130). Also, transcription/translation using, as a template, a linear prokaryotic DNA of a supercoil non-sensitive promoter, such as lacUV5, tac, ⁇ PL(con), ⁇ PL, or the like, can be carried out using an in vitro transcription/translation system E. coli S30 Extract System for Linear Templates (manufactured by Promega, catalogue No. L1030).
  • linear prokaryotic DNA used as a template examples include a DNA fragment, a PCR-amplified DNA product, a duplicated oligonucleotide ligation, an in vitro transcriptional RNA, a prokaryotic RNA, and the like.
  • the polypeptide produced by the transformant of the present invention can be isolated and purified using the general method for isolating and purifying an enzyme.
  • the polypeptide of the present invention when expressed as a soluble product in the host cells, the cells are collected by centrifugation after cultivation, suspended in an aqueous buffer, and disrupted using an ultrasonicator, a French press, a Manton Gaulin homogenizer, a Dynomill, or the like to obtain a cell-free extract.
  • a purified product can be obtained by the general method used for isolating and purifying an enzyme, for example, solvent extraction, salting out using ammonium sulfate or the like, desalting, precipitation using an organic solvent, anion exchange chromatography using a resin, such as diethylaminoethyl (DEAE)-Sepharose, DIAION HPA-75 (manufactured by Mitsubishi Chemical) or the like, cation exchange chromatography using a resin, such as S-Sepharose FF (manufactured by Pharmacia) or the like, hydrophobic chromatography using a resin, such as butyl sepharose, phenyl sepharose or the like, gel filtration using a molecular sieve, affinity chromatography, chromatofocusing, or electrophoresis, such as isoelectronic focusing or the like, alone or in combination thereof.
  • solvent extraction salting out using ammonium sulfate or the like
  • desalting precipitation using
  • the cells are collected in the same manner, disrupted and centrifuged to recover the insoluble product of the polypeptide as the precipitate fraction.
  • the insoluble product of the polypeptide is solubilized with a protein denaturing agent.
  • the solubilized solution is diluted or dialyzed to lower the concentration of the protein denaturing agent in the solution.
  • the normal configuration of the polypeptide is reconstituted.
  • a purified product of the polypeptide can be obtained by a purification/isolation method similar to the above.
  • the polypeptide of the present invention or its derivative (for example, a polypeptide formed by adding a sugar chain thereto) is secreted out of cells
  • the polypeptide or its derivative can be collected in the culture supernatant.
  • the culture supernatant is obtained by treating the culture medium in a treatment similar to the above (for example, centrifugation). Then, a purified product can be obtained from the culture medium using a purification/isolation method similar to the above.
  • polypeptide obtained by the above method is within the scope of the polypeptide of the present invention, and examples include a polypeptide encoded by a polynucleotide comprising the nucleotide sequence selected from SEQ ID NOS:2 to 3431, and a polypeptide comprising an amino acid sequence represented by any one of SEQ ID NOS:3502 to 6931.
  • polypeptide comprising an amino acid sequence in which at least one amino acids is deleted, replaced, inserted or added in the amino acid sequence of the polypeptide and having substantially the same activity as that of the polypeptide is included in the scope of the present invention.
  • substantially the same activity as that of the polypeptide means the same activity represented by the inherent function, enzyme activity or the like possessed by the polypeptide which has not been deleted, replaced, inserted or added.
  • the polypeptide can be obtained using a method for introducing part-specific mutation(s) described in, for example, Molecular Cloning, 2nd ed., Current Protocols in Molecular Biology, Nuc. Acids. Res., 10:6487 (1982), Proc. Natl. Acad.
  • the polypeptide can be obtained by introducing mutation(s) to DNA encoding a polypeptide having the amino acid sequence represented by any one of SEQ ID NOS:3502 to 6931.
  • the number of the amino acids which are deleted, replaced, inserted or added is not particularly limited; however, it is usually 1 to the order of tens, preferably 1 to 20, more preferably 1 to 10, and most preferably 1 to 5, amino acids.
  • the at least one amino acid deletion, replacement, insertion or addition in the amino acid sequence of the polypeptide of the present invention is used herein to refer to that at least one amino acid is deleted, replaced, inserted or added to at one or plural positions in the amino acid sequence.
  • the deletion, replacement, insertion or addition may be caused in the same amino acid sequence simultaneously.
  • the amino acid residue replaced, inserted or added can be natural or non-natural.
  • Examples of the natural amino acid residue include L-alanine, L-asparagine, L-asparatic acid, L-glutamine, L-glutamic acid, glycine, L-histidine, L-isoleucine, L-leonine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, L-valine, L-cysteine, and the like.
  • amino acid residues which are replaced with each other are shown below.
  • the amino acid residues in the samie group can be replaced with each other.
  • leonine isoleucine, norleucine, valine, norvaline, alanine, 2-aminobutanoic acid, methionine, 0-methylserine, t-butylglycine, t-butylalanine, cyclohexylalanine;
  • asparatic acid glutamic acid, isoasparatic acid, isoglutamic acid, 2-aminoadipic acid, 2-aminosuberic acid;
  • proline 3-hydroxyproline, 4-hydroxyproline
  • the mutant polypeptide has a homology of 60% or more, preferably 80% or more, and particularly preferably 95% or more, with the polypeptide which has not been mutated, when calculated, for example, using default (initial setting) parameters by a homology searching software, such as BLAST, FASTA, or the like.
  • polypeptide of the present invention can be produced by a chemical synthesis method, such as Fmoc (fluorenylmethyloxycarbonyl) method, tboc (t-butyloxycarbonyl) method, or the like. It can also be synthesized using a peptide synthesizer manufactured by Advanced ChemTech, Perkin-Elmer, Pharmacia, Protein Technology Instrument, Synthecell-Vega, PerSeptive, Shimadzu Corporation, or the like.
  • a chemical synthesis method such as Fmoc (fluorenylmethyloxycarbonyl) method, tboc (t-butyloxycarbonyl) method, or the like. It can also be synthesized using a peptide synthesizer manufactured by Advanced ChemTech, Perkin-Elmer, Pharmacia, Protein Technology Instrument, Synthecell-Vega, PerSeptive, Shimadzu Corporation, or the like.
  • transformant of the present invention can be used for objects other than the production of the polypeptide of the present invention.
  • At least one component selected from an amino acid, a nucleic acid, a vitamin, a saccharide, an organic acid, and analogues thereof can be produced by culturing the transformant containing the polynucleotide or recombinant vector of the present invention in a medium to produce and accumulate at least one component selected from amino acids, nucleic acids, vitamins, saccharides, organic acids, and analogues thereof, and recovering the same from the medium.
  • the biosynthesis pathways, decomposition pathways and regulatory mechanisms of physiologically active substances differ from organism to organism.
  • the productivity of such a physiologically active substance can be improved using these differences, specifically by introducing a heterogeneous gene relating to the biosynthesis thereof.
  • the content of lysine, which is one of the essential amino acids, in a plant seed was improved by introducing a synthase gene derived from a bacterium (WO 93/19190).
  • arginine is excessively produced in a culture by introducing an arginine synthase gene derived from Escherichia coli (Japanese Examined Patent Publication 23750/93).
  • the transformant according to the present invention can be cultured by the same method as employed in culturing the transformant for producing the polypeptide of the present invention as described above. Also, the physiologically active substance can be recovered from the culture medium in combination with, for example, the ion exchange resin method, the precipitation method and other known methods.
  • Examples of methods known to one of ordinary skill in the art include electroporation, calcium transfection, the protoplast method, the method using a phage, and the like, when the host is a bacterium; and microinjection, calcium phosphate transfection, the positively charged lipid-mediated method and the method using a virus, and the like, when the host is a eukaryote ( Molecular Cloning, 2nd ed.; Spector et al., Cells/a laboratory manual, Cold Spring Harbour Laboratory Press, 1998)).
  • Examples of the host include prokaryotes, lower eukaryotes (for example, yeasts), higher eukaryotes (for example, mammals), and cells isolated therefrom.
  • a recombinant polynucleotide fragment present in the host cells it can be integrated into the chromosome of the host. Alternatively, it can be integrated into a factor (for example, a plasmid) having an independent replication unit outside the chromosome.
  • These transformants are usable in producing the polypeptides of the present invention encoded by the ORF of the genome of Corynebacterium glutamicum, the polynucleotides of the present invention and fragments thereof. Alternatively, they can be used in producing arbitrary polypeptides under the regulation by an EMF of the present invention.
  • An antibody which recognizes the polypeptide of the present invention such as a polyclonal antibody, a monoclonal antibody, or the like, can be produced using, as an antigen, a purified product of the polypeptide of the present invention or a partial fragment polypeptide of the polypeptide or a peptide having a partial amino acid sequence of the polypeptide of the present invention.
  • a polyclonal antibody can be produced using, as an antigen, a purified product of the polypeptide of the present invention, a partial fragment polypeptide of the polypeptide, or a peptide having a partial amino acid sequence of the polypeptide of the present invention, and immunizing an animal with the same.
  • Examples of the animal to be immunized include rabbits, goats, rats, mice, hamsters, chickens and the like.
  • a dosage of the antigen is preferably 50 to 100 ⁇ g per animal.
  • the peptide is used as the antigen, it is preferably a peptide covalently bonded to a carrier protein, such as keyhole limpet haemocyanin, bovine thyroglobulin, or the like.
  • a carrier protein such as keyhole limpet haemocyanin, bovine thyroglobulin, or the like.
  • the peptide used as the antigen can be synthesized by a peptide synthesizer.
  • the administration of the antigen is, for example, carried out 3 to 10 times at the intervals of 1 or 2 weeks after the first administration.
  • a blood sample is collected from the venous plexus of the eyeground, and it is confirmed that the serum reacts with the antigen by the enzyme immunoassay ( Enzyme-linked Ixmunosorbent Assay (ELISA), Igaku Shoin (1976); Antibodies—A Laboratory Manual, Cold Spring Harbor Laboratory (1988)) or the like.
  • Serum is obtained from the immunized non-human mammal with a sufficient antibody titer against the antigen used for the immunization, and the serum is isolated and purified to obtain a polyclonal antibody.
  • Examples of the method for the isolation and purification include centrifugation, salting out by 40-50% saturated ammonium sulfate, caprylic acid precipitation ( Antibodies, A Laboratory manual, Cold Spring Harbor Laboratory (1988)), or chromatography using a DEAE-Sepharose column, an anion exchange column, a protein A- or G-column, a gel filtration column, and the like, alone or in combination thereof, by methods known to those of ordinary skill in the art.
  • a rat having a serum showing an enough antibody titer against a partial fragment polypeptide of the polypeptide of the present invention used for immunization is used as a supply source of an antibody-producing cell.
  • the spleen is cut to pieces in MEM medium (manufactured by Nissui Pharmaceutical), loosened using a pair of forceps, followed by centrifugation at 1,200 rpm for 5 minutes, and the resulting supernatant is discarded.
  • the spleen in the precipitated fraction is treated with a Tris-ammonium chloride buffer (pH 7.65) for 1 to 2 minutes to eliminate erythrocytes and washed three times with MEM medium, and the resulting spleen cells are used as antibody-producing cells.
  • a Tris-ammonium chloride buffer pH 7.65
  • myeloma cells an established cell line obtained from mouse or rat is used.
  • useful cell lines include those derived from a mouse, such as P3-X63Ag8-Ul (hereinafter referred to as “P3-U1”) ( Curr. Topics in Microbiol. Immunol., 81:1 (1978); Europ. J. Immunol., 6:511 (1976)); SP2/O-Ag14 (SP-2) ( Nature, 276:269 (1978)):P3-X63-Ag8653 (653) ( J.
  • 8-azaguanine medium medium in which, to a medium obtained by adding 1.5 mmol/l glutamine, 5 ⁇ 10 ⁇ 5 mol/l 2-mercaptoethanol, 10 ⁇ g/ml gentamicin and 10% fetal calf serum (FCS) (manufactured by CSL) to RPMI-1640 medium (hereinafter referred to as the “normal medium”), 8-azaguanine is further added at 15 ⁇ g/ml) and cultured in the normal medium 3 or 4 days before cell fusion, and 2 ⁇ 10 7 or more of the cells are used for the fusion.
  • FCS fetal calf serum
  • MEM medium or PBS disodium hydrogen phosphate:1.83 g, sodium dihydrogen phosphate:0.21 g, sodium chloride:7.65 g, distilled water:1 liter, pH:7.2
  • MEM medium is added to give a total amount of 50 ml.
  • the resulting prepared solution is centrifuged at 900 rpm for 5 minutes, and then the supernatant is discarded.
  • the cells in the resulting precipitated fraction were gently loosened and then gently suspended in 100 ml of HAT medium (the normal medium to which 10 ⁇ 4 mol/l hypoxanthine, 1.5 ⁇ 10 ⁇ 5 mol/l thymidine and 4 ⁇ 10 ⁇ 7 mol/l aminopterin have been added) by repeated drawing up into and discharging from a measuring pipette.
  • HAT medium the normal medium to which 10 ⁇ 4 mol/l hypoxanthine, 1.5 ⁇ 10 ⁇ 5 mol/l thymidine and 4 ⁇ 10 ⁇ 7 mol/l aminopterin have been added
  • the suspension is poured into a 96 well culture plate at 100 fil/well and cultured at 37° C. for 7 to 14 days in a 5% CO 2 incubator.
  • a hybridoma which specifically reacts with a partial fragment polypeptide of the polypeptide of the present invention is selected according to the enzyme immunoassay described in Antibodies, A Laboratory manual, Cold Spring Harbor Laboratory, Chapter 14 (1998) and the like.
  • the partial fragment polypeptide of the polypeptide of the present invention used as the antigen in the immunization is spread on a suitable plate, is allowed to react with a hybridoma culturing supernatant or a purified antibody obtained in (d) described below as a first antibody, and is further allowed to react with an anti-rat or anti-mouse immunoglobulin antibody labeled with an enzyme, a chemical luminous substance, a radioactive substance or the like as a second antibody for reaction suitable for the labeled substance.
  • a hybridoma which specifically reacts with the polypeptide of the present invention is selected as a hybridoma capable of producing a monoclonal antibody of the present invention.
  • Cloning is repeated using the hybridoma twice by limiting dilution analysis (HT medium (a medium in which aminopterin has been removed from HAT medium) is firstly used, and the normal medium is secondly used), and a hybridoma which is stable and contains a sufficient amount of antibody titer is selected as a hybridoma capable of producing a monoclonal antibody of the present invention.
  • HT medium a medium in which aminopterin has been removed from HAT medium
  • the normal medium is secondly used
  • a hybridoma which is stable and contains a sufficient amount of antibody titer is selected as a hybridoma capable of producing a monoclonal antibody of the present invention.
  • the monoclonal antibody-producing hybridoma cells obtained in (c) are injected intraperitoneally into 8- to 10-week-old mice or nude mice treated with pristane (intraperitoneal administration of 0.5 ml of 2,6,10,14-tetramethylpentadecane (pristane), followed by 2 weeks of feeding) at 5 ⁇ 10 6 to 2 ⁇ 10 6 cells/animal.
  • the hybridoma causes ascites tumor in 10 to 21 days.
  • the ascitic fluid is collected from the mice or nude mice, and centrifuged to remove solid contents at 3000 rpm for 5 minutes.
  • a monoclonal antibody can be purified and isolated from the resulting supernatant according to the method similar to that used in the polyclonal antibody.
  • the subclass of the antibody can be determined using a mouse monoclonal antibody typing kit or a rat monoclonal antibody typing kit.
  • the polypeptide amount can be determined by the Lowry method or by calculation based on the absorbance at 280 nm.
  • the antibody can be used for the general assay using an antibody, such as a radioactive material labeled immunoassay (RIA), competitive binding assay, an immunotissue chemical staining method (ABC method, CSA method, etc.), immunoprecipitation, Western blotting, ELISA assay, and the like (ACI method, CSA method, etc.), immunoprecipitation, Western blotting, ELISA assay, and the like ( An introduction to Radioimmunoassay and Related Techniques, Elsevier Science (1986); Techniques in Immunocytochemistry, Academic Press, Vol. 1 (1982), Vol. 2 (1983) & Vol.
  • the antibody of the present invention can be used as it is or after being labeled with a label.
  • Examples of the label include radioisotope, an affinity label (e.g., biotin, avidin, or the like), an enzyme label (e.g., horseradish peroxidase, alkaline phosphatase, or the like), a fluorescence label (e.g., FITC, rhodamine, or the like), a label using a rhodamine atom, ( J. Histochem. Cytochem., 18:315 (1970); Meth. Enzym., 62:308 (1979); Immunol., 109:129 (1972); J. Immunol., Meth., 13:215 (1979)), and the like.
  • an affinity label e.g., biotin, avidin, or the like
  • an enzyme label e.g., horseradish peroxidase, alkaline phosphatase, or the like
  • a fluorescence label e.g., FITC, rhodamine, or the like
  • Expression of the polypeptide of the present invention fluctuation of the expression, the presence or absence of structural change of the polypeptide, and the presence or absence in an organism other than coryneform bacteria of a polypeptide corresponding to the polypeptide can be analyzed using the antibody or the labeled antibody by the above assay, or a polypeptide array or proteome analysis described below.
  • polypeptide recognized by the antibody can be purified by immunoaffinity chromatography using the antibody of the present invention.
  • a polypeptide array can be produced using the polypeptide of the present invention obtained in the above item 10 or the antibody of the present invention obtained in the above item 11.
  • the polypeptide array of the present invention includes protein chips, and comprises a solid support and the polypeptide or antibody of the present invention adhered to the surface of the solid support.
  • solid support examples include plastic such as polycarbonate or the like; an acrylic resin, such as polyacrylamide or the like; complex carbohydrates, such as agarose, sepharose, or the like; silica; a silica-based material, carbon, a metal, inorganic glass, latex beads, and the like.
  • polypeptides or antibodies according to the present invention can be adhered to the surface of the solid support according to the method described in Biotechniques, 27:1258-61 (1999); Molecular Medicine Today, 5:326-7 (1999); Handbook of Experimental Immunology, 4th edition, Blackwell Scientific Publications, Chapter 10 (1986); Meth. Enzym., 34 (1974); Advances in Experimental Medicine and Biology, 42 (1974); U.S. Pat. Nos. 4,681,870; 4,282,287; 4,762,881, or the like.
  • a polypeptide or a compound capable of binding to and interacting with the polypeptides of the present invention adhered to the array can be identified using the polypeptide array to which the polypeptides of the present invention have been adhered thereto as described in the above (1).
  • polypeptide or a compound capable of binding to and interacting with the polypeptides of the present invention can be identified by subjecting the polypeptides of the present invention to the following steps (i) to (iv):
  • polypeptide array to which the polypeptide of the present invention has been adhered include a polypeptide array containing a solid support to which at least one of a polypeptide containing an amino acid sequence selected from SEQ ID NOS:3502 to 7001, a polypeptide containing an amino acid sequence in which at least one amino acids is deleted, replaced, inserted or added in the amino acid sequence of the polypeptide and having substantially the same activity as that of the polypeptide, a polypeptide containing an amino acid sequence having a homology of 60% or more with the amino acid sequences of the polypeptide and having substantially the same activity as that of the polypeptides, a partial fragment polypeptide, and a peptide comprising an amino acid sequence of a part of a polypeptide.
  • the amount of production of a polypeptide derived from coryneform bacteria can be analyzed using a polypeptide array to which the antibody of the present invention has been adhered in the above (1).
  • the expression amount of a gene derived from a mutant of coryneform bacteria can be analyzed by subjecting the gene to the following steps (i) to (iv):
  • polypeptide array to which the antibody of the present invention is adhered include a polypeptide array comprising a solid support to which at least one of an antibody which recognizes a polypeptide comprising an amino acid sequence selected from SEQ ID NOS:3502 to 7001, a polypeptide comprising an amino acid sequence in which at least one amino acids is deleted, replaced, inserted or added in the amino acid sequence of the polypeptide and having substantially the same activity as that of the polypeptide, a polypeptide comprising an amino acid sequence having a homology of 60% or more with the amino acid sequences of the polypeptide and having substantially the same activity as that of the polypeptides, a partial fragment polypeptide, or a peptide comprising an amino acid sequence of a part of a polypeptide.
  • a fluctuation in an expression amount of a specific polypeptide can be monitored using a polypeptide obtained in the time course of culture as the polypeptide derived from coryneform bacteria.
  • the culturing conditions can be optimized by analyzing the fluctuation.
  • the proteome is used herein to refer to a method wherein a polypeptide is separated by two-dimensional electrophoresis and the separated polypeptide is digested with an enzyme, followed by identification of the polypeptide using a mass spectrometer (Ms) and searching a data base.
  • Ms mass spectrometer
  • the two dimensional electrophoresis means an electrophoretic method which is perforned by combining two electrophoretic procedures having different principles. For example, polypeptides are separated depending on molecular weight in the primary electrophoresis. Next, the gel is rotated by 90° or 180° and the secondary electrophoresis is carried out depending on isoelectric point. Thus, various separation patterns can be achieved (JIS K 3600 2474).
  • the amino acid sequence information of the polypeptides of the present invention and the recording medium of the present invention provide for in the above items 2 and 8 can be used.
  • proteome analysis of a wild type strain of coryneform bacteria and a production strain showing an improved productivity of a target product makes it possible to efficiently identify a mutation protein which is useful in breeding for improving the productivity of a target product or a protein of which expression amount is fluctuated.
  • a wild type strain of coryneform bacteria and a lysine-producing strain thereof are each subjected to the proteome analysis. Then, a spot increased in the lysine-producing strain, compared with the wild type strain, is found and a data base is searched so that a polypeptide showing an increase in yield in accordance with an increase in the lysine productivity can be identified. For example, as a result of the proteome analysis on a wild type strain and a lysine-producing strain, the productivity of the catalase having the amino acid sequence represented by SEQ ID NO:3785 is increased in the lysine-producing mutant.
  • nucleotide sequence of the gene encoding this protein and the nucleotide sequence in the upstream thereof can be searched at the same time, and thus, a nucleotide sequence having a high expression promoter can be efficiently selected.
  • the modified protein can be efficiently identified using the recording medium storing the nucleotide sequence information, the amino acid sequence information, of the genome of coryneform bacteria, and the recording medium storing the sequences, according to the present invention.
  • a useful mutation point in a useful mutant can be easily specified by searching a nucleotide sequence (nucleotide sequence of promoters, ORF, or the like) relating to the thus identified protein using a recording medium storing the nucleotide sequence information and the amino acid sequence information, of the genome of coryneform bacteria of the present invention, and a recording medium storing the sequences and using a primer designed on the basis of the detected nucleotide sequence.
  • a nucleotide sequence nucleotide sequence of promoters, ORF, or the like
  • Corynebacterium glutamicum ATCC 13032 was cultured in BY medium (7 g/l meat extract, 10 g/l peptone, 3 g/l sodium chloride, 5 g/l yeast extract, pH 7.2) containing 1% of glycine at 30° C. overnight and the cells were collected by centrifugation. After washing with STE buffer (10.3% sucrose, 25 mmol/l Tris hydrochloride, 25 nmuol/l EDTA, pH 8.0), the cells were suspended in 10 ml of STE buffer containing 10 mg/ml lysozyme, followed by gently shaking at 37° C. for 1 hour.
  • BY medium 7 g/l meat extract, 10 g/l peptone, 3 g/l sodium chloride, 5 g/l yeast extract, pH 7.2
  • STE buffer 10.3% sucrose, 25 mmol/l Tris hydrochloride, 25 nmuol/l EDTA, pH 8.0
  • the genome DNA was dissolved again in 3 ml of TE buffer (10 mmol/l Tris hydrochloride, 1 mmol/l EDTA, pH 8.0) containing 0.02 mg/ml of RNase and maintained at 37° C. for 45 minutes. The extractions with phenol, phenol/chloroform and chloroform were carried out successively in the same manner as the above.
  • the genome DNA was subjected to isopropanol precipitation.
  • the thus formed genome DNA precipitate was washed with 70% ethanol three times, followed by air-drying, and dissolved in 1.25 ml of TE buffer to give a genome DNA solution (concentration:0.1 mg/ml).
  • TE buffer was added to 0.01 mg of the thus prepared genome DNA of Corynebacterium glutamicum ATCC 13032 to give a total volume of 0.4 ml, and the mixture was treated with a sonicator (Yamato Powersonic Model 150) at an output of 20 continuously for 5 seconds to obtain fragments of 1 to 10 kb.
  • the genome fragments were blunt-ended using a DNA blunting kit (manufactured by Takara Shuzo) and then fractionated by 6% polyacrylamide gel electrophoresis.
  • Genome fragments of 1 to 2 kb were cut out from the gel, and 0.3 ml MG elution buffer (0.5 mol/l ammonium acetate, 10 mmol/l magnesium acetate, 1 mmol/l EDTA, 0.1% SDS) was added thereto, followed by shaking at 37° C. overnight to elute DNA.
  • the DNA eluate was treated with phenol/chloroform, and then precipitated with ethanol to obtain a genome library insert.
  • the total insert and 500 ng of pUC18 SmaIl/BAP (manufactured by Amersham Pharmacia Biotech) were ligated at 16° C. for 40 hours.
  • the ligation product was precipitated with ethanol and dissolved in 0.01 ml of TE buffer.
  • the ligation solution (0.001 ml) was introduced into 0.04 ml of E. coli ELECTRO MAX DH10B (manufactured by Life Technologies) by the electroporation under conditions according to the manufacture's instructions.
  • LB plate medium (LB medium (10 g/l bactotrypton, 5 g/l yeast extract, 10 g/l sodium chloride, pH 7.0) containing 1.6% of agar) containing 0.1 mg/ml ampicillin, 0.1 mg/ml X-gal and 1 mmol/l isopropyl- ⁇ -D-thiogalactopyranoside (IPTG) and cultured at 37° C. overnight.
  • LB medium (10 g/l bactotrypton, 5 g/l yeast extract, 10 g/l sodium chloride, pH 7.0) containing 1.6% of agar
  • IPTG isopropyl- ⁇ -D-thiogalactopyranoside
  • the transformant obtained from colonies formed on the plate medium was stationarily cultured in a 96-well titer plate having 0. 05 ml of LB medium containing 0.1 mg/ml ampicillin at 37° C. overnight. Then, 0.05 ml of LB medium containing 20% glycerol was added thereto, followed by stirring to obtain a glycerol stock.
  • the DNA fragment was ligated to the BamHI site of superCosl (manufactured by Stratagene) in accordance with the manufacture's instructions.
  • the ligation product was incorporated into Escherichia coli XL-1-BlueMR strain (manufactured by Stratagene) using Gigapack III Gold Packaging Extract (manufactured by Stratagene) in accordance with the manufacture's instructions.
  • the Escherichia coli was spread on LB plate medium containing 0.1 mg/ml ampicillin and cultured therein at 37° C. overnight to isolate colonies. The resulting colonies were stationarily cultured at 37° C.
  • the full nucleotide sequence of Corynebacterium glutamicum ATCC 13032 was determined mainly based on the whole genome shotgun method.
  • the template used in the whole geenome shotgun method was prepared by the PCR method using the library prepared in the above (2).
  • the clone derived from the whole genome shotgun library was inoculated using a replicator (manufactured by GENETIX) into each well of a 96-well plate containing the LB medium containing 0.1 mg/ml of ampicillin at 0.08 ml per each well and then stationarily cultured at 37° C. overnight.
  • a replicator manufactured by GENETIX
  • the culturing solution was transported using a copy plate (manufactured by Tokken) into a 96-well reaction plate (manufactured by PE Biosystems) containing a PCR reaction solution (TaKaRa Ex Taq (manufactured by Takara Shuzo)) at 0.08 ml per each well. Then, PCR was carried out in accordance with the protocol by Makino et al. ( DNA Research, 5:1-9 (1998)) using GeneAmp PCR System 9700 (manufactured by PE Riosystems) to amplify the inserted fragment.
  • nucleotide sequences were determined using a double-stranded DNA plasmid as a template.
  • the double-stranded DNA plasmid as the template was obtained by the following method.
  • the clone derived from the whole genome shotgun library was inoculated into a 24- or 96-well plate containing a 2 ⁇ YT medium (16 g/l bactotrypton, 10 g/l yeast extract, 5 g/l sodium chloride, pH 7 0) containing 0.05 mg/ml ampicillin at 1. 5 ml per each well and then cultured under shaking at 37° C. overnight.
  • a 2 ⁇ YT medium (16 g/l bactotrypton, 10 g/l yeast extract, 5 g/l sodium chloride, pH 7 0
  • the double-stranded DNA plasmid was prepared from the culturing solution using an automatic plasmid preparing machine, K BO PI-50 (manufactured by Kurabo Industries) or a multiscreen (manufactured by Millipore) in accordance with the protocol provided by the manufacturer.
  • Dye terminator sequencing reaction of 45 cycles was carried out with GeneAmp PCR System 9700 (manufactured by PE Biosystems) using the reaction solution.
  • the cycle parameter was determined in accordance with the manufacturer's instruction accompanying ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction Kit.
  • the sample was purified using MultiScreen HV plate (manufactured by Millipore) according to the manufacture's instructions.
  • the thus purified reaction product was precipitated with ethanol, followed by drying, and then stored in the dark at ⁇ 30° C.
  • the dry reaction product was analyzed by ABI PRISM 377 DNA Sequencer and ABI PRISM 3700 DNA Analyzer (both manufactured by PE Biosystems) each in accordance with the manufacture's instructions.
  • Each cosmid in the cosmid library constructed in the above (3) was prepared by a method similar to the preparation of the double-stranded DNA plasmid described in the above (4-1).
  • the nucleotide sequence at the end of the inserted fragment of the cosmid was determined by using ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction Kit (manufactured by PE Biosystems) according to the manufacture's instructions.
  • Clones containing sequences positioned at the ends of contigs were selected. Among these clones, about 1,000 clones wherein only one end of the inserted fragment had been determined were selected and the sequence at the opposite end of the inserted fragment was determined. A shotgun library clone or a cosmid clone containing the sequences at the respective ends of the inserted fragment in two contigs was identified, the full nucleotide sequence of the inserted fragment of this clone was determined, and thus the nucleotide sequence of the gap part was determined.
  • ORFs in the nucleotide sequence represented by SEQ ID NO:1 were identified according to the following method. First, the ORF regions were determined using software for identifying ORF, i.e., Glimmer, Generk and GeMark.hmm on UNIX platform according to the respective manual attached to the software.
  • the putative function of an ORF was determined by searching the homology of the identified amino acid sequence of the OR against an amino acid database consisting of protein-encoding domains derived from Swiss-Prot, PIR or Genpept database constituted by protein encoding domains derivezd from Gersank database, Frame Search (manufactured by Compugen), or by searching the homology of the identified amino acid sequence of the ORF against an amino acid database consisting of protein-encoding domains derived from Swiss-Prot, PIR or Genpept database constituted by protein encoding domains derived from GenBank database, BLAST
  • the nucleotide sequences of the thus determined ORFs are shown in SEQ ID NOS:2 to 3501, and the amino acid sequences encoded by these ORFs are shown in SEQ ID NOS:3502 to 7001.
  • nucleotide sequences such as TTG, TOT, GGT, and the like, other than ATG, are read as an initiating codon encoding Met.
  • the preferred nucleotide sequences are SEQ ID NOS:2 to 355 and 357 to 3501, and the preferred amino acid sequences are shown in SEQ ID NOS:3502 to 3855 and 3857 to 7001
  • Table 1 shows the registration numbers in the above-described databases of sequences which were judged as having the highest homology with the nucleotide sequences of the ORFs as the results of the homology search in the amino acid sequences using the homology-searching software Frame Search (manufactured by Compugen) names of the genes of these sequences, the functions of the genes, and the matched length, identities and analogies compared with publicly known amino acid-translation sequences Moreover, the corresponding positions were confirmed via the alignment of the nucleotide sequence of an arbitrary ORF with the nucleotide sequence of SEQ ID NO:1. Also, the positions of nucleotide sequences other than the ORFs (for example, ribosomal RNA genes, transfer RN genes, IS sequences, and the like) on the genome were determined.
  • the positions of nucleotide sequences other than the ORFs for example, ribosomal RNA genes, transfer RN genes, IS sequences, and the like
  • FIG. 1 shows the positions of typical genes of the Corynebacterium glutamicum ATCC 13032 on the genome.
  • SEQ NO. SEQ NO. Identity Similarity Matched (DNA) (a.a.) Initial (nt) Terminal (nt) ORF (bp) db Match Homologous gene (%) (%) length (a.a.) Function 2 3502 1 1572 1572 gsp:R98523 Brevibacterium flavum dnaA 99.8 99.8 524 replication initiation protein DnaA 3 3503 1920 1597 324 4 3504 2292 3473 1182 sp:DP3B_MYCSM Mycobacterium smegmatis dnaN 50.5 81.8 390 DNA polymerase III beta chain 5 3505 3585 4766 1182 sp:RECF_MYCSM Mycobacterium smegmatis recF 53.3 79.9 392 DNA replication protein (recF protein) 6 3506 4766 5299 5
  • As4 arsB 52.2 84.2 341 arsenic oxyanion-translocation pump membrane subunit 294 3794 279893 280279 387 sp:ARSC_STAXY Staphylococcus xylosus arsC 31.1 68.9 119 arsenate reductase 295 3795 280666 280349 318 296 3796 280939 280670 270 297 3797 281401 280949 453 298 3798 282933 281404 1530 gp:AF097740_4 Bacillus firmus OF4 mrpD 32.4 70.4 503 Na+/H+ antiporter or multiple resistance and pH regulation related protein D 299 3799 283317 282937 381 prf:2504285D Staphylococcus aureus m
  • rpsK 626 4126 574615 575217 603 prf:2211287F Mycobacterium tuberculosis 82.6 93.9 132 30S ribosomal protein S4 H37Rv RV3458C rpsD 627 4127 575338 576351 1014 sp:RPOA_BACSU Bacillus subtilis 168 rpoA 51.1 77.8 311 RNA polymerase alpha subunit 628 4128 575366 575211 156 629 4129 576410 576898 489 sp:RL17_ECOLI Escherichia coli K12 rplQ 51.6 77.1 122 50S ribosomal protein L17 630 4130 577057 577923 867 sp:TRUA_ECOLI Escherichia coli K12 truA 37.0 61.1 265 pseudouridylate synthase A 631 4131 578033 580429 2397 pir:G70695
  • rplM 647 4147 595382 595927 546 sp:RS9_STRCO Streptomyces coelicolor A3(2) 49.2 72.4 181 30S ribosomal protein S9 SC6G4.13.
  • rpsl 648 4148 596109 597449 1341 prf:2320260A Staphylococcus aureus 48.9 76.4 450 phosphoglucosamine mutase femR315 649 4149 597892 598194 303 650 4150 598194 599702 1509 pir:S75138 Synechocystis sp.
  • GTP pyrophosphokinase (ATP:GTP 3′-pyrophosphotransferase) (ppGpp synthetase I) 1303 4803 1238125 1236545 1581 gsp:R80504 Streptomyces lividans tap 26.6 49.3 601 tripeptidyl aminopeptidase 1304 4804 1242156 1241554 603 1305 4805 1242275 1242156 120 1306 4806 1243621 1243728 108 GSP:P61449 Corynebacterium glutamicum 95.0 98.0 24 homoserine dehydrogenase 1307 4807 1245201 1243942 1260 1308 4808 1245532 1244843 690 1309 4809 1246496 1245720 777 sp:NARI_BACSU Bacillus subtilis narl 45.0 69.6 220 nitrate reductase gamma chain 1310 4810 12472
  • vanA 39.5 68.6 357 vanillate demethylase(oxygenase) 2616 6116 2526233 2527207 975 gp:FSU12290_2 Sphingomonas flava ATCC 32.8 59.2 338 pentachlorophenol 4- 39723 pcpD monooxygenase reductase 2617 6117 2527135 2528559 1425 prf:2513416G Acinetobacter sp.
  • vanK 40.8 76.8 444 transport protein 2618 6118 2529480 2528551 930 gp:KPU95087_7 Klebsiella pneumoniae mdcF 28.0 58.4 286 malonate transporter 2619 6119 2530761 2529484 1278 prf:2303274A Bacillus subtilis clpX 59.8 85.8 430 class-III heat-shock protein or ATP- dependent protease 2620 6120 2530891 2531976 1086 gp:SCF55_28 Streptomyces coelicolor A3(2) 45.6 73.0 366 hypothetical protein SCF55.28c 2621 6121 2532601 2531969 633 gp:AF109386_2 Streptomyces sp.
  • Corynebacterium glutamicum B-6 which is resistant to S-(2-aminoethyl)cysteine (AEC), rifampicin, streptomycin and 6-azauracil, is a lysine-producing mutant having been mutated and bred by subjecting the wild type ATCC 13032 strain to multiple rounds of random mutagenesis with a mutagen, N-methyl-N′-nitro-N-nitrosoguanidine (NTG) and screening ( Appl. Microbiol. Biotechnol., 32:269-273 (1989)).
  • NTG N-methyl-N′-nitro-N-nitrosoguanidine
  • screening Appl. Microbiol. Biotechnol., 32:269-273 (1989)
  • the genes relating to the lysine production include lyse and lysG which are lysine-excreting genes; ddh, dapA, hom and lysC (encoding diaminopimelate dehydrogenase, dihydropicolinate synthase, homoserine dehydrogenase and aspartokinase, respectively) which are lysine-biosynthesis genes; and pyc and zwf (encoding private carboxylase and glucose-6-phosphate dehydrogenase, respectively) which are glucose-metabolizing genes.
  • the nucleotide sequences of the genes derived from the production strain were compared with the corresponding nucleotide sequences of the ATCC 13032 strain genome represented by SEQ ID NOS:1 to 3501 and analyzed.
  • mutation points were observed in many genes. For example, no mutation site was observed in lysE, lysG, ddh, dapA, and the like, whereas amino acid replacement mutations were found in hom, lysC, pyc, zvf, and the like.
  • those which are considered to contribute to the production were extracted on the basis of known biochemical or genetic information.
  • a mutation, Val59Ala, in hor and a mutation, Pro458Ser, in pyc were evaluated whether or not the mutations were effective according to the following method.
  • a plasmid vector pCES30 for the gene replacement for the introduction was constructed by the following method.
  • the pCE53 fragment and the 2.6 kb DNA fragment were ligated using Ligation Kit ver. 2 (manufactured by Takara Shuzo), introduced into the ATCC 13032 strain by the electroporation method ( FEMS Microbiology Letters, 65:299 (1989)), and cultured on BYG agar medium (medium prepared by adding 10 g of glucose, 20 g of peptone (manufactured by Kyokuto Pharmaceutical), 5 g of yeast extract (manufactured by Difco), and 16 g of Bactoagar (manufactured by Difco) to 1 liter of water, and adjusting its pH to 7.2) containing 25 ⁇ g/ml kanamycin at 30° C.
  • BYG agar medium medium prepared by adding 10 g of glucose, 20 g of peptone (manufactured by Kyokuto Pharmaceutical), 5 g of yeast extract (manufactured by Difco), and 16 g of Bactoagar (manufactured
  • pCES30 was digested with BamHI (manufactured by Takara Shuzo), subjected to an agarose gel electrophoresis, and extracted and purified using GENECLEAN Kit (manufactured by BIO 101). The both ends of the resulting pCES30 fragment were blunted with DNA Blunting Kit (manufactured by Takara Shuzo) according to the attached protocol.
  • the blunt-ended pCES30 fragment was concentrated by extraction with phenol/chloroform and precipitation with ethanol, and allowed to react in the presence of Taq polymerase (manufactured by Roche Diagnostics) and dTTP at 70° C. for 2 hours so that a nucleotide, thymine (T), was added to the 3′-end to prepare a T vector of pCES30.
  • Taq polymerase manufactured by Roche Diagnostics
  • chromosomal DNA was prepared from the lysine-producing B-6 strain according to the method of Saito et al. ( Biochem. Biophys. Acta, 72:619 (1963)). Using the chromosomal DNA as a template, PCR was carried out with Pfu turbo DNA polymelase (manufactured by stratagene). In the mutated hom gene, the DNAs having the nucleotide sequences represented by SEQ ID NOS:7002 and .7003 were used as the primer set. In the mutated pyc gene, the DNAs having the nucleotide sequences represented by SEQ ID NOS:7004 and 7005 were used as the primer set.
  • the resulting PCR product was subjected to agarose gel electrophoresis, and extracted and purified using GENEGLEAN Kit (manufactured by BIO 101). Then, the PCR product was allowed to react in the presence of Taq polymerase (manufactured by Roche Diagnostics) and DATP at 72° C. for 10 minutes so that a nucleotide, adenine (A), was added to the 3′-end.
  • GENEGLEAN Kit manufactured by BIO 101
  • Each of the resulting transformants was cultured overnight in BYG liquid medium containing 25 ⁇ g/ml kanamycin, and a plasmid was extracted from the culturing solution medium according to the alkali SDS method.
  • a plasmid was extracted from the culturing solution medium according to the alkali SDS method.
  • the plasmids thus constructed were named respectively pChom59 and pCpyc458.
  • the stains in which the second homologous recombination was carried out were selected by a selection method, making use of the fact that the Bacillus subtilis levansucrase encoded by pCES30 produced a suicidal substance ( J. of Bacteriol., 174:5462 (1992)).
  • strains in which the wild type hom and pyc genes possessed by the ATCC 13032 strain and the No. 58 strain were replaced with the mutated hom and pyc genes, respectively were isolated. The method is specifically explained below.
  • One strain was selected from the transformants containing the plasmid, pChom59 or pCpyc458, and the selected strain was cultured in BYG medium containing 20 gg/ml kanamycin, and pCGll (Japanese Published Examined Patent Application No. 91827/94) was introduced thereinto by the electroporation method.
  • pCGll is a plasmid vector having a spectinomycin-resistant gene and a replication origin which is the same as pCE53. After introduction of the pCGll, the strain was cultured on BYG agar medium containing 20 ⁇ g/ml kanamycin and 100 ⁇ g/ml spectinomycin at 30° C.
  • a strain in which the sacb gene was deleted due to the second homologous recombination between the wild type and the mutated hom or pyc genes positioned closely to each other forms no suicide substrate and, therefore, can grow in this medium.
  • the homologous recombination either the wild type gene or the mutated gene is deleted together with the sacB gene.
  • the gene replacement into the mutated type arises.
  • Chromosomal DNA of each the thus obtained second recombinants was prepared by the above method of Saito et al. PCR was carried out using Pfu turbo DNA polymerase (manufactured by Stratagene) and the attached buffer.
  • Pfu turbo DNA polymerase manufactured by Stratagene
  • DNAs having the nucleotide sequences represented by SEQ ID NOS:7002 and 7003 were used as the primer set.
  • DNAs having the nucleotide sequences represented by SEQ ID NOS:7004 and 7005 were used as the primer set.
  • the nucleotide sequences of the PCR products were determined by the conventional method so that it was judged whether the hom or pyc gene of the second recombinant was a wild type or a mutant.
  • the second recombinant which were called HD-1 and No. 58pyc were target strains having the mutated hor gene and pyc gene, respectively.
  • the HD-1 strain (strain obtained by incorporating the mutation, Val59Ala, in the hor gene into the ATCC 13032 strain) and the No. 58pyc strain (strain obtained by incorporating the mutation, Pro458Ser, in the pyc gene into the lysine-producing No. 58 strain) were subjected to a culture test in a 5 1 jar fermenter by using the ATCC 13032 strain and the lysine-producing No. 58 strain respectively as a control. Thus lysine production was examined.
  • each strain was inoculated into 250 ml of a seed medium (medium prepared by adding 50 g of sucrose, 40 g of corn steep liquor, 8.3 g of ammonium sulfate, 1 g of urea, 2 g of potassium dihydrogenphosphate, 0.83 g of magnesium sulfate heptahydrate, 10 mg of iron sulfate heptahydrate, 1 mg of copper sulfate pentahydrate, 10 mg of zinc sulfate heptahydrate, 10 mg of ⁇ -alanine, 5 mg of nicotinic acid, 1.5 mg of thiamin hydrochloride, and 0.5 mg of biotin to 1 liter of water, and adjusting its pH to 7.2, then to which 30 g of calcium carbonate had been added) contained in a 2 1 buffle-attached Erlenmeyer flask and cultured therein at
  • a total amount of the seed culturing medium was inoculated into 1,400 ml of a main culture medium (medium prepared by adding 60 g of glucose, 20 g of corn steep liquor, 25 g of ammonium chloride, 2.5 g of potassium dihydrogenphosphate, 0.75 g of magnesium sulfate heptahydrate, 50 mg of iron sulfate heptahydrate, 13 mg of manganese sulfate pentahydrate, 50 mg of calcium chloride, 6.3 mg of copper sulfate pentahydrate, 1.3 mg of zinc sulfate heptahydrate, 5 mg of nickel chloride hexahydrate, 1.3 mg of cobalt chloride hexahydrate, 1.3 mg of ammonium molybdenate tetrahydrate, 14 mg of nicotinic acid, 23 mg of ⁇ -alanine, 7 mg of thiamin hydrochloride, and 0.42 mg of biotin to 1 liter of water) contained
  • the lysine-producing mutant B-6 strain ( Appl. Microbiol. Biotechnol., 32:269-273 (1989)), which has been constructed by multiple round random mutagenesis with NTG and screening from the wild type ATCC 13032 strain, produces a remarkably large amount of lysine hydrochloride when cultured in a jar at 32° C. using glucose as a carbon source. However, since the fermentation period is long, .the production rate is less than 2.1 g/l/h. Breeding to reconstitute only effective mutations relating to the production of lysine among the estimated at least 300 mutations introduced into the B-6 strain in the wild type ATCC 13032 strain was performed.
  • nucleotide sequences of genes derived from the B-6 strain were compared with the corresponding nucleotide sequences of the ATCC 13032 strain genome represented by SEQ ID NOS:1 to 3501 and analyzed to identify many mutation points accumulated in the chromosome of the B-6 strain.
  • a mutation, Val59lAla, in hor, a mutation, Thr311Ile, in lysC, a mutation, Pro458Ser, in pyc and a mutation, Ala2l3Thr, in zwf were specified as effective mutations relating to the production of lysine. Breeding to reconstitute the 4 mutations in the wild type strain and for constructing of an industrially important lysine-producing strain was carried out according to the method shown below.
  • chromosomal DNA was prepared from the lysine-producing B-6 strain according to the above method of Saito et al. Using the chromosomal DNA as a template, PCR was carried out with Pfu turbo DNA polymerase (manufactured by Stratagene). In the mutated lysC gene, the DNAs having the nucleotide sequences represented by SEQ ID NOS:7006 and 7007 were used as the primer set. In the mutated gene, the DNAs having the nucleotide sequences represented by SEQ ID NOS:7008 and 7009 as the primer set.
  • the resulting PCR product was subjected to agarose gel electrophoresis, and extracted and purified using GENEGLEAN Kit (manufactured by BIO 101). Then, the PCR product was allowed to react in the presence of Taq DNA polymerase (manufactured by Roche Diagnostics) and DATP at 72° C. for 10 minutes so that a nucleotide, adenine (A), was added to the 3′-end.
  • Taq DNA polymerase manufactured by Roche Diagnostics
  • Each of the resulting transformants was cultured overnight in BYG liquid medium containing 25 ⁇ g/ml kanamycin, and a plasmid was extracted from the culturing solution medium according to the alkali SDS method.
  • a plasmid was extracted from the culturing solution medium according to the alkali SDS method.
  • the plasmids thus constructed were named respectively pClysC311 and pCzwf2l3.
  • the strain which was named AHD-2 was a two point mutant having the mutated lysC gene in addition to the mutated hom gene.
  • the mutation, Pro458Ser, in pyc was introduced into the AHD-2 strain using the pCpyc458 produced in Example 2(2) by the gene replacement method described in Example 2 (2).
  • PCR was carried out using chromosomal DNA of the resulting strain and, as the primer set, DNAs having the nucleotide sequences represented by SEQ ID NOS:7004 and 7005 in the same manner as in Example 2 (2).
  • AHD-3 was a three point mutant having the mutated pyc gene in addition to the mutated hom gene and lysC gene.
  • the present invention provides a novel breeding method effective for eliminating the problems in the conventional mutants and acquiring industrially advantageous strains.
  • This methodology which reconstitutes the production strain by reconstituting the effective mutation is an approach which is efficiently carried out using the nucleotide sequence information of the genome disclosed in the present invention, and its effectiveness was found for the first time in the present invention.
  • a DNA microarray was produced based on the nucleotide sequence information of the ORF deduced from the full nucleotide sequences of Corynebacterium glutamicum ATCC 12032 using software, and genes of which expression is fluctuated depending on the carbon source during culturing were searched.
  • chromosomal DNA was prepared from Corynebacterium glutamicum ATCC 13032 by the method of Saito et al. ( Biochem. Biophys. Acta, 72:619 (1963)). Based on 24 genes having the nucleotide sequences represented by SEQ ID NOS:207, 3433, 281, 3435, 3439, 765, 3445, 1226, 1229, 3448, 3451, 3453, 3455, 1743, 3470, 2132, 3476, 3477, 3485, 3488, 3489, 3494, 3496, and 3497 from the ORFs shown in Table 1 deduced from the full genome nucleotide sequence of Corynebacterium glutamicum ATCC 13032 using software and the nucleotide sequence of rabbit globin gene (GenBank Accession No. V00882) used as an internal standard, oligo DNA primers for PCR amplification represented by SEQ ID NOS:7010 to 7059 targeting the nucleotide sequences of the genes were
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7010 and 7011 were used for the amplification of the DNA having the nucleotide sequence represented by SEQ ID NO:207,
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7012 and 7013 were used for the amplification of the DNA having the nucleotide sequence represented by SEQ ID NO:3433,
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7014 and 7015 were used for the amplification of the DNA having the nucleotide sequence represented by SEQ ID NO:281,
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7016 and 7017 were used for the amplification of the DNA having the nucleotide sequence represented by SEQ ID NO:3435,
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7018 and 7019 were used for the amplification of the DNA having the nucleotide sequence represented by SEQ ID No:3439,
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7020 and 7021 were used for the amplification of the DNA having the nucleotide sequence represented by SEQ ID NO:765,
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7022 and 7023 were used for the amplification of the DNA having the nucleotide sequence represented by SEQ ID NO:3445,
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7024 and 7025 were used for the amplification of the DNA having the nucleotide sequence represented by SEQ ID NO:1226,
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7026 and 7027 were used for the amplification of the DNA having the nucleotide sequence represented by SEQ ID NO:1229,
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7028 and 7029 were used for the amplification of the DNA having the nucleotide sequence represented by SEQ ID NO:3448,
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7030 and 7031 were used for the amplification of the DNA having the nucleotide sequence represented by SEQ ID NO:3451,
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7032 and 7033 were used for the amplification of the DNA having the nucleotide sequence represented by SEQ ID NO:3453,
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7034 and 7035 were used for the amplification of the DNA having the nucleotide sequence represented by SEQ ID NO:3455,
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7036 and 7037 were used for the amplification of the DNA having the nucleotide sequence represented by SEQ ID NO:1743,
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7038 and 7039 were used for the amplification of the DNA having the nucleotide sequence represented by SEQ ID NO:3470,
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7040 and 7041 were used for the amplification of the DNA having the nucleotide sequence represented by SEQ ID NO:2132,
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7042 and 7043 were used for the amplification of the DNA having the nucleotide sequence represented by SEQ ID NO:3476,
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7044 and 7045 were used for the amplification of the DNA having the nucleotide sequence represented by SEQ ID NO:3477,
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7046 and 7047 were used for the amplification of the DNA having the nucleotide sequence represented by SEQ ID NO:3485,
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7048 and 7049 were used for the amplification of the DNA having the nucleotide sequence represented by SEQ ID NO:3488,
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7050 and 7051 were used for the amplification of the DNA having the nucleotide sequence represented by SEQ ID NO:3489,
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7052 and 7053 were used for the amplification of the DNA having the nucleotide sequence represented by SEQ ID NO:3494,
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7054 and 7055 were used for the amplification of the DNA having the nucleotide sequence represented by SEQ ID NO:3496,
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7056 and 7057 were used for the amplification of the DNA having the nucleotide sequence represented by SEQ ID NO:3497, and
  • DNAs having the nucleotide sequence represented by SEQ ID NOS:7058 and 7059 were used for the amplification of the DNA having the nucleotide sequence of the rabbit globin gene,
  • the PCR was carried for 30 cycles with each cycle consisting of 15 seconds at 95° C. and 3 minutes at 68° C. using a thermal cycler (GeneAmp PCR system 9600, manufactured by Perkin Elmer), TaKaRa EX-Taq (manufactured by Takara Shuzo), 100 ng of the chromosomal DNA and the buffer attached to the TaKaRa Ex-Taq reagent.
  • a thermal cycler GeneAmp PCR system 9600, manufactured by Perkin Elmer
  • TaKaRa EX-Taq manufactured by Takara Shuzo
  • 100 ng the chromosomal DNA
  • the buffer attached to the TaKaRa Ex-Taq reagent 100 ng of the chromosomal DNA
  • the buffer attached to the TaKaRa Ex-Taq reagent 100 ng of the chromosomal DNA
  • the buffer attached to the TaKaRa Ex-Taq reagent 100 ng of the chromoso
  • the PCR product of each gene thus amplified was subjected to agarose gel electrophoresis and extracted and purified using QIAquick Gel Extraction Kit (manufactured by QIAGEN).
  • the purified PCR product was concentrated by precipitating it with ethanol and adjusted to a concentration of 200 ng/ ⁇ l.
  • Each PCR product was spotted on a slide glass plate (manufactured by Matsunami Glass) having MAS coating in 2 runs using GTMASS SYSTEM (manufactured by Nippon Laser & Electronics Lab.) according to the manufacture's instructions.
  • the ATCC 13032 strain was spread on BY agar medium (medium prepared by adding 20 g of peptone (manufactured by Kyokuto Pharmaceutical), 5 g of yeast extract (manufactured by Difco), and 16 g of Bactoagar (manufactured by Difco) to in 1 liter of water and adjusting its pH to 7.2) and cultured at 30° C. for 2 days. Then, the cultured strain was further inoculated into 5 ml of BY liquid medium and cultured at 30° C. overnight.
  • BY agar medium medium prepared by adding 20 g of peptone (manufactured by Kyokuto Pharmaceutical), 5 g of yeast extract (manufactured by Difco), and 16 g of Bactoagar (manufactured by Difco) to in 1 liter of water and adjusting its pH to 7.2) and cultured at 30° C. for 2 days. Then, the cultured strain was further inoculated into 5 ml of B
  • the cultured strain was further inoculated into 30 ml of a minimum medium (medium prepared by adding 5 g of ammonium sulfate, 5 g of urea, 0.5 g of monopotassium dihydrogenphosphate, 0.5 g of dipotassium monohydrogenphosphate, 20.9 g of morpholinopropanesulfonic acid, 0.25 g of magnesium sulfate heptahydrate, 10 mg of calcium chloride dihydrate, 10 mg of manganese sulfate monohydrate, 10 mg of ferrous sulfate heptahydrate, 1 mg of zinc sulfate heptahydrate, 0.2 mg copper sulfate, and 0.2 mg biotin to 1 liter of water, and adjusting its pH to 6.5) containing 110 mmol/l glucose or 200 mmol/l ammonium acetate, and cultured in an Erlenmyer flask at 30° to give 1.0 of absorbance at 660 nm.
  • RNA was prepared from the resulting cells according to the method of Bormann et al. ( Molecular Microbiology, 6:317-326 (1992)). To avoid contamination with DNA, the RNA was treated with DnaseI (manufactured by Takara Shuzo) at 37° C. for 30 minutes and then further purified using Qiagen RNeasy MiniKit (manufactured by QIAGEN) according to the manufacture's instructions.
  • DnaseI manufactured by Takara Shuzo
  • Qiagen RNeasy MiniKit manufactured by QIAGEN
  • RNA To 30 fg of the resulting total RNA, 0.6 ⁇ l of rabbit globin MRNA (50 ng/ ⁇ l, manufactured by Life Technologies) and 1 ⁇ l of a random 6 mer primer (500 ng/ ⁇ l, manufactured by Takara Shuzo) were added for denaturing at 65° C. for 10 minutes, followed by quenching on ice.
  • rabbit globin MRNA 50 ng/ ⁇ l, manufactured by Life Technologies
  • a random 6 mer primer 500 ng/ ⁇ l, manufactured by Takara Shuzo
  • RNA extracted from the cells using glucose as the carbon source and the RNA extracted from the cells using ammonium acetate were labeled with Cy5-dUTP and Cy3-dUTP, respectively.
  • the RNA was digested by adding 1.5 ⁇ l of 1 mol/l sodium hydroxide-20 mmol/l EDTA solution and 3.0 ⁇ l of 10% SDS solution, and allowed to stand at 65° C. for 10 minutes.
  • the two cDNA solutions after the labeling were mixed and purified using Qiagen PCR purification Kit (manufactured by QIAGEN) according to the manufacture's instructions to give a volume of 10 ⁇ l.
  • UltraHyb 110 ⁇ l (manufactured by Ambion) and the fluorescence-labeled CDNA solution (10 ⁇ l) were mixed and subjected to hybridization and the subsequent washing of slide glass using GeneTAC Hybridization Station (manufactured by Genomic Solutions) according to the manufacture's instructions. The hybridization was carried out at 50° C., and the washing was carried out at 25° C.
  • Table 5 shows the Cy3 and Cy5 signal intensities of the genes having been corrected on the basis of the data of the rabbit globin used as the internal standard and the Cy3/Cy5 ratios.
  • SEQ ID NOS:3488 and 3489 are a maleate synthase gene and an isocitrate lyase gene, respectively. It is known that these genes are transcriptionally induced by acetic acid in Corynebacterium glutamicum (Archives of Microbiology, 168:262-269 (1997)).
  • This Example shows that the expression amount can be analyzed using a DNA microarray in the 24 genes.
  • the present DNA microarray techniques make it possible to prepare DNA microarrays having thereon several thousand gene probes at once. Accordingly, it is also possible to prepare DNA microarrays having thereon all of the ORF gene probes deduced from the full genomic nucleotide sequence of Corynebacterium glutamicum ATCC 13032 determined by the present invention, and analyze the expression profile at the total gene level of Corynebacterium glutamicum using these arrays.
  • the amino acid sequence (ADDECOLI) of Escherichia coli adenosine deaminase was obtained from Swiss-prot Database as the amino acid sequence of the protein of which function had been confirmed as adenosine deaminase (EC3.5.4.4).
  • a homology search was carried out on a nucleotide sequence database of the genome sequence of Corynebacterium glutamicum or a database of the amino acids in the ORF region deduced from the genome sequence using FASTA program ( Proc. Natl. Acad. Sci. ISA, 85:2444-2448 (1988)).
  • amino acid sequences encoded by two ORFS namely, an ORF positioned in the region of the nucleotide sequence No. 615336 to 616853 (or ORF having the nucleotide sequence represented by SEQ ID NO:672) and another ORF positioned in the region of the nucleotide sequence No. 616973 to 618094 (or ORF having the nucleotide sequence represented by SEQ ID NO:674) were significantly homologous with the ORFs of Escherichia coli IMP dehydrogenase.
  • GenBank http://www.ncbi.nlm.nih.gov/
  • nr-aa database amino acid sequence database constructed on the basis of GenBankCDS translation products, PDB database, Swiss-Prot database, PIR database, PRF database by eliminating duplicated registrations
  • both of the two amino acid sequences showed significant homologies with IMP dehdyrogenases of other organisms and clearly higher homologies with IMP dehdyrogenases than with amino acid sequences of other proteins, and thus, it was assumed that the two ORFs would function as IMP dehydrogenase. Based on these results, it was therefore assumed that Corynebacterium glutamicum has two ORFs having the IMP dehydrogenase activity.
  • the washed cells described above were suspended in a disruption buffer (10 mmol/l Tris-HCl, pH 7.4, 5 mmol/l magnesium chloride, 50 mg/l RNase, 1.6 mg/ml protease inhibitor (COMPLETE:manufactured by Boehringer Mannheim)), and disrupted with a disruptor (manufactured by Brown) under cooling.
  • a disruption buffer (10 mmol/l Tris-HCl, pH 7.4, 5 mmol/l magnesium chloride, 50 mg/l RNase, 1.6 mg/ml protease inhibitor (COMPLETE:manufactured by Boehringer Mannheim)
  • a disruptor manufactured by Brown
  • urea was added to give a concentration of 9 mol/l, and an equivalent amount of a lysis buffer (9.5 mol/l urea, 2% NP-40, 2% Ampholine, 5% mercaptoethanol, 1.6 mg/ml protease inhibitor (COMPLETE; manufactured by Boehringer Mannheim) was added thereto, followed by thoroughly stirring at room temperature for dissolving.
  • a lysis buffer 9.5 mol/l urea, 2% NP-40, 2% Ampholine, 5% mercaptoethanol, 1.6 mg/ml protease inhibitor (COMPLETE; manufactured by Boehringer Mannheim) was added thereto, followed by thoroughly stirring at room temperature for dissolving.
  • a molded dry IPG strip gel (pH 4-7, 13 cm, Immobiline DryStrips; manufactured by Amersham Pharmacia Biotech) was set in an electrophoretic apparatus (Multiphor II or IPGphor; manufactured by Amersham Pharmacia Biotech) and a swelling solution (9 mol/l urea, 0.5% Triton X-100, 0.6% dithiothreitol, 0.5%W mpholine, pH 3-10) was packed therein, and the gel was allowed to stand for swelling 12 to 16 hours.
  • the protein sample prepared above was dissolved in a sample solution (9 mol/l urea, 2% CHAPS, 1% dithiothreitol, 2% Ampholine, pH 3-10), and then about 100 to 500 ⁇ g (in terms of protein) portions thereof were taken and added to the swollen IPG strip gel.
  • step 3 4 hours under a gradient mode of 1,000 to 8,000 V;
  • the IPG strip gel was put off from the holder and soaked in an equilibration buffer A (50 mmol/l Tris-HCl, pH 6.8, 30% glycerol, 1% SDS, 0.25t dithiothreitol) for 15 minutes and another equilibration buffer B (50 nmol/l Tris-HCl, pH 6.8, 6 mol/l urea, 30t glycerol, 1% SDS, 0.45% iodo acetamide) for 15 minutes to sufficiently equilibrate the gel.
  • equilibration buffer A 50 mmol/l Tris-HCl, pH 6.8, 30% glycerol, 1% SDS, 0.25t dithiothreitol
  • another equilibration buffer B 50 nmol/l Tris-HCl, pH 6.8, 6 mol/l urea, 30t glycerol, 1% SDS, 0.45% iodo acetamide
  • the IPG strip gel was lightly rinsed in an SDS electrophoresis buffer (1.4% glycine, 0.1% SDS, 0.3% Tris-HCl, pH 8.5), and the second dimensional electrophoresis depending on molecular weight was carried out as described below to separate the proteins.
  • the above IPG strip gel was closely placed on 14% polyacrylamide slub gel (14% polyacrylamide, 0.37% bisacrylamide, 37.5 mmol/l Tris-HCl, pH 8.8, 0.1% SDS, 0.1% TEMED, 0.1% ammonium persulfate) and subjected to electrophoresis under a constant voltage of 30 mA at 20° C for 3 hours to separate the proteins.
  • Coomassie staining was performed by the method of Gorg et al. ( Electrophoresis, 9:531-546 (1988)) for the slub gel after the second dimensional electrophoresis. Specifically, the slub gel was stained under shaking at 25° C. for about 3 hours, the excessive coloration was removed with a decoloring solution, and the gel was thoroughly washed with distilled water.
  • the detected spots were each cut out from the gel and transferred into siliconized tube, and 400 ⁇ l of 100 mmol/l ammonium bicarbonate:acetonitrile solution (1:1, v/v) was added thereto, followed by shaking overnight and freeze-dried as such.
  • 100 mmol/l ammonium bicarbonate:acetonitrile solution (1:1, v/v) was added thereto, followed by shaking overnight and freeze-dried as such.
  • 10 ⁇ l of a lysylendopeptidase (LysC) solution manufactured by WAKO, prepared with 0.1% SDS-containing 50 mmol/l ammonium bicarbonate to give a concentration of 100 ng/ ⁇ l
  • the sample solution for analysis was mixed in the equivalent amount with a solution of a peptide mixture for mass calibration (300 nmol/l Angiotensin II, 300 nmol/l Neurotensin, 150 nmol/l ACTHclip 18-39, 2.3 ⁇ mol/l bovine insulin B chain), and 1 ⁇ l of the obtained solution was spotted on a stainless probe and crystallized by spontaneously drying.
  • a solution of a peptide mixture for mass calibration 300 nmol/l Angiotensin II, 300 nmol/l Neurotensin, 150 nmol/l ACTHclip 18-39, 2.3 ⁇ mol/l bovine insulin B chain
  • PSD post-source decay
  • Spot-1 corresponded to enolase which was a protein having the amino acid sequence of SEQ ID NO:4585
  • Spot-2 corresponded to phosphoglycelate kinase which was a protein having the amino acid sequence of SEQ ID NO:5254
  • Spot-3 corresponded to glyceraldehyde-3-phosphate dehydrogenase which was a protein having the amino acid sequence represented by SEQ ID NO:5255
  • Spot-4 corresponded to fructose bis-phosphatg aldolase which was a protein having the amino acid sequence represented by SEQ ID NO:6543
  • Spot-5 corresponded to triose phosphate isomerase which was a protein having the amino acid sequence represented by SEQ ID NO:5252.
  • Spot-9 was an elongation factor Tu which was a protein having the amino acid sequence represented by SEQ ID No:6937, and that the protein was encoded by DNA having the nucleotide sequence represented by SEQ ID NO:3437.
  • the proteins having high expression level were identified by proteome analysis using the genome sequence database of Corynebacterium glutamicum constructed in Example 1.
  • the nucleotide sequences of the genes encoding the proteins and the nucleotide sequences upstream thereof could be searched simultaneously. Accordingly, it is shown that nucleotide sequences having a function as a high-expression promoter can be efficiently selected.
  • FIG. 2A ATCC 13032:wild type strain
  • FIG. 2B FRM BP-7134:lysine-producing strain
  • FIG. 2C FRM BP-158:lysine-highly producing strain
  • useful mutation points of useful mutants can be easily specified by searching the nucleotide sequences (nucleotide sequences of promoter, ORF, or the like) relating to the identified proteins using the above database and using primers designed on the basis of the sequences.
  • nucleotide sequences nucleotide sequences of promoter, ORF, or the like
  • primers designed on the basis of the sequences As a result of the fact that the mutation points are specified, industrially useful mutants which have the useful mutations or other useful mutations derived therefrom can be easily bred.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
US09/738,626 1999-12-16 2000-12-18 Novel Polynucleotides Abandoned US20020197605A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/805,394 US7332310B2 (en) 1999-12-16 2004-03-22 Mutant of homoserine dehydrogenase from Corynebacterium and DNA encoding thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JPP.HEI11-377484 1999-12-16
JP37748499 1999-12-16
JPP.2000-159162 2000-04-07
JP2000159162 2000-04-07
JPP.2000-280988 2000-08-03
JP2000280988 2000-08-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/805,394 Division US7332310B2 (en) 1999-12-16 2004-03-22 Mutant of homoserine dehydrogenase from Corynebacterium and DNA encoding thereof

Publications (1)

Publication Number Publication Date
US20020197605A1 true US20020197605A1 (en) 2002-12-26

Family

ID=27341889

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/738,626 Abandoned US20020197605A1 (en) 1999-12-16 2000-12-18 Novel Polynucleotides
US10/805,394 Expired - Fee Related US7332310B2 (en) 1999-12-16 2004-03-22 Mutant of homoserine dehydrogenase from Corynebacterium and DNA encoding thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/805,394 Expired - Fee Related US7332310B2 (en) 1999-12-16 2004-03-22 Mutant of homoserine dehydrogenase from Corynebacterium and DNA encoding thereof

Country Status (6)

Country Link
US (2) US20020197605A1 (fr)
EP (2) EP1108790B1 (fr)
JP (1) JP4623825B2 (fr)
KR (2) KR100961398B1 (fr)
AT (1) ATE441724T1 (fr)
DE (1) DE60042872D1 (fr)

Cited By (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055115A1 (en) * 2000-09-09 2002-05-09 Degussa Ag Nucleotide sequences coding for the Dep33 efflux protein
US20020064839A1 (en) * 2000-08-26 2002-05-30 Degusa Ag Nucleotide sequences which code for the oxyR gene
US20020086404A1 (en) * 2000-08-10 2002-07-04 Degussa Ag Nucleotide sequences coding for the luxR gene
US20020103357A1 (en) * 2000-09-26 2002-08-01 Brigitte Bathe Nucleotide sequences which code for the msiK gene
US20020103356A1 (en) * 2000-09-02 2002-08-01 Bettina Mockel Sequences which code for the sigE gene
US20020102664A1 (en) * 2000-09-02 2002-08-01 Degussa Ag Nucleotide sequences which code for the metR and metZ genes
US20020106760A1 (en) * 2000-09-20 2002-08-08 Brigitte Bathe Nucleotide sequences which code for the dps gene
US20020106757A1 (en) * 2000-09-09 2002-08-08 Mike Farwick Nucleotide sequences which code for the dep34 gene
US20020106755A1 (en) * 2000-09-02 2002-08-08 Brigitte Bathe Nucleotide sequences coding for the sigM gene
US20020111468A1 (en) * 2000-09-02 2002-08-15 Brigitte Bathe Nucleotide sequences coding for the sigD gene
US20020115161A1 (en) * 2000-09-27 2002-08-22 Mike Farwick Nucleotide sequences which code for the deaD gene
US20020137912A1 (en) * 2000-08-26 2002-09-26 Bettina Mockel Nucleotide sequences which code for the cstA gene
US20020192674A1 (en) * 2001-01-30 2002-12-19 Degussa Ag Nucleotide sequence coding for the OtsA protein
US20030092026A1 (en) * 2001-05-30 2003-05-15 Degussa Ag Nucleotide sequences which code for the metD gene
US20030092139A1 (en) * 2001-08-09 2003-05-15 Degussa Ag Process for the fermentative preparation of L-amino acids using coryneform bacteria
US20030199045A1 (en) * 1999-07-09 2003-10-23 Kevin Burke Process for the preparation of L-amino acids with amplification of the zwf gene
US6689587B2 (en) * 2000-11-10 2004-02-10 Degussa Ag Polynucleotides encoding the nadC gene and methods of producing nicotinic acid or nicotinic acid derivatives
US20040043953A1 (en) * 2000-12-22 2004-03-04 Markus Pompejus Genes of corynebacterium
US6746854B2 (en) * 2000-09-09 2004-06-08 Degussa Ag Nucleotide sequences encoding histidine kinase from corynebacterium glutamicum
US20040121428A1 (en) * 1999-12-24 2004-06-24 Masakazu Sugimoto Process for producing l-amino acid and novel gene
US20040180408A1 (en) * 1999-06-25 2004-09-16 Markus Pompejus Corynebacterium glutamicum genes encoding proteins involved in carbon metabolism and energy production
US6825030B2 (en) * 2000-08-31 2004-11-30 Degussa Ag Nucleotide sequences encoding a sensor kinase, citA, from corynebacterium glutamicum
US20040259215A1 (en) * 2001-11-05 2004-12-23 Oskar Zelder Genes coding for dna replication and for proteins related to pathogenesis
US20050009152A1 (en) * 2001-11-05 2005-01-13 Oskar Zelder Genes encoding for genetic stability, gene expression and folding proteins
US20050043526A1 (en) * 2001-12-20 2005-02-24 Brigitte Bathe Alleles of the siga gene from coryneform bacteria
US6893852B1 (en) 1999-07-02 2005-05-17 Ajinomoto Co., Inc. Dna encoding sucrose pts enzyme II
US20050112733A1 (en) * 2000-03-20 2005-05-26 Degussa Ag Process for the preparation of L-amino acids with amplification of the zwf gene
US6924134B2 (en) * 2000-09-12 2005-08-02 Degussa Ag Nucleotide sequences which code for the gorA gene
US20060019357A1 (en) * 2001-02-16 2006-01-26 Degussa Ag Nucleotide sequences which code for the rpsL gene
US20060172401A1 (en) * 2003-07-09 2006-08-03 Mitsubishi Chemical Corporation Method for producing organic acid
US20060205048A1 (en) * 2003-08-28 2006-09-14 Mitsubishi Chemical Corporation Process for producing succinic acid
US20060234356A1 (en) * 2003-05-16 2006-10-19 Yoshihiro Usuda Novel polynucleotides encoding useful polypeptides in corynebacterium glutamicum ssp. lactofermentum
US20060276674A1 (en) * 2003-09-30 2006-12-07 Ajinomoto Co., Inc. Method for purifying succinic acid from fermentation broth
US20060281156A1 (en) * 2003-09-17 2006-12-14 Mitsubishi Chemical Corporation Method for producing non-amino organic acid
US20070092951A1 (en) * 2005-03-24 2007-04-26 Degussa Ag Alleles of the zwf gene from coryneform bacteria
US20070122888A1 (en) * 2003-12-18 2007-05-31 Matthias Boy Method for the production of methionine
US7307160B1 (en) * 2000-07-05 2007-12-11 Ajinomoto Co. Inc. OtsA gene encoding trehalose-6-phosphate synthase from a coryneform bacterium
US20070292914A1 (en) * 2003-06-26 2007-12-20 Degussa Ag Feedback Resistant Acetohydroxy Acid Synthethase Mutants
US20080026432A1 (en) * 2003-12-10 2008-01-31 Park Young-Hoon Novel L-Threonine Importer From Corynebacterium And A Preparation Method Of A Strain Producing L-Threonine
US20080076154A1 (en) * 2004-05-18 2008-03-27 Kao Corporation Maltose-1-phosphate-producing enzyme
KR100838038B1 (ko) 2006-12-29 2008-06-12 씨제이제일제당 (주) Ｌ-라이신 생산능이 향상된 코리네박테리움 속 미생물 및그를 이용한 ｌ-라이신 생산 방법
WO2008082180A1 (fr) * 2006-12-29 2008-07-10 Cj Cheiljedang Corporation Micro-organisme du genre corynebacterium possédant une capacité de production de l-lysine améliorée et procédé de production de l-lysine l'utilisant
US20080166775A1 (en) * 2003-12-18 2008-07-10 Basf Aktiengesellschaft P ef-tu expression units
US20080274516A1 (en) * 2003-12-18 2008-11-06 Burkhard Kroger Psod Expression Units
US20080286841A1 (en) * 2003-12-18 2008-11-20 Basf Aktiengesellschaft Pgro expression units
US20080293112A1 (en) * 2004-05-20 2008-11-27 Ajinomoto Co., Inc. Succinic acid-producing bacterium and process for producing succinic acid
US20080293113A1 (en) * 2005-10-18 2008-11-27 Ajinomoto Co., Inc. Process for production of succinic acid
US20090061482A1 (en) * 2003-03-13 2009-03-05 Petra Peters-Wendisch Nucleotide sequences of coryneform bacteria coded for proteins participating in l-serine metabolism and method for microbial production of l-serine
WO2008127290A3 (fr) * 2006-10-12 2009-05-28 Univ Johns Hopkins Compositions d'alginate et d'alginate-lyase et procédés d'utilisation
US20090156779A1 (en) * 2006-02-24 2009-06-18 Mitsubishi Chemical Corporation Bacterium capable of producing organic acid, and method for production of organic acid
US20090246836A1 (en) * 2003-12-18 2009-10-01 Paik Kwang Industrial Co., Ltd Pgro expression units
US20100047900A1 (en) * 2004-12-30 2010-02-25 Young Hoon Park Novel l-Lysine-inducible promoter
US20100129884A1 (en) * 2007-01-24 2010-05-27 Cj Cheiljedang Corporation Process for Producing Fermentation Product from Carbon Sources Containing Glycerol using Corynebacteria
US20100261256A1 (en) * 2007-01-15 2010-10-14 Cj Cheiljedang Corp. Novel promoter nucleic acid molecule derived from corynebacterium glutamicum, recombinant vector comprising the promoter, host cell comprising the recombinant vector and method of expressing gene using the host cell
WO2010017196A3 (fr) * 2008-08-04 2010-11-04 Bayer Healthcare Llc Anticorps monoclonaux contre l'inhibiteur de la voie du facteur tissulaire (tfpi)
US20100330624A1 (en) * 2008-04-10 2010-12-30 Cj Cheiljedang Corporation Vector for transformation using transposons, microorganisms transformed by the vector, and method for producing L-lysine using the same
US20130095534A1 (en) * 2010-02-23 2013-04-18 Toray Industries Inc Process for production of cadaverine
US8481030B2 (en) 2010-03-01 2013-07-09 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
US8530203B2 (en) 2008-09-01 2013-09-10 Shinshu University Process for producing useful substance
US20140065186A1 (en) * 2011-05-18 2014-03-06 Ajinomoto Co., Inc. Immunostimulant for Animals, Feed Containing the Same, and Method for Producing the Same
US8932861B2 (en) 2008-04-10 2015-01-13 Cj Cheiljedang Corporation Transformation vector comprising transposon, microorganisms transformed with the vector, and method for producing L-lysine using the microorganism
US20150031101A1 (en) * 2013-07-26 2015-01-29 Samsung Electronics Co., Ltd. Bacterial cell having enhanced succinic acid production and a method for producing the succinic acid using the same
US9359413B2 (en) 2011-04-04 2016-06-07 Evonik Degussa Gmbh Microorganism and method for the fermentative production of an organic-chemical compound
US9506094B2 (en) 2013-05-13 2016-11-29 Ajinomoto Co., Inc. Method for producing L-amino acid using microorganism having increased phosphate transporter activity
WO2018009372A1 (fr) * 2016-07-05 2018-01-11 Zymergen Inc. Perturbation génétique du complexe protéique dégradosome de l'arn
WO2018005655A3 (fr) * 2016-06-30 2018-02-22 Zymergen Inc. Procédés de génération d'une bibliothèque d'hémoglobines bactériennes et utilisations associées
CN108314713A (zh) * 2017-01-16 2018-07-24 中国科学院微生物研究所 L-苏氨酸转运蛋白ThrG及其编码基因与应用
US10047358B1 (en) 2015-12-07 2018-08-14 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
US10188722B2 (en) 2008-09-18 2019-01-29 Aviex Technologies Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic pH and/or osmolarity for viral infection prophylaxis or treatment
CN109517771A (zh) * 2017-09-18 2019-03-26 赢创德固赛有限公司 发酵生产l-氨基酸的方法
CN109929887A (zh) * 2017-12-15 2019-06-25 宁夏伊品生物科技股份有限公司 改进的发酵生产l-赖氨酸的方法
US10544411B2 (en) 2016-06-30 2020-01-28 Zymergen Inc. Methods for generating a glucose permease library and uses thereof
CN110964090A (zh) * 2019-12-26 2020-04-07 江南大学 一种促进n-乙酰氨基葡萄糖生产的蛋白质起始因子if3突变体及其应用
CN111961635A (zh) * 2020-08-07 2020-11-20 内蒙古伊品生物科技有限公司 一种产l-赖氨酸的重组菌株及其构建方法与应用
CN112266891A (zh) * 2020-10-15 2021-01-26 内蒙古伊品生物科技有限公司 一种产l-氨基酸的重组菌株及其构建方法与应用
CN112585263A (zh) * 2018-07-11 2021-03-30 于利奇研究中心有限公司 来自棒状细菌的d-木糖-脱氢酶和制备d-木糖酸的方法
CN113121658A (zh) * 2020-01-15 2021-07-16 中国农业大学 根瘤菌中含有sh3结构域的蛋白的基因及其相关生物材料和应用
CN113201524A (zh) * 2021-05-08 2021-08-03 廊坊梅花生物技术开发有限公司 肌醇-3-磷酸合酶突变体及其在构建高产谷氨酰胺的谷氨酸棒杆菌中的应用
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11208649B2 (en) 2015-12-07 2021-12-28 Zymergen Inc. HTP genomic engineering platform
CN113906044A (zh) * 2021-04-07 2022-01-07 Cj第一制糖株式会社 新转录调节因子变体及使用其生产l-缬氨酸的方法
US11293029B2 (en) 2015-12-07 2022-04-05 Zymergen Inc. Promoters from Corynebacterium glutamicum
CN114457178A (zh) * 2021-12-07 2022-05-10 浙江省农业科学院 用于预测杨梅果实可溶性固形物的kasp分子标记及其应用
CN114645051A (zh) * 2016-09-15 2022-06-21 日本电气方案创新株式会社 分泌型免疫球蛋白A（sIgA）结合核酸分子、sIgA分析用传感器和sIgA分析方法
CN114774387A (zh) * 2022-03-22 2022-07-22 上海威高医疗技术发展有限公司 嗜热羧酸酯酶突变体及其应用
US11421200B2 (en) * 2018-01-25 2022-08-23 Cj Cheiljedang Corporation Microorganism of the genus Corynebacterium producing purine nucleotide and a method for producing purine nucleotide by using the same
CN114981293A (zh) * 2021-01-29 2022-08-30 Cj第一制糖株式会社 新引发体组装蛋白变体及使用其生产l-赖氨酸的方法
CN115244070A (zh) * 2021-01-29 2022-10-25 Cj第一制糖株式会社 新膜蛋白TerC变体及使用其生产L-赖氨酸的方法
WO2022226190A1 (fr) * 2021-04-23 2022-10-27 Board Of Trustees Of Michigan State University Synthèse d'acide 3-hydroxypropionique par hydratation d'acide acétylènecarboxylique
CN115725490A (zh) * 2022-10-19 2023-03-03 天津大学 一种合成与分泌高效电子传递载体吩嗪-1-羧酸的重组希瓦氏菌株构建方法及用途
US11667936B2 (en) 2018-02-13 2023-06-06 Cj Cheiljedang Corporation Modified polypeptide with attenuated activity of citrate synthase and method for producing L-amino acid using the same

Families Citing this family (304)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1683859A3 (fr) * 1999-06-25 2006-08-02 Basf Aktiengesellschaft Eventuel gène codant pour Catechol 1,2-Dioxygenase de Corynebacterium glutamicum
WO2001000844A2 (fr) * 1999-06-25 2001-01-04 Basf Aktiengesellschaft Proteines codant pour les genes corynebacterium glutamicum, intervenant dans le metabolisme du carbone et dans la production d'energie
US7892798B2 (en) 1999-06-25 2011-02-22 Evonik Degussa Gmbh Nucleic acid molecules encoding metabolic regulatory proteins from Corynebacterium glutamicum, useful for increasing the production of methionone by a microorganism
EP1634952A3 (fr) * 1999-06-25 2006-03-29 BASF Aktiengesellschaft Gènes codants pour des protéines de Corynebacterium glutamicum, qui participent à l'homéostasie et à l'adaptation
EP1246922B1 (fr) * 1999-07-01 2010-10-13 Paik Kwang Industrial Co., Ltd. Genes de corynebacterium glutamicum codant pour des proteines du systeme de transport des sucres phosphotransferase: phosphoenolpyruvate
US20020086371A1 (en) 1999-07-07 2002-07-04 Degussa-Huls Aktiengesellschaft L-lysine-producing corynebacteria and process for the preparation of L-lysine
US6797509B1 (en) 1999-07-09 2004-09-28 Degussa-Huls Ag Nucleotide sequences which code for the tal gene
PL206384B1 (pl) 1999-07-09 2010-08-31 Degussa Izolowany polinukleotyd z bakterii maczugowatych i izolowany polinukleotyd o sekwencji komplementarnej, ich zastosowanie, zawierające je wektor i bakteria oraz sposób wytwarzania L-aminokwasów
US6569650B1 (en) * 1999-08-13 2003-05-27 Degussa Ag Process for the fermentative preparation of metabolic products and for the nucleotide sequences encoding for the sod gene
DE19943587A1 (de) 1999-09-11 2001-03-15 Degussa Neue für das dapF-Gen codierende Nukleotidsequenzen
US6586214B1 (en) * 1999-09-15 2003-07-01 Degussa Ag Method for increasing the metabolic flux through the pentose phosphate cycle in coryneform bacteria by regulation of the phosphoglucose isomerase (pgi gene)
US6872553B2 (en) 1999-10-20 2005-03-29 Degussa Ag Nucleotide sequences which code for the pck gene
DE19950409A1 (de) 1999-10-20 2001-04-26 Degussa Neue für das pck-Gen codierende Nukleotidsequenzen
DE19951708A1 (de) * 1999-10-27 2001-05-03 Degussa Für den Export verzweigtkettiger Aminosäuren kodierende Nikleotidsequenzen, Verfahren zu deren Isolierung und ihre Verwendung
US6911326B1 (en) 1999-11-19 2005-06-28 Kyowa Hakko Kogyo Co., Ltd. GlmU polypeptide and DNA encoding the polypeptide
EP1106622A3 (fr) * 1999-11-23 2004-01-02 Degussa AG Nouvelles séquences nucléotidiques codant pour le gène pfKA
DE19958160A1 (de) 1999-12-02 2001-06-07 Degussa Neue für das gpm-Gen codierende Nukleotidsequenzen
DE19958159A1 (de) 1999-12-02 2001-06-07 Degussa Neue für das glk-Gen codierende Nukleotidsequenzen
US6927046B1 (en) 1999-12-30 2005-08-09 Archer-Daniels-Midland Company Increased lysine production by gene amplification using coryneform bacteria
DE10001101A1 (de) * 2000-01-13 2001-07-19 Degussa Neue für das ptsH-Gen codierende Nukleotidsequenzen
DE10044831A1 (de) * 2000-03-01 2002-04-04 Forschungszentrum Juelich Gmbh Verbessertes Verfahren zur mikrobiellen Herstellung von L-Serin sowie ein dazu geeigneter genetisch veränderter Mikroorganismus
CN1452659A (zh) * 2000-03-09 2003-10-29 Basf公司 编码代谢途径蛋白的谷氨酸棒杆菌基因
WO2001070995A1 (fr) * 2000-03-20 2001-09-27 Degussa Ag Procede pour la preparation fermentative d'acides amines l avec amplification du gene zwf
DE10014546A1 (de) * 2000-03-23 2001-09-27 Degussa Für das dapC-Gen kodierende Nukleotidsequenzen und Verfahren zur Herstellung von L-Lysin
US6562607B2 (en) 2000-05-04 2003-05-13 Degussa-Huls Aktiengesellschaft Nucleotide sequences coding for the cls gene
DE10021831A1 (de) * 2000-05-04 2001-11-08 Degussa Neue für das fadD15-Gen kodierende Nukleotidsequenzen
DE10021829A1 (de) * 2000-05-04 2001-11-08 Degussa Neue für das pgsA2-Gen kodierende Nukleotidsequenzen
DE10021826A1 (de) * 2000-05-04 2001-11-08 Degussa Neue für das cls-Gen kodierende Nukleotidsequenzen
US6949374B2 (en) 2000-05-04 2005-09-27 Degussa Ag FadD15 gene of Corynebacterium glutamicum, encoding an acyl-CoA synthase polypeptide
DE10021832A1 (de) * 2000-05-04 2001-11-08 Degussa Neue für das cma-Gen kodierende Nukleotidsequenzen
DE10021828A1 (de) * 2000-05-04 2001-11-08 Degussa Neue für das cdsA-Gen kodierende Nukleotidsequenzen
DE10023400A1 (de) 2000-05-12 2001-11-15 Degussa Neue für das acp-Gen kodierende Nukleotidsequenzen
US6586229B1 (en) * 2000-06-01 2003-07-01 North Carolina State University Method for the production of ρ-Hydroxybenzoate in species of pseudomonas and agrobacterium
US20020081673A1 (en) * 2000-06-02 2002-06-27 Bettina Mockel Novel nucleotide sequences coding for the glbO gene
DE10032173A1 (de) 2000-07-01 2002-01-17 Degussa Neue für das plsC-Gen kodierende Nukleotidsequenzen
DE10032350A1 (de) 2000-07-04 2002-01-24 Degussa Neue für das mdhA-Gen kodierende Nukleotidsequenzen
EP1174520A3 (fr) * 2000-07-18 2004-02-18 Degussa AG Procédé pour contrôler la fermentation avec un réseau d'expression
US7402660B2 (en) 2000-08-02 2008-07-22 The Johns Hopkins University Endothelial cell expression patterns
WO2002010209A1 (fr) * 2000-08-02 2002-02-07 Degussa Ag Sequences nucleotidiques codant pour le gene meth
EP1307476A1 (fr) * 2000-08-02 2003-05-07 Degussa AG Sequences nucleotidiques codant pour le gene mete
US6958228B2 (en) 2000-08-02 2005-10-25 Degussa Ag Nucleotide sequence which code for the metH gene
AU2001276385A1 (en) * 2000-08-10 2002-02-18 Degussa A.G. Nucleotide sequences which code for the lysr3 gene
DE10039044A1 (de) 2000-08-10 2002-02-21 Degussa Neue für das IysR1-Gen kodierende Nukleotidsequenzen
ES2223900T3 (es) * 2000-08-10 2005-03-01 Degussa Ag Secuencias de nucleotidos que codifican el gen iysr2.
DE10110346A1 (de) * 2000-08-10 2002-02-21 Degussa Neue für das IysR2-Gen kodierende Nukleotidsequenzen
DE10039049A1 (de) 2000-08-10 2002-02-21 Degussa Neue für das IysR3-Gen kodierende Nukleotidsequenzen
ATE357523T1 (de) * 2000-08-26 2007-04-15 Degussa Für das ccpa1-gen kodierende nukleotidsequenzen
AU2001291658A1 (en) 2000-08-26 2002-03-13 Degussa A.G. Nucleotide sequences which code for the ccpa2 gene
US6838267B2 (en) 2000-08-26 2005-01-04 Degussa Ag Nucleotide sequences coding for the ccpA1 gene
EP1313758A1 (fr) * 2000-08-26 2003-05-28 Degussa AG Sequences du nucleotide codant le gene oxyr
ATE357524T1 (de) * 2000-08-31 2007-04-15 Degussa Citb gen aus corynebakterien und seine verwendung zur herstellung von l-aminosäuren
US6812016B2 (en) 2000-09-02 2004-11-02 Degussa Ag Nucleotide sequences which code for the metY gene
DE10109690A1 (de) * 2000-09-02 2002-03-14 Degussa Neue für das metY-Gen kodierende Nukleotidsequenzen
WO2002018430A2 (fr) * 2000-09-02 2002-03-07 Degussa Ag Sequences nucleotidiques codant les genes metr et metz
AU2001285843A1 (en) * 2000-09-02 2002-03-13 Degussa A.G. Sequences which code for the sige gene
AU2001282084A1 (en) * 2000-09-02 2002-03-13 Degussa A.G. Nucleotide sequences which code for the sigh gene
EP1320543A2 (fr) 2000-09-02 2003-06-25 Degussa AG Sequences nucleotidiques codant le gene sigc de corynebacterium glutamicum
US6822085B2 (en) 2000-09-03 2004-11-23 Degussa Ag Nucleotide sequences which code for the cysD, cysN, cysK, cysE and cysH genes
DE10136986A1 (de) * 2000-09-03 2002-03-21 Degussa Für Gene cysD, cysN, cysK, cysE und cysH kodierende Nukleotidsequenzen
EP1315825A2 (fr) * 2000-09-09 2003-06-04 Degussa AG Sequences nucleotidiques codant pour le gene gpmb
EP1315819A2 (fr) * 2000-09-09 2003-06-04 Degussa AG Sequences nucleotidiques codant pour le gene chrs
WO2002020574A1 (fr) * 2000-09-09 2002-03-14 Degussa Ag Sequences nucleotidiques codant le gene clpc
US20020155554A1 (en) * 2000-09-09 2002-10-24 Brigitte Bathe Nucleotide sequences which code for the chrA gene
US6759224B2 (en) 2000-09-09 2004-07-06 Degussa Ag Nucleotide sequences which code for the sahH gene
EP1315745B1 (fr) * 2000-09-09 2006-06-14 Degussa AG Bacteries coryneformes recombinantes surexprimant la glyceraldehyde-3-phosphate dehydrogenase -2, et leur utilisation pour la production de la l-lysine
AU2001279804A1 (en) * 2000-09-09 2002-03-22 Degussa A.G. Nucleotide sequences coding for the hisc2 gene
ATE304598T1 (de) * 2000-09-09 2005-09-15 Degussa Sahh (s-adenosyl homocysteinase) kodierende nukleotidsequenzen
DE10044681A1 (de) * 2000-09-09 2002-03-21 Degussa Neue für das lldD2-Gen kodierende Nukleotidsequenzen
AU2001282132A1 (en) * 2000-09-12 2002-03-26 Degussa A.G. Isolation and sequencing of the pknb gene of c. glutamicum
US6927052B2 (en) 2000-09-12 2005-08-09 Degussa Ag Nucleotide sequences coding for the pknD gene
AU2001285878A1 (en) 2000-09-12 2002-03-26 Degussa A.G. Nucleotide sequences which code for the roda gene
WO2002022632A2 (fr) * 2000-09-12 2002-03-21 Degussa Ag Sequences nucleotidiques codantes pour le gene pknd
US6939692B2 (en) 2000-09-12 2005-09-06 Degussa Ag Nucleotide sequences coding for the pknB gene
WO2002022670A1 (fr) * 2000-09-12 2002-03-21 Degussa Ag Sequences nucleotidiques codant pour le gene ftsx
DE10045497A1 (de) * 2000-09-13 2002-03-28 Degussa Neue für das ppsA-Gen kodierende Nukleotidsequenzen
DE10045496A1 (de) 2000-09-14 2002-03-28 Degussa Neue für das ptsi-Gen kodierende Nukleotidsequenzen
DE10045486A1 (de) * 2000-09-14 2002-04-11 Degussa Neue für das pstC2-Gen kodierende Nukleotidsequenzen
AU2001293741A1 (en) * 2000-09-14 2002-03-26 Degussa A.G. Nucleotide sequences coding for the suga gene
DE10045487A1 (de) * 2000-09-14 2002-04-11 Degussa Neue für das ccsB-Gen kodierende Nukleotidsequenzen
DE10045579A1 (de) * 2000-09-15 2002-04-11 Degussa Neue für das atr61-Gen kodierende Nukleotidsequenzen
AU2001278509A1 (en) * 2000-09-15 2002-03-26 Degussa A.G. Nucleotide sequences which code for the atr43 gene
EP1319077B1 (fr) * 2000-09-19 2005-08-31 Degussa AG Sequences nucleotidiques codant pour le gene tmk
US20020098554A1 (en) * 2000-09-19 2002-07-25 Mike Farwick Nucleotide sequences coding for the pepC gene
US20020106750A1 (en) * 2000-09-19 2002-08-08 Mike Farwick Nucleotide sequences which code for the def gene
US6946271B2 (en) * 2000-09-20 2005-09-20 Degussa Ag Nucleotide sequences which code for the menE gene
DE10046625A1 (de) * 2000-09-20 2002-04-11 Degussa Neue für das ndkA-Gen kodierende Nukleotidsequenzen
AU2001279809A1 (en) * 2000-09-20 2002-04-02 Degussa A.G. Nucleotide sequences coding for the thya gene
DE10047403A1 (de) * 2000-09-26 2002-04-11 Degussa Neue für das ppgK-Gen kodierende Nukleotidsequenzen
DE10047866A1 (de) * 2000-09-27 2002-04-11 Degussa Neue für das dep67-Gen kodierende Nukleotidsequenzen
US7026158B2 (en) 2000-09-27 2006-04-11 Degussa Ag Nucleotide sequences which code for the mikE17 gene
DE10047864A1 (de) * 2000-09-27 2002-04-11 Degussa Neue für das truB-Gen kodierende Nukleotidsequenzen
WO2002026992A1 (fr) * 2000-09-27 2002-04-04 Degussa Ag Sequences nucleotidiques codant le gene cobw
AU2002218223A1 (en) * 2000-10-28 2002-05-06 Degussa A.G. Nucleotide sequences encoding the hemd and hemb genes
US20020168732A1 (en) * 2000-11-10 2002-11-14 Bettina Moeckel Process for the fermentative preparation of L-amino acids using coryneform bacteria
WO2002038598A1 (fr) * 2000-11-10 2002-05-16 Degussa Ag Sequences nucleotidiques codant pour le gene nada
DE10055869A1 (de) 2000-11-10 2002-05-29 Degussa Neue für das nadA-Gen kodierende Nukleotidsequenzen
AU2002230431A1 (en) 2000-11-15 2002-05-27 Archer-Daniels-Midland Company Corynebacterium glutamicum promoters
AU2002223637A1 (en) * 2000-11-22 2002-06-03 Degussa A.G. Nucleotide sequences which code for the mtra and mtrb gene
DE10057801A1 (de) * 2000-11-22 2002-05-23 Degussa Neue für das cysQ-Gen kodierende Nukleotidsequenzen
DE10063314A1 (de) * 2000-12-20 2002-07-04 Degussa Neue für das ilvE-Gen kodierende Nukleotidsequenzen
EP1354051A1 (fr) * 2001-01-25 2003-10-22 Degussa AG Nouvelles sequences nucleotidiques codant pour le gene de cite
US6783967B2 (en) 2001-02-16 2004-08-31 Degussa Ag Nucleotide sequences which code for the rpoB gene
EP1239040A3 (fr) * 2001-02-16 2003-01-08 Degussa AG Mutations du gène rpoB derivées des souches de Corynebacterium glutamicum productrices de L-lysine et procédé pour la préparation de L-lysine
DE10112992A1 (de) * 2001-03-17 2002-09-26 Degussa Verfahren zur fermentativen Herstellung von L-Aminosäuren unter Verwendung coryneformer Bakterien
US20030113879A1 (en) 2001-06-06 2003-06-19 Mike Farwick Novel nucleotide sequences coding the citE gene
DE10128510A1 (de) * 2001-06-13 2002-12-19 Degussa Methode zur Fermentationskontrolle
CN101982546A (zh) * 2001-07-26 2011-03-02 味之素株式会社 二肽的制备方法
US7160711B2 (en) * 2001-08-06 2007-01-09 Degussa Ag Coryneform bacteria which produce chemical compounds I
CN100336901C (zh) * 2001-08-06 2007-09-12 德古萨股份公司 生产化合物ⅱ的棒状细菌
CN100554426C (zh) * 2001-08-06 2009-10-28 德古萨股份公司 用遗传修饰的谷氨酸棒杆菌生产l-赖氨酸
DE10154270A1 (de) 2001-11-05 2003-05-15 Basf Ag Gene die für Kohlenstoffmetabolismus- und Energieproduktion-Proteine codieren
DE10154245A1 (de) * 2001-11-05 2003-06-05 Basf Ag Gene die für regulatorische Proteine codieren
DE10154175A1 (de) * 2001-11-05 2003-05-15 Basf Ag Gene die für Homeostase-und Adaptions-Proteine codieren
DE10154292A1 (de) * 2001-11-05 2003-05-15 Basf Ag Gene die für Stoffwechselweg-Proteine codieren
DE10154181A1 (de) * 2001-11-05 2003-05-15 Basf Ag Gene die für Stressresistenz-und Toleranz-Proteine codieren
DE10154177A1 (de) * 2001-11-05 2003-05-08 Basf Ag Gene die für neue Proteine codieren
DE10155505A1 (de) 2001-11-13 2003-05-22 Basf Ag Gene die für Glucose-6-Phosphat-Dehydrogenase Proteine codieren
US7524667B2 (en) 2001-12-03 2009-04-28 Kyowa Hakko Food Specialties Co., Ltd. Mutated 6-phosphogluconate dehydrogenase
DE10162730A1 (de) * 2001-12-20 2003-07-03 Degussa Allele des glk-Gens aus coryneformen Bakterien
DE10163167A1 (de) * 2001-12-21 2003-07-03 Degussa Verfahren zur fermentativen Herstellung von L-Aminosäuren und Verwendung coryneformer Bakterien
AUPR977601A0 (en) * 2001-12-28 2002-01-31 Delta Biotechnology Limited Defective entities and uses therefor
DE10210527A1 (de) 2002-03-09 2003-09-18 Degussa Allele des aceA-Gens aus coryneformen Bakterien
WO2003078620A1 (fr) 2002-03-19 2003-09-25 Kyowa Hakko Kogyo Co., Ltd. Isopropylmalate isomerase mutee
DE10217058A1 (de) 2002-04-17 2003-11-27 Basf Ag Verfahren zur Herstellung von schwefelhaltigen Feinchemikalien
EP1362866A1 (fr) 2002-05-16 2003-11-19 Basf Aktiengesellschaft Utilisation du répresseur glxR pour la synthèse de lysine par corynebacterium glutamicum
DE10222858A1 (de) 2002-05-23 2003-12-04 Basf Ag Verfahren zur fermentativen Herstellung schwefelhaltiger Feinchemikalien
DE10232776A1 (de) * 2002-07-18 2004-04-08 Henkel Kgaa Oligonukleotide zum Nachweis von Mikroorganismen
DE10239082A1 (de) 2002-08-26 2004-03-04 Basf Ag Verfahren zur fermentativen Herstellung schwefelhaltiger Feinchemikalien
DE10239073A1 (de) 2002-08-26 2004-03-11 Basf Ag Verfahren zur fermentativen Herstellung schwefelhaltiger Feinchemikalien
DE10239308A1 (de) 2002-08-27 2004-03-11 Basf Ag Verfahren zur fermentativen Herstellung von schwefelhaltigen Feinchemikalien
DE10254074A1 (de) * 2002-11-19 2004-06-17 Forschungszentrum Jülich GmbH Verfahren zur mikrobiellen Herstellung von Stoffwechselprodukten
JP2004166592A (ja) * 2002-11-20 2004-06-17 Ajinomoto Co Inc メチロトローフを用いたｌ−アミノ酸の製造法
JP2004187684A (ja) * 2002-11-26 2004-07-08 Ajinomoto Co Inc Ｌ−グルタミンの製造法及びｌ−グルタミン生産菌
EP1424397B1 (fr) 2002-11-26 2011-01-19 Ajinomoto Co., Inc. Méthode de production de L-glutamine et bactérie produisant de la L-glutamine
JP2006521083A (ja) * 2002-11-29 2006-09-21 ビーエーエスエフ　アクチェンゲゼルシャフト メチオニンの生産方法
DE10261579A1 (de) 2002-12-23 2004-07-15 Basf Ag Verfahren zur Herstellung von Trehalose-freien Aminosäuren
WO2004079008A1 (fr) * 2003-03-04 2004-09-16 Suntory Limited Methode de criblage de genes de brassage de levure
JP4529183B2 (ja) * 2003-05-27 2010-08-25 味の素株式会社 飲食品の呈味および／または風味の改善方法
DE10344739A1 (de) * 2003-09-26 2005-04-14 Degussa Ag Verfahren zur fermentativen Herstellung von L-Aminosäuren unter Verwendung coryneformer Bakterien
DE10359661A1 (de) * 2003-12-18 2005-07-28 Basf Ag Genvarianten die für Proteine aus dem Stoffwechselweg von Feinchemikalien codieren
EP1939296A3 (fr) * 2003-12-18 2010-08-25 Basf Se Procédés pour la préparation de produits chimiques fins par fermentation
EP1724344B1 (fr) * 2004-02-27 2011-02-23 Kyowa Hakko Bio Co., Ltd. Procede de production d'acide amino
DE102004009454A1 (de) * 2004-02-27 2005-09-15 Degussa Ag Verfahren zur fermentativen Herstellung von L-Aminosäuren unter Verwendung von rekombinanten Mikroorganismen
DE102004009453A1 (de) * 2004-02-27 2005-09-15 Degussa Ag Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von coryneformen Bakterien
DE102004013503A1 (de) 2004-03-18 2005-10-06 Degussa Ag Verfahren zur Herstellung von L-Aminosäuren unter Verwendung coryneformer Bakterien
WO2005113745A1 (fr) * 2004-05-20 2005-12-01 Ajinomoto Co., Inc. Bactérie produisant de l'acide succinique et procédé servant à produire de l'acide succinique
DE102004035065A1 (de) 2004-07-20 2006-02-16 Basf Ag P-ET-TS-Expressionseinheiten
DE102004035067A1 (de) * 2004-07-20 2006-02-16 Basf Ag P1-35-Expressionseinheiten
DE102004035052A1 (de) 2004-07-20 2006-02-16 Basf Ag Mikroorganismen zur Herstellung von schwefelhaltigen Verbindungen
DE102004035074A1 (de) * 2004-07-20 2006-02-16 Basf Ag P1-34-Expressionseinheiten
JP4595506B2 (ja) 2004-11-25 2010-12-08 味の素株式会社 Ｌ−アミノ酸生産菌及びｌ−アミノ酸の製造方法
DE102004061846A1 (de) * 2004-12-22 2006-07-13 Basf Ag Mehrfachpromotoren
KR101233739B1 (ko) * 2004-12-28 2013-02-18 아지노모토 가부시키가이샤 Ｌ-글루탐산 생산 미생물 및 ｌ-글루탐산의 제조방법
US7794989B2 (en) 2004-12-28 2010-09-14 Ajinomoto Co., Inc. L-glutamic acid-producing microorganism and a method for producing L-glutamic acid
DE102005032429A1 (de) 2005-01-19 2006-07-20 Degussa Ag Allele des mqo-Gens aus coryneformen Bakterien
DE102005013676A1 (de) 2005-03-24 2006-09-28 Degussa Ag Allele des zwf-Gens aus coryneformen Bakterien
DE102005023829A1 (de) 2005-05-24 2006-11-30 Degussa Ag Allele des opcA-Gens aus coryneformen Bakterien
KR100906263B1 (ko) * 2005-05-27 2009-07-06 에보니크 데구사 게엠베하 메티오닌의 생산 방법
DK1910527T3 (da) * 2005-08-05 2013-03-25 Kao Corp Maltose-1-phosphat producerende enzym
CN101248170B (zh) 2005-08-26 2011-01-26 味之素株式会社 产生l-谷氨酸的细菌和用于产生l-谷氨酸的方法
DE102005043979A1 (de) * 2005-09-15 2007-03-22 Forschungszentrum Jülich GmbH Verfahren zur Produktion von Aminosäuren in aminosäureproduzierenden Mikroorganismen
DE102005047596A1 (de) 2005-10-05 2007-04-12 Degussa Ag Verfahren zur fermentativen Herstellung von L-Aminosäuren unter Verwendung coryneformer Bakterien
KR100789271B1 (ko) 2005-11-30 2008-01-02 씨제이 주식회사 Ｌ-라이신 생산능이 향상된 코리네박테리움 속 미생물 및그를 이용하여 ｌ-라이신을 생산하는 방법
KR100789270B1 (ko) * 2005-11-30 2008-01-02 씨제이 주식회사 Ｌ-라이신 생산능이 향상된 코리네박테리움 속 미생물 및그를 이용하여 ｌ-라이신을 생산하는 방법
JP2007185184A (ja) * 2005-12-16 2007-07-26 Ajinomoto Co Inc Ｌ−アミノ酸生産菌及びｌ−アミノ酸の製造法
ES2382207T3 (es) 2005-12-27 2012-06-06 Kyowa Hakko Bio Co., Ltd. Procedimiento para la producción de L-glutamina
BRPI0708680A2 (pt) * 2006-03-09 2011-06-07 Basf Se processo para produção de beta-lisina, para a produção de beta-amino-epsilon-caprolactama, para a produção de epsilon-caprolactama, e para a produção de ácido epsilon-amino-capróico
HUE030521T2 (en) * 2006-03-30 2017-05-29 Basf Se A method for producing cadaverine
DE102006026328A1 (de) * 2006-06-02 2008-01-03 Evonik Degussa Gmbh Verfahren zur Herstellung eines L-Lysin enthaltenden Futtermitteladditivs
DE102006032634A1 (de) 2006-07-13 2008-01-17 Evonik Degussa Gmbh Verfahren zur Herstellung von L-Aminosäuren
US8187843B2 (en) 2006-09-01 2012-05-29 Kyowa Hakko Bio Co., Ltd. Method for production of L-glutamine
JP5034395B2 (ja) * 2006-09-13 2012-09-26 三菱化学株式会社 有機酸生産菌及び有機酸の製造方法
DE102006050489A1 (de) 2006-10-26 2008-04-30 Evonik Degussa Gmbh Allele des prpD1-Gens aus coryneformen Bakterien
WO2008063650A2 (fr) * 2006-11-20 2008-05-29 President And Fellows Of Harvard College Systèmes de production d'hydrogène et d'acide formique dans une levure
KR100822041B1 (ko) * 2006-12-21 2008-04-15 씨제이제일제당 (주) 몰리브덴 보조인자 생합성 효소 에이 코딩 유전자의 발현이강화된 코리네박테리움 속 미생물 및 이를 이용한엘-라이신 생산방법
DE102007005072A1 (de) 2007-02-01 2008-08-07 Evonik Degussa Gmbh Verfahren zur fermentativen Herstellung von Cadaverin
KR100860932B1 (ko) * 2007-02-08 2008-09-29 씨제이제일제당 (주) 신규한 프로모터 및 이의 용도
DE102007051024A1 (de) 2007-03-05 2008-09-11 Evonik Degussa Gmbh Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von Stämmen der Familie Enterobacteriaceae
WO2008126896A1 (fr) * 2007-04-10 2008-10-23 Ajinomoto Co., Inc. Procédé de production d'acide organique
BRPI0812515A2 (pt) * 2007-06-15 2014-12-30 Evonik Degussa Gmbh Micro-organismo com sistema de vitamina b12 desregulado
EP2205758B1 (fr) * 2007-10-10 2013-12-04 Givaudan SA Procédés enzymatiques et enzymes
KR100987281B1 (ko) * 2008-01-31 2010-10-12 씨제이제일제당 (주) 개량된 프로모터 및 이를 이용한 ｌ-라이신의 생산 방법
KR20110004368A (ko) 2008-02-21 2011-01-13 바스프 에스이 감마-아미노부티르산의 제조 방법
DE102008001874A1 (de) 2008-05-20 2009-11-26 Evonik Degussa Gmbh Verfahren zur Herstellung von L-Aminosäuren
DE102008044768A1 (de) 2008-08-28 2010-03-04 Evonik Degussa Gmbh Verfahren zur Herstellung von organisch-chemischen Verbindungen unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae
WO2010095642A1 (fr) 2009-02-18 2010-08-26 国立大学法人信州大学 Procédé de production d'une substance utile
US8637295B1 (en) 2009-02-20 2014-01-28 Evonik Degussa Gmbh Process for the production of L-lysine
DE102009030342A1 (de) 2009-06-25 2010-12-30 Evonik Degussa Gmbh Verfahren zur fermentativen Herstellung von organisch chemischen Verbindungen
WO2011009801A1 (fr) * 2009-07-23 2011-01-27 Basf Plant Science Company Gmbh Plantes à rendement amélioré
JP5663859B2 (ja) * 2009-11-13 2015-02-04 三菱化学株式会社 非アミノ有機酸生産菌および非アミノ有機酸の製造方法
WO2011073278A1 (fr) 2009-12-17 2011-06-23 Basf Se Procédés et microorganismes recombinants pour la production de cadavérine
KR101174267B1 (ko) * 2010-01-06 2012-08-14 씨제이제일제당 (주) Ｌ-오르니틴 또는 ｌ-아르기닌 생산 변이주 및 이의 제조방법
KR101134700B1 (ko) 2010-02-24 2012-04-13 씨제이제일제당 (주) 코리네형 세포의 정지기에 분비되는 자가유도체에 의해 조절받는 뉴클레오티드 및 이를 이용한 스크리닝 방법
DE102010003419B4 (de) 2010-03-30 2019-09-12 Evonik Degussa Gmbh Verfahren zur fermentativen Herstellung von L-Ornithin
EP2430152B1 (fr) * 2010-07-15 2016-08-24 CJ CheilJedang Corporation Micro-organisme ayant une productivité de l-lysine améliorée et procédé de production de l-lysine l'utilisant
KR101269810B1 (ko) 2010-07-15 2013-05-30 씨제이제일제당 (주) Ｌ－라이신 생산능이 향상된 미생물 및 이를 이용한 ｌ－라이신 생산방법
KR101972556B1 (ko) * 2010-11-10 2019-04-25 그린 케미칼즈 가부시키가이샤 코리네형 세균 형질 전환체 및 그것을 사용하는 페놀의 제조 방법
WO2012083363A1 (fr) 2010-12-22 2012-06-28 Murdoch Childrens Research Institute Méthode de traitement
KR101922742B1 (ko) * 2011-02-22 2019-02-20 바스프 에스이 카다베린의 생산을 위한 방법 및 재조합 미생물
RU2496867C2 (ru) * 2011-04-25 2013-10-27 Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО "АГРИ") Способ получения l-аминокислоты семейства глутамата с использованием коринеформной бактерии
DE102011118019A1 (de) 2011-06-28 2013-01-03 Evonik Degussa Gmbh Varianten des Promotors des für die Glyzerinaldehyd-3-phosphat-Dehydrogenase kodierenden gap-Gens
US10703784B2 (en) * 2011-09-30 2020-07-07 La Jolla Institute For Allergy And Immunology Antigens and epitopes derived from Mycobacterium tuberculosis
WO2013093737A1 (fr) 2011-12-22 2013-06-27 Basf Se Procédés et microorganismes recombinants pour la production de produits chimiques fins
CN102604881B (zh) * 2012-03-31 2013-12-18 福建省麦丹生物集团有限公司 生产l-异亮氨酸的工程菌及其应用
WO2013160124A1 (fr) 2012-04-27 2013-10-31 Evonik Industries Ag Aloha-isopropylmalate synthases résistant à la rétroaction
US20150147792A1 (en) * 2012-06-29 2015-05-28 Archer Daniels Midland Company Betaine Enhancement of Fermentation to make C4 Diacids
KR20140014648A (ko) 2012-07-25 2014-02-06 삼성전자주식회사 1,4-부탄디올의 고효율 생산을 위한 변형 미생물
DE102012016716A1 (de) 2012-08-22 2014-02-27 Forschungszentrum Jülich GmbH Verfahren zur Herstellung von Vektoren enthaltend ein für in seiner feedback-Inhibierung gemindertes oder ausgeschaltetes Enzym kodierendes Gen und deren Verwendung für die Herstellung von Aminosäuren und Nukleotiden
EP2762571A1 (fr) 2013-01-30 2014-08-06 Evonik Industries AG Microorganisme et procédé de fabrication par fermentation d'acides aminés
WO2015122569A1 (fr) * 2014-02-12 2015-08-20 씨제이제일제당(주) Micro-organisme de recombinaison de genre escherichia à productivité de l-thréonine et procédé de production l-thréonine l'utilisant
KR20140102393A (ko) 2013-02-13 2014-08-22 씨제이제일제당 (주) L-쓰레오닌 생산능을 가지는 재조합 에스케리키아 속 미생물 및 이를 이용한 l-쓰레오닌의 생산방법
KR101607741B1 (ko) * 2013-03-20 2016-03-31 씨제이제일제당 (주) 퓨트레신 생산 재조합 미생물 및 이를 이용한 퓨트레신 생산방법
KR20140140215A (ko) * 2013-05-28 2014-12-09 경상대학교산학협력단 사이코스 3-에피머라제 효소를 코딩하는 폴리뉴클레오티드를 포함하는 코리네박테리움 및 이를 이용한 사이코스의 생산 방법
EP2811028B1 (fr) 2013-06-03 2017-02-01 Evonik Degussa GmbH Procédé de production de L-valine en utilisant des Corynebactéries recombinantes comprenant l'opéron ilvBN inductible par le propionate
EP2818551B1 (fr) * 2013-06-28 2017-04-05 Samsung Electronics Co., Ltd Corynebacterium, dans lequel le gène succinate-semialdehyde déshydrogénase indépendant de CoA et le gène L-lactate déshydrogénase sont supprimés et un procédé pour produire des composés C4, par exemple le 4-hydroxybutyrate
KR101582008B1 (ko) * 2013-10-15 2015-12-31 씨제이제일제당 (주) 생물막 형성 억제 활성을 가지는 유전자 및 이 유전자가 불활성화된 균주를 이용한 l-라이신 생산 방법
KR101498630B1 (ko) * 2013-10-28 2015-03-04 씨제이제일제당 주식회사 Ｌ-라이신 생산능이 향상된 코리네박테리움 속 미생물 및 이를 이용한 l-라이신 생산방법
EP2868666A1 (fr) * 2013-11-05 2015-05-06 Samsung Electronics Co., Ltd Micro-organisme présentant une activité accrue de transporteur ABC régulée par le fer et procédé de fabrication d'acide hydroxycarboxylique en utilisant le micro-organisme
CN103698530B (zh) * 2013-11-25 2015-08-19 广东体必康生物科技有限公司 结核分支杆菌蛋白在制备诊断活动性肺结核的产品中的用途
KR101565770B1 (ko) * 2013-12-13 2015-11-04 씨제이제일제당 주식회사 L-라이신 생산능이 향상된 코리네박테리움 속 미생물 및 이를 이용한 l-라이신을 생산하는 방법
CN104845923B (zh) * 2014-02-14 2018-03-23 中国科学院微生物研究所 生产l‑组氨酸的方法及其专用重组菌
ES2778037T3 (es) * 2014-04-30 2020-08-07 Evonik Operations Gmbh Procedimiento para la producción de L-aminoácidos bajo empleo de una bacteria alcalífila
EP2940144A1 (fr) 2014-04-30 2015-11-04 Evonik Degussa GmbH Procédé de production de L-lysine en utilisant une bactérie alcaliphile
CN106574254A (zh) * 2014-04-30 2017-04-19 赢创德固赛有限公司 使用嗜碱性细菌生产l‑氨基酸的方法
KR101530819B1 (ko) * 2014-05-08 2015-06-22 씨제이제일제당 (주) L-라이신 생산능이 향상된 미생물 및 이를 이용한 l-라이신 생산방법
KR101539370B1 (ko) * 2014-05-14 2015-07-24 씨제이제일제당 주식회사 L-라이신을 생산하는 코리네박테리움 속 미생물 및 이를 이용한 l-라이신의 생산방법
KR101720836B1 (ko) 2014-08-05 2017-04-03 씨제이제일제당 (주) 피드백 저항성 아세토하이드록시산 신타아제 변이체 및 이를 이용한 l-발린의 생산방법
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
WO2016139667A1 (fr) 2015-03-04 2016-09-09 Ariel-University Research And Development Company Ltd. Peptides et compositions les comprenant, et utilisations de ces derniers dans le traitement de maladies
KR101640711B1 (ko) * 2015-04-20 2016-07-19 씨제이제일제당 (주) 글루코네이트 리프레서 변이체, 이를 포함하는 l-라이신을 생산하는 미생물 및 이를 이용한 ｌ－라이신 생산방법
KR101766964B1 (ko) 2015-08-27 2017-08-09 씨제이제일제당 (주) L-라이신 생산능을 가지는 코리네박테리움 속 미생물 및 이를 이용한 l-라이신 생산방법
KR101740807B1 (ko) 2015-08-27 2017-05-26 씨제이제일제당 (주) L-라이신 생산능을 가지는 코리네박테리움 속 미생물 및 이를 이용한 l-라이신 생산방법
US11034985B2 (en) * 2015-11-27 2021-06-15 Evonik Operations Gmbh Method for producing L-methionine
US10457963B2 (en) 2016-09-20 2019-10-29 Novogy, Inc. Heterologous production of 10-methylstearic acid
CN106395051B (zh) * 2016-10-19 2018-09-07 石家庄钢铁有限责任公司 一种成捆圆钢端面自动贴标系统中贴标机器人的优选方法
KR101863456B1 (ko) 2016-11-15 2018-06-01 씨제이제일제당 (주) L-라이신을 생산하는 코리네박테리움 속 미생물 및 이를 이용한 l-라이신의 생산방법
KR101917480B1 (ko) * 2016-12-29 2018-11-09 씨제이제일제당 (주) Ｌ－라이신을 생산하는 코리네박테리움 속 미생물 및 이를 이용한 ｌ－라이신의 생산방법
CN111551742B (zh) * 2016-12-30 2023-06-16 首都医科大学附属北京胸科医院 结核分枝杆菌蛋白在制备诊断结核潜伏感染者和/或活动性肺结核产品中的用途
DE102017004566A1 (de) * 2017-05-11 2018-11-15 Forschungszentrum Jülich GmbH Pyruvatcarboxylase und für die Pyruvatcarboxylase kodierende DNA, Plasmid enthaltend die DNA, sowie Mikroorganismus zur Produktion und Verfahren zur Herstellung von Produkten, deren Biosynthese Oxalacetat als Vorstufe beinhaltet, Chromosom und Screeningverfahren
US20200239897A1 (en) 2017-06-07 2020-07-30 Zymergen Inc. Promoters from corynebacterium glutamicum and uses thereof in regulating ancillary gene expression
WO2019004780A2 (fr) * 2017-06-30 2019-01-03 씨제이제일제당 (주) Nouveau mutant d'o-succinyl homosérine transférase, et procédé de production d'o-succinyl homosérine utilisant ledit mutant
US11021697B2 (en) 2017-07-11 2021-06-01 Cj Cheiljedang Corporation Acetohydroxy acid synthase variant, microorganism comprising the same, and method of producing L-branched-chain amino acid using the same
KR101996129B1 (ko) 2017-07-11 2019-07-04 씨제이제일제당 (주) 아세토하이드록시산 신타아제 변이체, 이를 포함하는 미생물 또는 이를 이용하는 l-분지쇄 아미노산 생산 방법
EP3467099A1 (fr) 2017-10-05 2019-04-10 Evonik Degussa GmbH Procédé de production d'acides aminés l par fermentation
CN109750069A (zh) * 2017-11-01 2019-05-14 北京中科伊品生物科技有限公司 生产l-赖氨酸的重组菌、其构建方法以及l-赖氨酸的生产方法
EP3498853A1 (fr) 2017-12-14 2019-06-19 Evonik Degussa GmbH Procédé de production de l-lysine par fermentation
KR101999454B1 (ko) 2017-12-19 2019-07-11 씨제이제일제당 (주) L-아르기닌을 생산하는 코리네박테리움 속 미생물 및 이를 이용한 l-아르기닌 생산방법
KR101947945B1 (ko) * 2018-01-25 2019-02-13 씨제이제일제당 (주) L-아미노산을 생산하는 코리네박테리움 속 미생물 및 이를 이용한 l-아미노산의 생산방법
KR101947959B1 (ko) 2018-05-28 2019-02-13 씨제이제일제당 (주) 변이형 호모세린 디하이드로게나제 및 이를 이용한 호모세린 또는 호모세린 유래 l-아미노산의 생산 방법
WO2019228937A1 (fr) * 2018-05-28 2019-12-05 Universitaet Des Saarlandes Moyens et méthodes pour la production de glutarate
EP3594355A1 (fr) 2018-07-12 2020-01-15 Evonik Operations GmbH Procédé de production de l-lysine par fermentation
EP3599282B1 (fr) 2018-07-24 2021-03-17 Evonik Operations GmbH Procédé de production de l-lysine par fermentation
RU2019128538A (ru) 2018-09-26 2021-03-11 Эвоник Оперейшенс ГмбХ Способ ферментативного получения l-лизина
CN115819529A (zh) * 2018-10-19 2023-03-21 中国科学院天津工业生物技术研究所 提高苹果酸产量的新突变蛋白
CN109182556B (zh) * 2018-11-01 2021-11-23 菏泽学院 一种与瓦氏黄颡鱼生长性状相关的snp分子标记及应用
EP3660158A1 (fr) 2018-11-29 2020-06-03 Evonik Operations GmbH Procédé de production de l-lysine par fermentation
EP3670525A1 (fr) 2018-12-18 2020-06-24 Evonik Operations GmbH Procédé de production de l-lysine par fermentation à l'aide de souches de c. glutamicum avec un transporteur de kup muté
CN109765379B (zh) * 2018-12-19 2021-11-23 南华大学 结核分枝杆菌蛋白的应用
KR101996769B1 (ko) * 2018-12-21 2019-10-01 씨제이제일제당 (주) 변이형 호모세린 디하이드로게나제 및 이를 이용한 호모세린 또는 호모세린 유래 l-아미노산의 생산 방법
US10829746B2 (en) 2019-01-23 2020-11-10 Evonik Operations Gmbh Method for the fermentative production of L-lysine
WO2021037190A1 (fr) 2019-08-29 2021-03-04 天津科技大学 2-isopropylmalate synthase, bactéries génétiquement modifiées associées, et leurs applications
CN110540976B (zh) * 2019-08-29 2020-07-24 天津科技大学 一种异丙基苹果酸合成酶及其应用
CN111088202B (zh) * 2019-12-25 2022-01-04 南京工业大学 一种通过生物成膜连续化发酵生产赖氨酸的重组谷氨酸棒杆菌及其构建方法
CN110885364B (zh) * 2019-12-26 2021-02-02 江南大学 一种促进N-乙酰氨基葡萄糖生产的RamA转录因子突变体及其应用
CN112877269B (zh) * 2020-01-15 2021-12-24 中国科学院天津工业生物技术研究所 生产赖氨酸的微生物以及赖氨酸的生产方法
CN111394374A (zh) * 2020-04-27 2020-07-10 广西大学 一种编码纤维素酶家族GH30的纤维素酶基因gk2691及其应用
KR102311391B1 (ko) * 2020-05-21 2021-10-12 씨제이제일제당 주식회사 L- 분지쇄 아미노산 생산능이 강화된 미생물 및 이를 이용하여 l-분지쇄 아미노산을 생산하는 방법
CN111635454B (zh) * 2020-06-04 2021-12-28 江南大学 利用生物传感器筛选精氨酸高产菌株的方法
US20230313122A1 (en) * 2020-06-08 2023-10-05 Inner Mongolia Eppen Biotech Co., Ltd. Recombinant strain for producing l-amino acid, construction method therefor, and application thereof
CN113755492B (zh) * 2020-07-20 2023-05-30 中国科学院天津工业生物技术研究所 丙酮酸羧化酶基因启动子的突变体及其应用
CN112471140A (zh) * 2020-12-22 2021-03-12 华中科技大学 一种细胞株冻存复苏的保护液及制备方法
CN112646766B (zh) * 2020-12-30 2023-08-18 内蒙古伊品生物科技有限公司 一种改造基因bbd29_04920的产l-谷氨酸的重组菌株及其构建方法与应用
KR102261851B1 (ko) * 2021-01-15 2021-06-04 씨제이제일제당 (주) 신규한 abc 트랜스포터 atp-결합 단백질 변이체 및 이를 이용한 l-라이신 생산 방법
KR102257841B1 (ko) * 2021-01-15 2021-05-28 씨제이제일제당 주식회사 신규한 피토엔 신타제 변이체 및 이를 이용한 xmp 또는 gmp 생산 방법
KR102281366B1 (ko) * 2021-01-26 2021-07-22 씨제이제일제당 (주) 신규한 테트라하이드로디피콜리네이트 n-숙시닐트랜스퍼라제 변이체 및 이를 이용한 l-발린 생산 방법
CN113950525B (zh) * 2021-01-27 2022-06-03 Cj第一制糖株式会社 新型核糖核酸酶p变体及使用其生产l-谷氨酸的方法
KR102281368B1 (ko) * 2021-01-28 2021-07-23 씨제이제일제당 (주) 신규한 단백질 변이체 및 이를 이용한 l-발린 생산 방법
KR102258159B1 (ko) * 2021-01-29 2021-05-27 씨제이제일제당 (주) 신규한 말레이트 디하이드로게나제 변이체 및 이를 이용한 l-라이신 생산 방법
KR102344057B1 (ko) * 2021-01-29 2021-12-27 씨제이제일제당 (주) 신규한 단백질 변이체 및 이를 이용한 l-라이신 생산 방법
KR102314885B1 (ko) * 2021-04-12 2021-10-18 씨제이제일제당 (주) 신규한 단백질 변이체 및 이를 이용한 l-라이신 생산 방법
KR102303747B1 (ko) * 2021-04-12 2021-09-16 씨제이제일제당 (주) 신규한 주요 촉진제 수퍼패밀리 퍼미에이즈 변이체 및 이를 이용한 l-라이신 생산 방법
KR102338875B1 (ko) * 2021-04-12 2021-12-10 씨제이제일제당 (주) 신규한 당 인산염 이성질화효소/에피머레이즈 변이체 및 이를 이용한 l-라이신 생산 방법
KR102314884B1 (ko) * 2021-04-12 2021-10-18 씨제이제일제당 (주) 신규한 세포분해 막단백질 변이체 및 이를 이용한 l-라이신 생산 방법
KR102339264B1 (ko) * 2021-05-07 2021-12-14 씨제이제일제당 주식회사 신규 프로모터 및 이의 용도
KR102339271B1 (ko) * 2021-05-07 2021-12-14 씨제이제일제당 주식회사 신규 프로모터 및 이의 용도
WO2022265130A1 (fr) * 2021-06-15 2022-12-22 씨제이제일제당 (주) Nouveau promoteur et son utilisation
KR20230031624A (ko) * 2021-08-27 2023-03-07 씨제이제일제당 (주) 신규한 초산 대사 조절자 a 변이체 및 이를 이용한 l-분지쇄 아미노산 생산 방법
CN113462583B (zh) * 2021-09-06 2021-12-10 中国科学院天津工业生物技术研究所 生产氨基酸的谷氨酸棒杆菌以及利用该谷氨酸棒杆菌生产氨基酸的方法
WO2023041425A1 (fr) 2021-09-20 2023-03-23 Evonik Operations Gmbh Procédé de production fermentative de l-lysine au moyen de souches de c. glutamicum exprimant des protéines répresseurs de gluconate modifiées gntr1 et gntr2
WO2023106351A1 (fr) * 2021-12-07 2023-06-15 花王株式会社 Procédé de fabrication de composé aromatique
JP2023087682A (ja) * 2021-12-13 2023-06-23 花王株式会社 新規プロモーター
CN114315998B (zh) * 2021-12-20 2024-02-06 宁夏伊品生物科技股份有限公司 Cey17_rs00300基因突变体及其在制备l-缬氨酸中的应用
CN114560918B (zh) * 2022-03-14 2024-06-14 宁夏伊品生物科技股份有限公司 Yh66_14275蛋白或其突变体在制备l-精氨酸中的应用
CN115124605B (zh) * 2022-03-15 2023-08-04 吉林大学 耐高温元件突变体及其在生产氨基酸中的应用
WO2023222515A1 (fr) 2022-05-18 2023-11-23 Evonik Operations Gmbh Production biotechnologique de bisucabérines, desferrioxamines et analogues de celles-ci
WO2023222510A1 (fr) 2022-05-18 2023-11-23 Evonik Operations Gmbh Production biotechnologique de desferrioxamines et analogues de celles-ci
WO2023222505A1 (fr) 2022-05-18 2023-11-23 Evonik Operations Gmbh Production biotechnologique de monomères de bisucabérines, desferrioxamines et d'analogues de celles-ci
KR20230161244A (ko) * 2022-05-18 2023-11-27 씨제이제일제당 (주) 신규한 글루타메이트 글루코네이트 리프레서 변이체 및 이를 이용한 l-아르기닌 생산 방법
JP2024003706A (ja) * 2022-06-27 2024-01-15 花王株式会社 芳香族化合物の製造方法
WO2024000364A1 (fr) * 2022-06-30 2024-01-04 江南大学 Mutant efficace de corynebacterium glutamicum, procédé de construction d'une bactérie recombinée et son utilisation
CN116716314A (zh) * 2023-07-03 2023-09-08 河南农业大学 番茄SlFolB基因在提高植物产量中的应用
CN117737037B (zh) * 2024-02-07 2024-04-19 中国林业科学研究院高原林业研究所 一种N-乙酰氨基葡萄糖苷酶突变体De266LΔ6及其制备与应用
CN117737038B (zh) * 2024-02-08 2024-04-23 中国林业科学研究院高原林业研究所 一种N-乙酰氨基葡萄糖苷酶突变体De254PΔ5及其制备与应用
CN117737039B (zh) * 2024-02-18 2024-04-23 中国林业科学研究院高原林业研究所 一种N-乙酰氨基葡萄糖苷酶突变体De259AΔ7及其制备与应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE282692T1 (de) 1983-01-13 2004-12-15 Max Planck Gesellschaft Nichtonkogenisches ti-plasmidvektorsystem und für das einschleusen expressionsfähiger gene in pflanzengenomen verwendbare rekombinante dna- moleküle
NL8300698A (nl) 1983-02-24 1984-09-17 Univ Leiden Werkwijze voor het inbouwen van vreemd dna in het genoom van tweezaadlobbige planten; agrobacterium tumefaciens bacterien en werkwijze voor het produceren daarvan; planten en plantecellen met gewijzigde genetische eigenschappen; werkwijze voor het bereiden van chemische en/of farmaceutische produkten.
EP0164575B1 (fr) 1984-05-11 1992-03-18 Novartis AG Transformation du génotype de plantes
IL84459A (en) 1986-12-05 1993-07-08 Agracetus Apparatus and method for the injection of carrier particles carrying genetic material into living cells
WO1988009819A2 (fr) * 1987-06-12 1988-12-15 Massachusetts Institute Of Technology Passage biosynthetique pour threonine de c. glutamicum
US6649379B1 (en) * 1987-06-12 2003-11-18 Massachusetts Institute Of Technology Method and deregulated enzyme for threonine production
GB2223754B (en) * 1988-09-12 1992-07-22 Degussa Dna encoding phosphoenolpyruvate carboxylase
JP2928287B2 (ja) 1988-09-29 1999-08-03 協和醗酵工業株式会社 新規ポリペプチド
DE3908201A1 (de) * 1989-03-14 1990-09-27 Degussa Verfahren zur fermentativen herstellung von l-lysin
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
DE4204361A1 (de) * 1992-02-14 1993-08-19 Degussa Verfahren zur herstellung von l-lysin durch fermentation von coryneformen bakterien
EP1983056A1 (fr) 1992-07-07 2008-10-22 Japan Tobacco Inc. Procédé de transformation de monocotylédones
KR0122509B1 (ko) * 1994-06-13 1997-11-24 김정순 L-라이신을 생산하는 미생물
KR0159812B1 (ko) * 1995-12-20 1998-11-16 손경식 코리네박테리움 글루타미컴 씨에이치 77 및 이 균주를 이용한 l-라이신의 제조 방법
JPH1087A (ja) * 1996-06-17 1998-01-06 Ajinomoto Co Inc 発酵法による目的物質の製造法
DE19831609B4 (de) * 1997-10-04 2009-11-12 Evonik Degussa Gmbh Verfahren zur Herstellung von Aminosäuren der Aspartat- und/oder Glutamatfamilie und im Verfahren einsetzbare Mittel
KR100253424B1 (ko) * 1997-12-15 2000-04-15 손 경 식 코리네박테리움 글루타미컴 cj88 및 이 균주를 이용한l-라이신의 제조방법
EP1257649B1 (fr) * 1999-06-25 2010-01-20 Paik Kwang Industrial Co., Ltd. Genes de corynebacterum glutamicum codant pour des proteines de voie metabolique

Cited By (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070082383A1 (en) * 1999-06-25 2007-04-12 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding proteins involved in carbon metabolism and energy production
US20040180408A1 (en) * 1999-06-25 2004-09-16 Markus Pompejus Corynebacterium glutamicum genes encoding proteins involved in carbon metabolism and energy production
US7393675B2 (en) 1999-06-25 2008-07-01 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding proteins involved in carbon metabolism and energy production
US7270984B1 (en) * 1999-06-25 2007-09-18 Basf Aktiengesellschaft Polynucleotides encoding a 6-phosphogluconolactonase polypeptide from corynebacterium glutamicum
US20070072265A1 (en) * 1999-06-25 2007-03-29 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding proteins involved in carbon metabolism and energy production
US6893852B1 (en) 1999-07-02 2005-05-17 Ajinomoto Co., Inc. Dna encoding sucrose pts enzyme II
US20030199045A1 (en) * 1999-07-09 2003-10-23 Kevin Burke Process for the preparation of L-amino acids with amplification of the zwf gene
US20060014259A9 (en) * 1999-07-09 2006-01-19 Kevin Burke Process for the preparation of L-amino acids with amplification of the zwf gene
US20040121428A1 (en) * 1999-12-24 2004-06-24 Masakazu Sugimoto Process for producing l-amino acid and novel gene
US20050112733A1 (en) * 2000-03-20 2005-05-26 Degussa Ag Process for the preparation of L-amino acids with amplification of the zwf gene
US7307160B1 (en) * 2000-07-05 2007-12-11 Ajinomoto Co. Inc. OtsA gene encoding trehalose-6-phosphate synthase from a coryneform bacterium
US6875586B2 (en) * 2000-08-10 2005-04-05 Degussa Ag Nucleotide sequences coding for the luxR gene
US7173105B2 (en) * 2000-08-10 2007-02-06 Degussa Ag Nucleotide sequences coding for the LuxR gene
US20020086404A1 (en) * 2000-08-10 2002-07-04 Degussa Ag Nucleotide sequences coding for the luxR gene
US20060134761A1 (en) * 2000-08-10 2006-06-22 Degussa Ag Nucleotide sequences coding for the LuxR gene
US6972190B2 (en) * 2000-08-26 2005-12-06 Degussa Ag Nucleotide sequences which code for the cstA gene
US20020137912A1 (en) * 2000-08-26 2002-09-26 Bettina Mockel Nucleotide sequences which code for the cstA gene
US6916636B2 (en) * 2000-08-26 2005-07-12 Degussa Ag Nucleotide sequences which code for the oxyR gene
US20020064839A1 (en) * 2000-08-26 2002-05-30 Degusa Ag Nucleotide sequences which code for the oxyR gene
US7205144B2 (en) * 2000-08-31 2007-04-17 Degussa Ag Nucleotide sequences encoding a sensor kinase, citA, from Corynebacterium glutamicum
US6825030B2 (en) * 2000-08-31 2004-11-30 Degussa Ag Nucleotide sequences encoding a sensor kinase, citA, from corynebacterium glutamicum
US20050112664A1 (en) * 2000-08-31 2005-05-26 Bettina Mockel Nucleotide sequences coding for the citA gene
US6995000B2 (en) * 2000-09-02 2006-02-07 Degussa Nucleotide sequences coding for the sigM gene
US6815196B2 (en) * 2000-09-02 2004-11-09 Degussa Ag Nucleotide sequences encoding o-succinylhomoserine sulfhydrylase
US20020111468A1 (en) * 2000-09-02 2002-08-15 Brigitte Bathe Nucleotide sequences coding for the sigD gene
US20050221450A1 (en) * 2000-09-02 2005-10-06 Degussa Ag Methods of making L-amino acids in coryneform bacteria using the sigE gene
US20020106755A1 (en) * 2000-09-02 2002-08-08 Brigitte Bathe Nucleotide sequences coding for the sigM gene
US6913908B2 (en) * 2000-09-02 2005-07-05 Degussa Ag Methods of making L-amino acids in coryneform using the sigE gene
US20020102664A1 (en) * 2000-09-02 2002-08-01 Degussa Ag Nucleotide sequences which code for the metR and metZ genes
US6890744B2 (en) * 2000-09-02 2005-05-10 Degussa Ag Methods for producing amino acids in coryneform bacteria using an enhanced sigD gene
US20020103356A1 (en) * 2000-09-02 2002-08-01 Bettina Mockel Sequences which code for the sigE gene
US20020055115A1 (en) * 2000-09-09 2002-05-09 Degussa Ag Nucleotide sequences coding for the Dep33 efflux protein
US20060177912A1 (en) * 2000-09-09 2006-08-10 Mike Farwick Nucleotide sequences which code for the dep34 gene
US20020106757A1 (en) * 2000-09-09 2002-08-08 Mike Farwick Nucleotide sequences which code for the dep34 gene
US7038034B2 (en) * 2000-09-09 2006-05-02 Degussa Ag Nucleotide sequences coding for the Dep33 efflux protein
US7029904B2 (en) * 2000-09-09 2006-04-18 Degussa Ag Nucleotide sequences which code for the dep34 gene
US6746854B2 (en) * 2000-09-09 2004-06-08 Degussa Ag Nucleotide sequences encoding histidine kinase from corynebacterium glutamicum
US6924134B2 (en) * 2000-09-12 2005-08-02 Degussa Ag Nucleotide sequences which code for the gorA gene
US20020106760A1 (en) * 2000-09-20 2002-08-08 Brigitte Bathe Nucleotide sequences which code for the dps gene
US20020103357A1 (en) * 2000-09-26 2002-08-01 Brigitte Bathe Nucleotide sequences which code for the msiK gene
US7252977B2 (en) * 2000-09-26 2007-08-07 Degussa Ag Nucleotide sequences which code for the msiK gene
US20020115161A1 (en) * 2000-09-27 2002-08-22 Mike Farwick Nucleotide sequences which code for the deaD gene
US6689587B2 (en) * 2000-11-10 2004-02-10 Degussa Ag Polynucleotides encoding the nadC gene and methods of producing nicotinic acid or nicotinic acid derivatives
US20040043953A1 (en) * 2000-12-22 2004-03-04 Markus Pompejus Genes of corynebacterium
US20040229255A1 (en) * 2001-01-30 2004-11-18 Degussa Ag Nucleotide sequence coding for the OtsA protein
US20020192674A1 (en) * 2001-01-30 2002-12-19 Degussa Ag Nucleotide sequence coding for the OtsA protein
US20060019357A1 (en) * 2001-02-16 2006-01-26 Degussa Ag Nucleotide sequences which code for the rpsL gene
US20050074802A1 (en) * 2001-05-30 2005-04-07 Degussa Ag Nucleotide sequences which code for the MetD gene
US20030092026A1 (en) * 2001-05-30 2003-05-15 Degussa Ag Nucleotide sequences which code for the metD gene
US20030092139A1 (en) * 2001-08-09 2003-05-15 Degussa Ag Process for the fermentative preparation of L-amino acids using coryneform bacteria
US20050266536A1 (en) * 2001-08-09 2005-12-01 Degussa Ag Process for the fermentative preparation of L-amino acids using coryneform bacteria
US20050009152A1 (en) * 2001-11-05 2005-01-13 Oskar Zelder Genes encoding for genetic stability, gene expression and folding proteins
US7323559B2 (en) 2001-11-05 2008-01-29 Basf Ag Genes encoding genetic stability, gene expression and folding proteins
US7339048B2 (en) 2001-11-05 2008-03-04 Basf Ag Genes encoding genetic stability, gene expression and folding proteins
US20070054381A1 (en) * 2001-11-05 2007-03-08 Basf Aktiengesellschaft Genes encoding genetic stability, gene expression and folding proteins
US7138513B2 (en) 2001-11-05 2006-11-21 Basf Aktiengesellschaft Genes encoding for genetic stability, gene expression and folding proteins
US20070072273A1 (en) * 2001-11-05 2007-03-29 Basf Aktiengesellschaft Genes encoding genetic stability, gene expression and folding proteins
US20070077631A1 (en) * 2001-11-05 2007-04-05 Basf Aktiengesellschaft Genes encoding genetic stability, gene expression and folding proteins
US7355028B2 (en) 2001-11-05 2008-04-08 Basf Ag Genes encoding genetic stability, gene expression and folding proteins
US20040259215A1 (en) * 2001-11-05 2004-12-23 Oskar Zelder Genes coding for dna replication and for proteins related to pathogenesis
US20050043526A1 (en) * 2001-12-20 2005-02-24 Brigitte Bathe Alleles of the siga gene from coryneform bacteria
US7524657B2 (en) * 2001-12-20 2009-04-28 Evonik Degussa Gmbh Alleles of the sigA gene from coryneform bacteria
US8119374B2 (en) * 2003-03-13 2012-02-21 Forschungszentrum Julich Gmbh Nucleotide sequences of coryneform bacteria coded for proteins participating in L-serine metabolism and method for microbial production of L-serine
US20090061482A1 (en) * 2003-03-13 2009-03-05 Petra Peters-Wendisch Nucleotide sequences of coryneform bacteria coded for proteins participating in l-serine metabolism and method for microbial production of l-serine
US7468262B2 (en) 2003-05-16 2008-12-23 Ajinomoto Co., Inc. Polynucleotides encoding useful polypeptides in corynebacterium glutamicum ssp. lactofermentum
US7696315B2 (en) 2003-05-16 2010-04-13 Ajinomoto Co., Inc. Polynucleotides encoding useful polypeptides in Corynebacterium glutamicum ssp. lactofermentum
US7695946B2 (en) 2003-05-16 2010-04-13 Ajinomoto Co., Inc. Polynucleotides encoding useful polypeptides in Corynebacterium glutamicum ssp. lactofermentum
US20060234357A1 (en) * 2003-05-16 2006-10-19 Yoshihiro Usuda Novel polynucleotides encoding useful polypeptides in corynebacterium glutamicum ssp. lactofermentum
US20060234356A1 (en) * 2003-05-16 2006-10-19 Yoshihiro Usuda Novel polynucleotides encoding useful polypeptides in corynebacterium glutamicum ssp. lactofermentum
US20070292914A1 (en) * 2003-06-26 2007-12-20 Degussa Ag Feedback Resistant Acetohydroxy Acid Synthethase Mutants
US7585959B2 (en) * 2003-06-26 2009-09-08 Evonik Degussa Gmbh Feedback resistant acetohydroxy acid synthethase mutants
US7833763B2 (en) 2003-07-09 2010-11-16 Mitsubishi Chemical Corporation Method for producing organic acid
US20060172401A1 (en) * 2003-07-09 2006-08-03 Mitsubishi Chemical Corporation Method for producing organic acid
US7763447B2 (en) 2003-08-28 2010-07-27 Ajinomoto Co., Inc. Method of producing succinic acid with bacterium comprising a modified fumarate reductase gene or a modified succinate dehydrogenase gene
US20060205048A1 (en) * 2003-08-28 2006-09-14 Mitsubishi Chemical Corporation Process for producing succinic acid
US20060281156A1 (en) * 2003-09-17 2006-12-14 Mitsubishi Chemical Corporation Method for producing non-amino organic acid
US7563606B2 (en) 2003-09-17 2009-07-21 Mitsubishi Chemical Corporation Method for producing non-amino organic acid
US20060276674A1 (en) * 2003-09-30 2006-12-07 Ajinomoto Co., Inc. Method for purifying succinic acid from fermentation broth
US20080026432A1 (en) * 2003-12-10 2008-01-31 Park Young-Hoon Novel L-Threonine Importer From Corynebacterium And A Preparation Method Of A Strain Producing L-Threonine
US7863435B2 (en) * 2003-12-10 2011-01-04 Cj Cheiljedang Corp. L-threonine importer from Corynebacterium and a preparation method of a strain producing L-threonine
US20090246836A1 (en) * 2003-12-18 2009-10-01 Paik Kwang Industrial Co., Ltd Pgro expression units
US7785846B2 (en) 2003-12-18 2010-08-31 Evonik Degussa Gmbh Method for the production of methionine
US20070122888A1 (en) * 2003-12-18 2007-05-31 Matthias Boy Method for the production of methionine
US8071365B2 (en) 2003-12-18 2011-12-06 Basf Se Psod expression units
US8728795B2 (en) 2003-12-18 2014-05-20 Basf Se Pgro expression units
US20080166775A1 (en) * 2003-12-18 2008-07-10 Basf Aktiengesellschaft P ef-tu expression units
US7785779B2 (en) 2003-12-18 2010-08-31 Paik Kwang Industrial Co., Ltd. P EF-TU expression units
US20090004705A1 (en) * 2003-12-18 2009-01-01 Basf Aktiengesellschaft PSOD Expression Units
US20080286841A1 (en) * 2003-12-18 2008-11-20 Basf Aktiengesellschaft Pgro expression units
US8044191B2 (en) 2003-12-18 2011-10-25 Basf Se P EF-TU expression units
US20080274516A1 (en) * 2003-12-18 2008-11-06 Burkhard Kroger Psod Expression Units
US20080076154A1 (en) * 2004-05-18 2008-03-27 Kao Corporation Maltose-1-phosphate-producing enzyme
US20080293112A1 (en) * 2004-05-20 2008-11-27 Ajinomoto Co., Inc. Succinic acid-producing bacterium and process for producing succinic acid
US7972823B2 (en) 2004-05-20 2011-07-05 Ajinomoto Co., Inc. Succinic acid-producing bacterium and process for producing succinic acid
US20100047900A1 (en) * 2004-12-30 2010-02-25 Young Hoon Park Novel l-Lysine-inducible promoter
US7851198B2 (en) * 2004-12-30 2010-12-14 Cj Cheiljedang Corporation L-lysine-inducible promoter
US7585650B2 (en) 2005-03-24 2009-09-08 Degussa Ag Alleles of the zwf gene from coryneform bacteria
US20070092951A1 (en) * 2005-03-24 2007-04-26 Degussa Ag Alleles of the zwf gene from coryneform bacteria
US8153404B2 (en) 2005-03-24 2012-04-10 Evonik Degussa Gmbh Alleles of the zwf gene from coryneform bacteria
US20090325242A1 (en) * 2005-03-24 2009-12-31 Degussa Ag Alleles of the zwf gene from coryneform bacteria
US7829316B2 (en) 2005-10-18 2010-11-09 Ajinomoto Co., Inc. Process for production of succinic acid
US20080293113A1 (en) * 2005-10-18 2008-11-27 Ajinomoto Co., Inc. Process for production of succinic acid
US7993888B2 (en) 2006-02-24 2011-08-09 Mitsubishi Chemical Corporation Bacterium having enhanced 2-oxoglutarate dehydrogenase activity
US20090156779A1 (en) * 2006-02-24 2009-06-18 Mitsubishi Chemical Corporation Bacterium capable of producing organic acid, and method for production of organic acid
WO2008127290A3 (fr) * 2006-10-12 2009-05-28 Univ Johns Hopkins Compositions d'alginate et d'alginate-lyase et procédés d'utilisation
US9220761B2 (en) 2006-10-12 2015-12-29 The John Hopkins University Alginate and alginate lyase compositions and methods of use
US8058036B2 (en) 2006-12-29 2011-11-15 Cj Cheiljedang Corporation Microorganism of Corynebacterium genus having enhanced L-lysine productivity and a method of producing L-lysine using the same
US20100028957A1 (en) * 2006-12-29 2010-02-04 Cj Cheiljedang Corporation Microorganism Of Corynebacterium Genus Having Enhanced L-Lysine Productivity And A Method Of Producing L-Lysine Using The Same
WO2008082180A1 (fr) * 2006-12-29 2008-07-10 Cj Cheiljedang Corporation Micro-organisme du genre corynebacterium possédant une capacité de production de l-lysine améliorée et procédé de production de l-lysine l'utilisant
US8048650B2 (en) 2006-12-29 2011-11-01 Cj Cheiljedang Corporation Microorganism of Corynebacterium genus having enhanced L-lysine productivity and a method of producing L-lysine using the same
WO2008082181A1 (fr) * 2006-12-29 2008-07-10 Cj Cheiljedang Corporation Micro-organisme du genre corynebacterium possédant une capacité de production de l-lysine améliorée et procédé de production de l-lysine l'utilisant
KR100838038B1 (ko) 2006-12-29 2008-06-12 씨제이제일제당 (주) Ｌ-라이신 생산능이 향상된 코리네박테리움 속 미생물 및그를 이용한 ｌ-라이신 생산 방법
US20100015673A1 (en) * 2006-12-29 2010-01-21 Cj Cheiljedang Corporation Microorganism Of Corynebacterium Genus Having Enhanced L-Lysine Productivity And A Method Of Producing L-Lysine Using The Same
US20100261256A1 (en) * 2007-01-15 2010-10-14 Cj Cheiljedang Corp. Novel promoter nucleic acid molecule derived from corynebacterium glutamicum, recombinant vector comprising the promoter, host cell comprising the recombinant vector and method of expressing gene using the host cell
US8426195B2 (en) * 2007-01-15 2013-04-23 Cj Cheiljedang Corp. Promoter nucleic acid molecule derived from corynebacterium glutamicum, recombinant vector comprising the promoter, host cell comprising the recombinant vector and method of expressing gene using the host cell
US8426165B2 (en) 2007-01-24 2013-04-23 Cj Cheiljedang Corporation Process for producing fermentation product from carbon sources containing glycerol using Corynebacteria
US20100129884A1 (en) * 2007-01-24 2010-05-27 Cj Cheiljedang Corporation Process for Producing Fermentation Product from Carbon Sources Containing Glycerol using Corynebacteria
US8323933B2 (en) 2008-04-10 2012-12-04 Cj Cheiljedang Corporation Vector for transformation using transposons, microorganisms transformed by the vector, and method for producing L-lysine using the same
US20100330624A1 (en) * 2008-04-10 2010-12-30 Cj Cheiljedang Corporation Vector for transformation using transposons, microorganisms transformed by the vector, and method for producing L-lysine using the same
US8932861B2 (en) 2008-04-10 2015-01-13 Cj Cheiljedang Corporation Transformation vector comprising transposon, microorganisms transformed with the vector, and method for producing L-lysine using the microorganism
WO2010017196A3 (fr) * 2008-08-04 2010-11-04 Bayer Healthcare Llc Anticorps monoclonaux contre l'inhibiteur de la voie du facteur tissulaire (tfpi)
US8530203B2 (en) 2008-09-01 2013-09-10 Shinshu University Process for producing useful substance
US10188722B2 (en) 2008-09-18 2019-01-29 Aviex Technologies Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic pH and/or osmolarity for viral infection prophylaxis or treatment
US20130095534A1 (en) * 2010-02-23 2013-04-18 Toray Industries Inc Process for production of cadaverine
US8871477B2 (en) * 2010-02-23 2014-10-28 Toray Industries, Inc. Process for production of cadaverine
USRE47150E1 (en) 2010-03-01 2018-12-04 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
US9309324B2 (en) 2010-03-01 2016-04-12 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
US8481030B2 (en) 2010-03-01 2013-07-09 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
US9359413B2 (en) 2011-04-04 2016-06-07 Evonik Degussa Gmbh Microorganism and method for the fermentative production of an organic-chemical compound
US20140065186A1 (en) * 2011-05-18 2014-03-06 Ajinomoto Co., Inc. Immunostimulant for Animals, Feed Containing the Same, and Method for Producing the Same
US9506094B2 (en) 2013-05-13 2016-11-29 Ajinomoto Co., Inc. Method for producing L-amino acid using microorganism having increased phosphate transporter activity
US20150031101A1 (en) * 2013-07-26 2015-01-29 Samsung Electronics Co., Ltd. Bacterial cell having enhanced succinic acid production and a method for producing the succinic acid using the same
US11312951B2 (en) 2015-12-07 2022-04-26 Zymergen Inc. Systems and methods for host cell improvement utilizing epistatic effects
US11085040B2 (en) 2015-12-07 2021-08-10 Zymergen Inc. Systems and methods for host cell improvement utilizing epistatic effects
US11208649B2 (en) 2015-12-07 2021-12-28 Zymergen Inc. HTP genomic engineering platform
US11155808B2 (en) 2015-12-07 2021-10-26 Zymergen Inc. HTP genomic engineering platform
US11293029B2 (en) 2015-12-07 2022-04-05 Zymergen Inc. Promoters from Corynebacterium glutamicum
US10047358B1 (en) 2015-12-07 2018-08-14 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
US10336998B2 (en) 2015-12-07 2019-07-02 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
US10457933B2 (en) 2015-12-07 2019-10-29 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
US11155807B2 (en) 2015-12-07 2021-10-26 Zymergen Inc. Automated system for HTP genomic engineering
US10968445B2 (en) 2015-12-07 2021-04-06 Zymergen Inc. HTP genomic engineering platform
US10883101B2 (en) 2015-12-07 2021-01-05 Zymergen Inc. Automated system for HTP genomic engineering
US10647980B2 (en) 2015-12-07 2020-05-12 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
US10745694B2 (en) 2015-12-07 2020-08-18 Zymergen Inc. Automated system for HTP genomic engineering
US10808243B2 (en) 2015-12-07 2020-10-20 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
US11352621B2 (en) 2015-12-07 2022-06-07 Zymergen Inc. HTP genomic engineering platform
WO2018005655A3 (fr) * 2016-06-30 2018-02-22 Zymergen Inc. Procédés de génération d'une bibliothèque d'hémoglobines bactériennes et utilisations associées
US10544390B2 (en) 2016-06-30 2020-01-28 Zymergen Inc. Methods for generating a bacterial hemoglobin library and uses thereof
US10544411B2 (en) 2016-06-30 2020-01-28 Zymergen Inc. Methods for generating a glucose permease library and uses thereof
WO2018009372A1 (fr) * 2016-07-05 2018-01-11 Zymergen Inc. Perturbation génétique du complexe protéique dégradosome de l'arn
US11549096B2 (en) 2016-07-05 2023-01-10 Zymergen Inc. Genetic perturbation of the RNA degradosome protein complex
CN114645051A (zh) * 2016-09-15 2022-06-21 日本电气方案创新株式会社 分泌型免疫球蛋白A（sIgA）结合核酸分子、sIgA分析用传感器和sIgA分析方法
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN108314713A (zh) * 2017-01-16 2018-07-24 中国科学院微生物研究所 L-苏氨酸转运蛋白ThrG及其编码基因与应用
CN109517771A (zh) * 2017-09-18 2019-03-26 赢创德固赛有限公司 发酵生产l-氨基酸的方法
CN109929887A (zh) * 2017-12-15 2019-06-25 宁夏伊品生物科技股份有限公司 改进的发酵生产l-赖氨酸的方法
US11421200B2 (en) * 2018-01-25 2022-08-23 Cj Cheiljedang Corporation Microorganism of the genus Corynebacterium producing purine nucleotide and a method for producing purine nucleotide by using the same
US11667936B2 (en) 2018-02-13 2023-06-06 Cj Cheiljedang Corporation Modified polypeptide with attenuated activity of citrate synthase and method for producing L-amino acid using the same
CN112585263A (zh) * 2018-07-11 2021-03-30 于利奇研究中心有限公司 来自棒状细菌的d-木糖-脱氢酶和制备d-木糖酸的方法
CN110964090B (zh) * 2019-12-26 2021-02-19 江南大学 一种促进n-乙酰氨基葡萄糖生产的蛋白质起始因子if3突变体及其应用
CN110964090A (zh) * 2019-12-26 2020-04-07 江南大学 一种促进n-乙酰氨基葡萄糖生产的蛋白质起始因子if3突变体及其应用
CN113121658A (zh) * 2020-01-15 2021-07-16 中国农业大学 根瘤菌中含有sh3结构域的蛋白的基因及其相关生物材料和应用
CN111961635A (zh) * 2020-08-07 2020-11-20 内蒙古伊品生物科技有限公司 一种产l-赖氨酸的重组菌株及其构建方法与应用
CN112266891A (zh) * 2020-10-15 2021-01-26 内蒙古伊品生物科技有限公司 一种产l-氨基酸的重组菌株及其构建方法与应用
CN114981293A (zh) * 2021-01-29 2022-08-30 Cj第一制糖株式会社 新引发体组装蛋白变体及使用其生产l-赖氨酸的方法
CN115244070A (zh) * 2021-01-29 2022-10-25 Cj第一制糖株式会社 新膜蛋白TerC变体及使用其生产L-赖氨酸的方法
CN113906044A (zh) * 2021-04-07 2022-01-07 Cj第一制糖株式会社 新转录调节因子变体及使用其生产l-缬氨酸的方法
WO2022226190A1 (fr) * 2021-04-23 2022-10-27 Board Of Trustees Of Michigan State University Synthèse d'acide 3-hydroxypropionique par hydratation d'acide acétylènecarboxylique
CN113201524A (zh) * 2021-05-08 2021-08-03 廊坊梅花生物技术开发有限公司 肌醇-3-磷酸合酶突变体及其在构建高产谷氨酰胺的谷氨酸棒杆菌中的应用
CN114457178A (zh) * 2021-12-07 2022-05-10 浙江省农业科学院 用于预测杨梅果实可溶性固形物的kasp分子标记及其应用
CN114774387A (zh) * 2022-03-22 2022-07-22 上海威高医疗技术发展有限公司 嗜热羧酸酯酶突变体及其应用
CN115725490A (zh) * 2022-10-19 2023-03-03 天津大学 一种合成与分泌高效电子传递载体吩嗪-1-羧酸的重组希瓦氏菌株构建方法及用途

Also Published As

Publication number Publication date
EP1108790A2 (fr) 2001-06-20
EP2107128B1 (fr) 2012-10-24
EP1108790A3 (fr) 2004-12-15
EP1108790B1 (fr) 2009-09-02
KR20010082585A (ko) 2001-08-30
KR100970106B1 (ko) 2010-07-15
JP4623825B2 (ja) 2011-02-02
US7332310B2 (en) 2008-02-19
US20060228712A1 (en) 2006-10-12
KR20090077738A (ko) 2009-07-15
EP2107128A3 (fr) 2009-10-14
ATE441724T1 (de) 2009-09-15
JP2002191370A (ja) 2002-07-09
KR100961398B1 (ko) 2010-06-09
DE60042872D1 (de) 2009-10-15
EP1108790A8 (fr) 2003-08-27
EP2107128A2 (fr) 2009-10-07

Similar Documents

Publication Publication Date Title
US7332310B2 (en) Mutant of homoserine dehydrogenase from Corynebacterium and DNA encoding thereof
Kalinowski et al. The complete Corynebacterium glutamicum ATCC 13032 genome sequence and its impact on the production of L-aspartate-derived amino acids and vitamins
US7439050B2 (en) Corynebacterium glutamicum genes encoding diaminopimelate epimerase
US7160711B2 (en) Coryneform bacteria which produce chemical compounds I
Anagnostopoulos et al. The genetic map of Bacillus subtilis
US20070161091A1 (en) Corynebacterium glutamicum genes encoding proteins involved in genetic stability, gene expression, and protein secretion and folding
EP2218789B1 (fr) Procédé de production de L-méthionine utilisant des bactéries coryneformes
US20040043458A1 (en) Coryneform bacteria which produce chemical compounds II
CN1715413A (zh) 编码代谢途径蛋白的谷氨酸棒杆菌基因
CA2611513A1 (fr) Biosynthese amelioree d'acides amines et de metabolites
AU2001223903B2 (en) Corynebacterium glutamicum genes encoding metabolic pathway proteins
EP1379549A2 (fr) Sequence du genome de photorhabdus luminescens souche tto1 et utilisations
EP2601209A1 (fr) Etude génomique d'actinoplanes utahensis
US20050255568A1 (en) Methods and compositions for amino acid production
Hartmann et al. Identification and characterization of the last two unknown genes, dapC and dapF, in the succinylase branch of the L-lysine biosynthesis of Corynebacterium glutamicum
US20060068386A1 (en) Complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
WO2002100530A2 (fr) Procede de controle de fermentation
AU783709B2 (en) Corynebacterium glutamicum genes encoding metabolic pathway proteins
US20080096211A1 (en) Corynebacterium glutamicum genes encoding proteins involved in genetic stability, gene expression, and protein secretion and folding
CA2592965A1 (fr) Genes de corynebacterum glutamicum codant pour des proteines de voie metabolique
JP2002051790A (ja) コリネ型細菌のアルギニンリプレッサー欠失株及びｌ−アルギニンの製造法
CN1371417A (zh) 编码代谢途径蛋白的谷氨酸棒杆菌基因
AU783707B2 (en) Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport
US20030148476A1 (en) Nucleotide sequences that code for the rplK gene and methods of use thereof
AU2007202317A1 (en) Corynebacterium glutamicum genes encoding phosphoenolpyruvate: sugar phosphotransferase system proteins

Legal Events

Date Code Title Description
AS Assignment

Owner name: KYOWA HAKKO KOGYO CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NAKAGAWA, SATOSHI;MIZOGUCHI, HIROSHI;ANDO, SEIKO;AND OTHERS;REEL/FRAME:011940/0732

Effective date: 20010605

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION